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Abstract 
Background:  Claudication is the most commonly recognized symptom of PAD.  It is 
classically described as an aching, cramping, painful, or tired feeling in the buttock or leg 
muscles.  However, classic claudication is only reported in 7.5% to 33% of patients with 
PAD.  Symptoms beyond classic claudication have been reported and suspected as being 
part of the symptom experience, but have not been validated as directly relating to 
changes in calf tissue oxygenation during exercise and subsequent recovery.    
Objective:  The purpose of this study was to characterize the symptom experience of 
individuals diagnosed with PAD.  Specific aims were to: (a) understand the symptom 
experience of individuals with PAD through in-depth qualitative interviews, and (b) 
simultaneously evaluate calf tissue oxygenation and self-reported symptoms experienced 
during treadmill exercise and throughout recovery.   
Method:  Adults experiencing lower extremity symptoms during exercise due to 
underlying PAD were asked to participate.  They were asked to: (a) complete a semi-
structured interview to report their symptoms and describe their symptom experience in 
detail; (b) use a numeric rating scale (NRS) (0 to 5) to rate their symptoms during 
exercise and recovery; (c) provide descriptions of their symptom(s) during exercise and 
recovery; and (d) wear a near-infrared spectroscopy device to obtain information on 
tissue oxygenation during the exercise and recovery phases.  Data were analyzed using 
content analysis, exploration of individual graphical trajectories, grouping trajectories, 
and multilevel modeling to examine the relationship between self-reported symptoms and 
calf tissue oxygenation.     
Results:  A total of 40 participants were enrolled in this study.  Participants were 
predominately Caucasian males.  The average age of participants was 67.55 years (SD 
iv 
9.18).  Six themes emerged from 27 participant interviews: symptom descriptors, 
maintaining equilibrium, temporal fluctuations, the role of exercise, the perceived impact 
on QOL, and disease presence and treatment.  During interviews, participants provided 
24 symptom descriptors in 10 lower extremity locations.  During treadmill exercise, 
participants provided 22 symptom descriptors in eight lower extremity locations.  Under 
static and dynamic conditions, classic and ‘atypical’ descriptors were used to describe 
discomfort in typical and ‘atypical’ lower extremity locations.  During three successive 
bouts of treadmill exercise, the largest drop in calf tissue oxygenation occurred between 
the start of exercise and the onset of symptom(s).  During recovery, calf tissue re-
saturation occurred steadily between maximum discomfort (i.e., a rating of 5 out of 5) 
and full symptom recovery.  Individual changes in tissue oxygenation were related to 
total exercise time, baseline calf tissue oxygenation, exercise and recovery ratings, 
disease severity, and body-mass index.   
Conclusions:  This study provides a preliminary understanding of the relationship 
between subjective symptom reporting and calf tissue oxygenation with a variety of PAD 
risk factors and individual characteristics.  Continued research is necessary to validate 
‘atypical’ participant symptom reporting and broaden the currently accepted PAD 
symptom locations and descriptors.  Despite the under-reporting of ‘atypical’ symptoms 
compared to classic claudication, they do exist and they are no less important for the 
early detection, diagnosis, and treatment of PAD to minimize the impact of this painful, 
debilitating, and deadly disease.   
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Chapter 1:  Introduction 
Background 
 Peripheral artery disease (PAD) is a progressive atherosclerotic occlusive disease 
affecting more than 8 million Americans, a number expected to rise sharply due to an 
aging population (Allison et al., 2007; Ostchega, Paulose-Ram, Dillon, Gu, & Hughes, 
2007; Selvin & Erlinger, 2004).  Early detection of PAD is crucial for timely treatment 
and prevention of amputation, heart attack, stroke, and death (Criqui, 2001b; Criqui, 
Ninomiya, Wingard, Ji, & Fronek, 2008; Diehm et al., 2009).   In PAD, arterial blood 
flow to the lower extremities is reduced, leading to exertional skeletal muscle ischemia 
that results in significant discomfort (e.g., claudication) while walking even short 
distances.  Claudication is the most commonly recognized symptom of PAD.  It typically 
commences shortly after walking begins and resolves only when the activity ceases and is 
classically described as an aching, cramping, painful or tired feeling in the calves (Rose, 
1962).   
 Although claudication is considered the classic and hallmark symptom of PAD, 
only 7.5% (T. C. Collins, Petersen, Suarez-Almazor, & Ashton, 2003) to 33% (Criqui et 
al., 1996; McDermott et al., 1999; Wang et al., 2005) of individuals report classic 
claudication as being part of their symptom experience.  Symptom reporting may differ 
based on disease severity, disease location, age, or the presence of certain comorbid 
conditions.  Women may also have different PAD symptoms, since PAD symptom 
definitions were based on male experiences and were established at a time when ischemic 
atherosclerotic diseases were thought to primarily affect men.  When individuals report 
symptoms that are not consistent with classic claudication, provider suspicion of disease 
presence is not triggered; therefore individuals may not receive the necessary diagnostic 
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testing and subsequent treatment for this chronic, debilitating disease. 
 Since many patients with PAD do not experience classic claudication, heavy 
reliance on this symptom for screening and detection can result in mis- or under-
diagnosis of the disease; thus significant comorbidities and mortality may increase 
(Criqui, Fronek, Klauber, Barrett-Connor, & Gabriel, 1985; McDermott, Mehta, & 
Greenland, 1999; McDermott et al., 2001; Weitz et al., 1996).  Indeed, age- and gender-
specific PAD symptoms beyond those of classic claudication are suspected, but 
unconfirmed (Stoffers, Rinkens, Kester, Kaiser, & Knottnerus, 1996).  Further, the 
relationship between subjective symptom reporting and the objective measurement of 
lower extremity tissue oxygenation during exercise is unknown.  Therefore, combining 
both perspectives has the potential to provide a more comprehensive understanding of the 
PAD symptom experience which is essential to increase disease detection, diagnosis, and 
subsequent treatment.   
Study Objectives 
 The purpose of this study was: (1) to obtain a comprehensive understanding of the 
PAD symptom experience beyond classic claudication, including symptom location, 
sensation, and duration; and (2) to evaluate the relationship between the symptoms 
experienced and physiologic changes in calf tissue oxygenation during treadmill exercise 
and throughout recovery.  The objectives of this project were to elicit a comprehensive 
description of PAD symptoms, attain related physiologic data, and obtain a preliminary 
understanding of the relationship between subjective and objective symptom reporting.  
The central premise of this study was that exploring the relationship between subjective 
and objective symptom data was a necessary first step toward increasing provider 
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understanding and use of a more comprehensive set of diagnostic PAD symptom 
descriptors.  This study leads to a long term goal of developing and refining age- and 
gender-specific PAD screening tools to improve and increase lifesaving detection, 
diagnosis, and treatment. During this investigation, the following specific aims were 
pursued:  
 Aim 1:  Understand the symptom experience of older and younger men and 
women with PAD through in-depth qualitative interviews.  Research Question:  How do 
older and younger male and female patients describe the PAD symptom experience?      
 Aim 2:  Simultaneously evaluate calf tissue oxygenation and the self-reported 
symptoms experienced by older and younger men and women with PAD during treadmill 
exercise and throughout recovery.  Research Question:  What is the relationship between 
calf tissue oxygenation and the onset and progression of symptoms?   
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    Chapter 2:  Literature Review 
Current Understanding of Peripheral Artery Disease (PAD) 
 PAD is a progressive atherosclerotic occlusive disease that causes insufficient 
blood flow to the lower extremities and can result in debilitating, activity-induced pain, 
even while walking short distances.  Estimates vary widely, but it is currently estimated 
that between 8 and 12 million Americans are afflicted with PAD (Allison et al., 2007; 
Hirsch et al., 2001; Hirsch, Hiatt, & PARTNERS Steering, 2001).  The prevalence of the 
disease has been shown to increase with age, particularly in individuals aged 60 years and 
older (Ostchega et al., 2007; Selvin & Erlinger, 2004).  Therefore, as the population ages, 
PAD will become increasingly prevalent.  Despite the high prevalence of PAD, it remains 
largely underdiagnosed and undertreated (Becker, McClenny, Kovacs, Raabe, & Katzen, 
2002; Hirsch et al., 2001).  Evidence suggests the underutilization of inexpensive and 
widely available diagnostic screening tools (Ferreira & Macedo, 2010), guideline-
recommended treatments (Mukherjee & Cho, 2009), and lifestyle modifications 
(Mukherjee & Cho, 2009).  Early detection of PAD is crucial for timely treatment and 
prevention of amputation, heart attack, stroke, and death (Caro, Migliaccio-Walle, Ishak, 
& Proskorovsky, 2005; Criqui et al., 1992; Criqui et al., 2008; Diehm et al., 2009).  
Individuals with PAD have 4 to 5 times the risk of dying of a cardiovascular event 
compared to those without PAD, which translates into a mortality risk that is 2 to 3 times 
higher (Bhatt et al., 2006; Newman et al., 1999). 
 Risk factors.  Risk factors associated with PAD are similar to those for coronary 
artery disease and include age >50 years (Criqui et al., 1985; Vogt, McKenna, Anderson, 
Wolfson, & Kuller, 1993), cigarette smoking (Drexel et al., 1996; Kannel, 1996a; 
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Krupski, 1991; Newman et al., 1993), diabetes mellitus (DM) (Murabito, D'Agostino, 
Silbershatz, & Wilson, 1997; Newman et al., 1993), hypertension (Drexel et al., 1996; 
Murabito et al., 1997; Newman et al., 1993), elevated lipid levels (Drexel et al., 1996; 
Hiatt, Hoag, & Hamman, 1995; Mowat et al., 1997; Murabito et al., 1997), and elevated 
homocysteine levels (Hoogeveen et al., 1998; Taylor, Moneta, Sexton, Schuff, & Porter, 
1999).  PAD is associated with a decreased quality of life (QOL) (Khaira, Hanger, & 
Shearman, 1996; Pell, 1995) and functional limitations (Dolan, Liu, Criqui, et al., 2002; 
McDermott, Greenland, Liu, et al.; 2001), and is a strong predictor of future 
cardiovascular morbidity and mortality (Criqui, Langer, Fronek, & Feigelson, 1991; 
Criqui et al., 2008; Leng et al., 1996).  Individuals with PAD suffer a 5-fold increased 
relative risk of a heart attack and a 2- to 3-fold greater risk of stroke and total mortality 
than those without PAD (Criqui et al., 1992).  PAD patients have higher rates of 
cardiovascular ischemic morbidity and mortality than those with coronary artery disease 
or cerebrovascular disease (Steg et al., 2007), and greater 5-year mortality rates than 
those with breast cancer and many other malignancies (Criqui, 2001a; McKenna, 
Wolfson, & Kuller, 1991).  Associations between PAD and cardiovascular mortality are 
independent of demographic characteristics, risk factors, or other comorbid conditions 
(Newman, Tyrrell, & Kuller, 1997; Resnick et al., 2004).  Given the significant morbidity 
and mortality associated with PAD, there is an obvious need to increase diagnosis and 
provide timely treatment in an attempt to minimize the significant risks previously 
discussed.   
 Diagnosis.  Claudication is the symptom that health care professionals most often 
associate with PAD, which triggers confirmatory diagnostic testing (Olson & Treat-
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Jacobson, 2004).  Classic intermittent claudication (IC), originally defined in the Rose 
Questionnaire (Rose, 1962), is exertional calf aching, cramping, pain, or fatigue that 
causes the patient to stop walking, resolves within 10 minutes of rest, does not resolve 
while the patient is walking, and does not begin at rest (Kannel, 1996b; Murabito et al., 
1997; Rose, 1962).  Although claudication is considered the hallmark symptom of PAD, 
up to 50% of patients do not report claudication (Hirsch et al., 2001; McDermott, Mehta, 
& Greenland, 1999), particularly those with comorbid conditions such as neuropathy, 
arthritis, and spinal stenosis (Dolan et al., 2002; McDermott, Mehta, & Greenland, 1999; 
McDermott et al., 2001). 
 The most commonly performed assessment to confirm disease presence is the 
ankle-brachial index (ABI).  The ABI is a simple, rapid, (on average requiring less than 
15 minutes to complete), accurate, inexpensive, and non-invasive method to identify 
(Dolan et al., 2002; McDermott, Mehta, & Greenland, 1999; McDermott et al., 2001)  
and monitor PAD (Ferreira & Macedo, 2010).  The ABI is a ratio of Doppler-recorded 
systolic blood pressure (BP) in the lower and upper extremities (Bernstein & Fronek, 
1982).  Under normal conditions, the systolic pressure at the ankle should be equal to or 
greater than the systolic pressure of the upper arm.  In PAD, systolic pressure decreases 
at sites distal to areas of arterial narrowing.  An ABI ≤ 0.90 is diagnostic of PAD 
(Aboyans et al., 2012; Albert et al., 2013; Coutinho, Rooke, & Kullo, 2011; Tendera et 
al., 2011).  Values between 0.91 and 0.99 are considered borderline abnormal, whereas 
normal values fall between 1.00 and 1.40.  Individuals with an ABI >1.40 are thought to 
have non-compressible arteries secondary to calcification and should have a toe-brachial 
index performed.  A low ABI at rest (≤0.90) provides significant evaluative and 
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prognostic information on cardiovascular risk (Norgren et al., 2007).  The presence of a 
low ABI more than doubles the risk of coronary heart disease and stroke, and more than 
quadruples the risk of cardiovascular death (Doobay & Anand, 2005).  Several studies 
have also shown that a high ABI at rest (>1.40) is associated with poorer outcomes in the 
general population (Aboyans et al., 2008; Collaboration et al., 2008; O’Hare, Katz, 
Shlipak, Cushman, & Newman, 2006; Resnick et al., 2004; Suominen, Rantanen, 
Venermo, Saarinen, & Salenius, 2008), as well as patients with a diagnosis of coronary 
artery disease (Aboyans et al., 2005).  Current guidelines from the American College of 
Cardiology/American Heart Association recommend utilizing a resting ABI to establish 
PAD diagnosis in patients with suspected PAD (e.g., exertional leg symptoms), with non-
healing wounds, and in those aged ≥70 years or ≥50 years with a history of smoking or 
DM (Hirsch et al., 2006).   
Current Understanding of PAD Symptoms  
  The presentation and progression of PAD is varied.  Some individuals remain 
asymptomatic despite disease progression, while others consistently experience 
discomfort upon exertion that subsides when physical activity ceases.  Critical limb 
ischemia (CLI) is the most severe form of PAD.  Individuals with CLI typically 
experience severe leg pain, even while resting, that usually occurs in the feet or toes.  
However, for some individuals with CLI, the first sign of the disease is the presence of 
tissue loss (Matzke & Lapantalo, 2001).  In patients with CLI, blood flow to the lower 
extremities is severely reduced, resulting in chronic non-healing wounds and tissue 
necrosis that if left untreated can lead to amputation.   
 Symptom assessment.  Symptom assessment often involves a combination 
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approach: an oral report of symptoms to a provider and written completion of a PAD 
symptom questionnaire by a patient.  During exercise, the onset and progression of PAD 
symptoms can be numerically assessed using a numeric rating scale (NRS).  However, 
the vast majority of patients with PAD descriptively report their symptoms on a 
questionnaire (i.e., using words to describe the symptom location and sensation), in a 
static condition (e.g., during an office visit).   
 Numeric rating scale (NRS).  The NRS attempts to capture an individual’s 
perception of a PAD symptom on a scale from 0 to 5 (see Figure 1).  A rating of 0 
represents no discomfort, whereas a rating of 5 is the maximum ischemia-related 
discomfort experienced.  This scale is most commonly used as a symptom assessment 
technique in PAD exercise studies and is considered valid and reliable for use in this 
patient population (Hiatt, Wolfel, Meier, & Regensteiner, 1994; Treat-Jacobson, Bronas, 
& Leon, 2009; Treat-Jacobson, Henly, Bronas, Leon, & Henly, 2011).   
   0  
  
   1 Mild 
  
   2  
  
   3 Moderate 
  
   4  
  
   5 Severe 
Figure 1.  The numeric rating scale (NRS) used to describe ischemia-related discomfort 
during treadmill exercise and subsequent recovery.    
 
Symptom questionnaires.  A more common form of reporting PAD symptoms is 
on a questionnaire.  Table 1 summarizes the evolution of claudication questionnaires, 
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including symptom categories and their associated characteristics that most frequently 
appear in the literature.  The Rose Questionnaire (Rose, 1962) was the first PAD 
symptom questionnaire developed.  It attempted to standardize the one and only symptom 
thought to be indicative of PAD at the time, claudication.  Originally, the Rose 
Questionnaire was developed for use in epidemiologic studies to determine prevalence 
rates and it was subsequently adopted by the World Health Organization (WHO) in 1968 
(Rose & Blackburn, 1968).  In 1977, minor changes were made to the wording of the 
questionnaire to make it suitable for self-administration; claudication criteria remained 
unchanged (Rose, McCartney, & Reid, 1977).  Results of the initial study revealed 91.9% 
sensitivity and 100% specificity in 37 patients with undoubted claudication (most verified 
by arteriograms) and 18 patients with other types of exertional leg pain (mainly sciatica, 
osteoarthritis (OA), and calf cramps) (Rose, 1962).  The WHO/Rose Questionnaire failed 
to identify three participants with undoubted claudication, but correctly ruled out all of 
the participants reporting leg pain unrelated to claudication.    
 Later studies with larger sample sizes, using physician diagnosis as a comparison 
(usually based on an ABI), resulted in a sensitivity and specificity as low as 8.6% 
(Newman et al., 2001) and 91% (Leng & Fowkes, 1992), respectively.  The low 
sensitivity in later studies may be explained by failure of the WHO/Rose Questionnaire to 
identify participants reporting symptoms in an ‘atypical’ location (e.g., buttock) or in 
multiple locations, as having claudication.  Further, a lower specificity may be explained 
when participants surveyed present with other types of non-ischemic leg pain and are 
classified as having claudication.    
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Table 1 
Evolution of Claudication Questionnaires 
Questionnaire Year Created/ 
Revised 
Symptom Category Symptom Characteristics 
Rose 1962 Intermittent claudication 
(Rose IC) 
● Exertional calf pain 
WHO/Rose 1968   
       Grade 1      Walking uphill or hurrying 
       Grade 2      Walking at ordinary pace on      
        the level  
   ● Never starts at rest (standing     
     or sitting) 
   ● Never disappears while  
     walking 
   ● Causes patient to slow down  
     or stop 
   ● Usually disappears within 10  
     minutes or less 
 1985 Possible IC ● Exertional calf pain 
   ● Never starts at rest 
   ● Otherwise not fully     
     concordant with Rose IC    
     criteria 
 1991 Probable IC ● Exertional calf pain 
   ● One WHO/Rose criteria not  
     fulfilled 
ECQ 1992 Definite IC (Rose IC) ● Fully concordant with Rose  
     IC criteria 
       Grade 1        Walking uphill or hurrying 
       Grade 2        Walking at an ordinary  
          pace on the level 
    
  Atypical IC ● Pain in thigh or buttock in the  
     absence of calf pain,  
     otherwise concordant with  
     Rose IC criteria 
SDCQ 1996 Rose IC ● Fully concordant with Rose  
     IC criteria 
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Table 1 – Continued.  
 
  Non-Rose exercise calf 
pain 
● Exertional calf pain; at least  
     one Rose IC criteria not  
     fulfilled 
    
  Non-calf exercise leg pain ● Pain in either leg excluding  
     calf (can be quadriceps or  
     buttock); does not begin at  
     rest 
    
  Leg pain on exertion and at 
rest 
● Exertional leg pain that starts  
     at rest 
    
  No pain ● Reports no pain in calf,  
     quadriceps, or buttock 
Note.  WHO=World Health Organization; IC=intermittent claudication; ECQ=Edinburgh 
Claudication Questionnaire; SDCQ=San Diego Claudication Questionnaire. 
 
 The low sensitivity and reduced specificity of the WHO/Rose Questionnaire led 
to the development of the Edinburgh Claudication Questionnaire (ECQ) in 1992 (Leng & 
Fowkes, 1992).  The revised questionnaire included a response for non-ambulatory 
patients and a lower extremity body diagram for patients to indicate leg symptoms in 
multiple locations.  The body diagram allowed for positive claudication classification to 
be separated into definite claudication and ‘atypical’ claudication depending on 
involvement (or lack thereof) of the calf.  Initial testing of the ECQ revealed 91.3% 
sensitivity and 99.3% specificity in comparison to the diagnosis of claudication made by 
a physician (Leng & Fowkes, 1992).  The study population consisted of 50 new patients 
attending a peripheral vascular clinic with leg pain, aged over 55 years and 300 patients 
aged over 55 years visiting their general practitioner with any complaint (Leng & 
Fowkes, 1992).                                                      
 A new questionnaire, the San Diego Claudication Questionnaire (SDCQ) (Criqui 
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et al., 1996), was developed in 1996.  The SDCQ was a revised and expanded version of 
the WHO/Rose Questionnaire.  It included buttock and thigh pain, which was also a 
component of the ECQ, but unlike the ECQ, the SDCQ inquired specifically whether 
symptoms were present in the right, left, or both legs.  The complete results of a 
structured review of claudication questionnaires has been published by the principal 
investigator (PI) (Schorr & Treat-Jacobson, 2013).  Of all the articles included in the 
structured review, the SDCQ was the most frequently used claudication questionnaire.  
Interestingly, all of the studies that utilized the SDCQ were conducted in the United 
States, whereas studies conducted abroad used the WHO/Rose and the ECQ.   
 Claudication questionnaires have undergone several revisions over time, but 
sensitivity remains low and specificity is variable.  All three questionnaires are seemingly 
insensitive to PAD detection compared to ABI as a gold standard for diagnosis.  This 
indicates the need for further questionnaire refinement to increase the sensitivity and 
correctly identify patients with disease, but with symptoms differing in location and/or 
sensation compared to those exhibiting classic claudication.  
 Symptom definitions.  A relatively strict definition of claudication (the ‘typical’ 
PAD symptom) has persisted over time.  As previously described, in its original form 
(Rose, 1962), classic claudication, is exertional pain restricted to one or both calves that 
causes a patient to slow down or stop walking, resolves within 10 minutes of standing 
still, does not resolve while the patient is walking, and does not begin at rest.  While the 
introduction of the ECQ allowed for the presence of symptoms elsewhere in the lower 
extremities, pain still had to be present in one or both calves to be classified as definite 
claudication (Criqui et al., 1985; Fowkes et al., 1991; Leng & Fowkes, 1992).                                                   
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 The creation of the SDCQ allowed for the presence of more specific symptom 
categories beyond classic claudication, and the assessment of leg-specific symptoms 
(right versus left) (Criqui et al., 1996).  The SDCQ consists of five possible symptom 
categories per leg:  Rose claudication, non-Rose exercise calf pain, previously referred to 
as ‘possible IC’ (Criqui et al., 1985)  and ‘probable IC’ (Fowkes et al., 1991), non-calf 
exercise leg pain, pain at rest, and no pain (Criqui et al., 1996).    
 Symptom report.  Despite the evolution of such questionnaires, patients 
reporting pain in the hamstrings, feet, shins, joints, or radiating pain in the absence of calf 
pain would still not classify as ‘symptomatic,’ and subsequently would not be suspected 
of having PAD.  Furthermore, although the number of symptom categories has increased 
on questionnaires, none allow for the reporting of symptom descriptors such as tingling, 
numbness, burning, throbbing, or shooting that have been reported by patients with PAD 
as being part of the symptom experience (Ruger et al., 2008; Tomczyk & Treat-Jacobson, 
2009; Treat-Jacobson et al., 2002).                                                   
 Typical symptoms.  The symptom most frequently recognized as the hallmark 
sign of arterial insufficiency is claudication.  Claudication comes from the Latin word 
claudicare, meaning to limp.  But, the use of this term is misleading, as patients who 
experience symptoms other than classic claudication are still shown to be functionally 
limited (McDermott et al., 2004; McDermott et al., 2010) and report a decreased QOL 
(Treat-Jacobson et al., 2002).  Aside from confusion about the meaning of claudication, 
using classic claudication as the gold standard for PAD symptom recognition results in 
significant under-diagnosis of the disease.  Over the last 10 to 15 years, the reported 
prevalence of classic claudication in patients with symptomatic PAD has been highly 
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variable, ranging from 7.5% (Collins et al., 2003) to 33% (Criqui et al., 1996; McDermott 
et al., 1999; Wang et al., 2005).  Higher prevalence has been reported in smaller 
populations (43.8%) (Makowsky et al., 2011) and specific populations including only 
individuals complaining of leg pain (78.8%) (Makdisse et al., 2007), or excluding 
individuals who have non-compressible arteries, CLI, or a history of revascularization 
(43.6%) (Van Zitteren et al., 2012).  Overall, research indicates that there are specific 
characteristics of individuals who are more likely to report classic claudication.  
Reporting appears to increase as age increases (Criqui et al., 1985; Fowkes et al., 1991; 
Leng et al., 1996; Stoffers, Rinkens et al., 1996; Wang et al., 2005), and be more 
prevalent among men (Leng et al., 1996; Stoffers, Rinkens et al., 1996; Wang et al., 
2005), and in individuals with DM (Wang et al., 2005), hypertension (Ogren, Hedblad, 
Engstrom, & Janzon, 2003), a previous diagnosis of PAD (Criqui et al., 1996; Hirsch et 
al., 2001), or a more severe form of the disease (Criqui et al., 1996; Stoffers, Rinkens et 
al., 1996; Wang et al., 2005).  Disease location may also influence the reporting of classic 
claudication, with higher prevalence among those with distal lesions (Van Zitteren et al., 
2012) or large vessel PAD (Criqui et al., 1985).                
 The highest reported prevalence of classic claudication is 100% (Gardner, 
Montgomery, & Afaq, 2007; Gardner et al., 2012; McDermott et al., 2001).  The most 
recent study conducted by Gardner et al. (2012) included 114 participants with 
symptomatic PAD recruited from vascular and primary care clinic referrals.  Prior to 
exercise testing, participants fell into the following three symptom categories: leg pain on 
exertion and rest (40.3%), ‘atypical’ leg pain (27.2%), and classic claudication (32.5%).  
However, during a graded treadmill test, all of the participants reported symptoms 
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consistent with classic claudication.   
 In 2007, Gardner and colleagues (Gardner et al., 2007) reported similar findings.  
Their study included 715 participants who self-reported exertional leg pain consistent 
with one of the first four categories on the SDCQ.  Initial classic claudication prevalence 
was 56.8%.  As with the 2012 study, during treadmill testing, all of the study participants 
experienced exertional leg pain that was consistent with classic claudication (i.e., 
participants stopped walking due to calf pain that resolved with subsequent rest).  
McDermott and colleagues (2001) reported similar findings with a group of 57 patients 
who initially self-reported no symptoms, but over half of whom became symptomatic 
during a 6-minute walking test.  These results raise important questions that have not 
been previously explored:  Are the patients classified in the literature as ‘asymptomatic’ 
truly not experiencing symptoms, or are they slowing their walking pace or limiting 
ambulation to prevent the onset and/or progression of leg symptoms which could be 
revealed under controlled exercise testing?  The issue of under-reporting versus true 
symptom prevalence deserves further attention.   
 ‘Atypical’ symptoms.  When Rose (1962) developed the first claudication 
questionnaire in 1962, the characteristics of PAD were thought to be well-delineated, 
which made it suitable for diagnosis in epidemiologic surveys.  However, over the last 
five decades, researchers have discovered a more diverse presentation of PAD symptoms.  
With classic claudication consistently being reported by less than one-third of patients 
with PAD, claudication questionnaires have been forced to evolve in order to capture the 
broad array of symptom experiences (Criqui et al., 1996; Leng & Fowkes, 1992).  
However, revised claudication questionnaires are still not sufficient, as patients are 
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reporting symptom locations and/or symptom descriptors that are not detected by these 
questionnaires.  Until a more comprehensive tool exists, it is essential for clinicians to 
recognize that patients with underlying PAD are reporting ‘atypical’ symptoms more 
frequently than classic claudication (Collins et al., 2003; Hirsch et al., 2001; Kownator et 
al., 2009; Lacroix et al., 2008; McDermott et al., 1999; McDermott, Mehta, & Greenland, 
1999; McDermott et al., 2011; Newman et al., 2001), and to adapt their assessment 
techniques accordingly.                                                
 In the literature reviewed, the prevalence of ‘atypical’ symptoms was difficult to 
ascertain compared to classic claudication, despite its increased frequency.  The main 
reasons were the use of a variety of definitions for ‘atypical’ symptoms and inconsistent 
use of symptom categories from study to study.  In its simplest form, ‘atypical’ symptoms 
included any lower extremity symptom that was not consistent with classic claudication 
(Criqui et al., 1996; Hirsch et al., 2001), and increased in complexity to include all lower 
extremity symptoms not located in the calf (Leng & Fowkes, 1992), exercise calf pain not 
present at rest, but otherwise not fully concordant with the Rose criteria (‘possible IC’) 
(Criqui et al., 1985; Sprynger, Fassotte, & Verhaeghe, 2007), calf pain, but one Rose 
criteria not fulfilled (‘probable IC’) (Fowkes et al., 1991), ‘atypical’ pain on exertion 
(non-Rose walk- through pain and non-Rose stop because of pain), and pain on exertion 
and rest (Gardner et al., 2007; McDermott et al., 2001).  ‘Atypical’ pain was used to refer 
to ‘walk-through pain’ and/or pain that was not consistently relieved within 10 minutes of 
rest (Ogren et al., 2003).  However, prolonged symptom recovery was also grouped 
together with pain at rest into a ‘no pain’ category (Manzano et al., 2009).  Pain that 
presented at rest and on exertion was often referred to as ‘leg pain on exertion and rest’ 
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(Gardner et al., 2007; Gardner et al., 2012; McDermott et al., 2001; McDermott et al., 
2011; Wang et al., 2005), but was also referred to as ‘pain at rest’ (Criqui et al., 1996; 
McDermott et al., 1999; McDermott, Mehta, & Greenland, 1999; Mourad et al., 2009), 
‘rest pain’(Lacroix et al., 2008; Siddiqi, Paracha, & Hammad, 2010), or ‘symptoms at 
rest’(Van Zitteren et al., 2012).   Some studies subdivided the ‘no symptoms with 
exertion’ category into active and inactive participants, resulting in a total of six leg 
categories (Collins, Petersen, & Suarez-Almazor, 2005; McDermott et al., 2001), whereas 
Collins and colleagues (2003), condensed the five symptom categories of the SDCQ into 
three: no pain, ‘atypical’ leg pain, (pain at rest, non-calf exercise pain, and non-Rose 
exercise calf pain), and Rose claudication.  Others followed the original five symptom 
categories established by the SDCQ (Wang et al., 2005) or used a general category of 
‘leg symptoms’(Kownator et al., 2009), or ‘symptomatic’ that included lower extremity 
revascularization, amputation secondary to PAD, or report of claudication regardless of 
ABI (Missault, Krygier, Lukito, Mary-Rabine, & OPERA Investigators Study, 2007).  
The use of either category, ‘leg symptoms’ or ‘symptomatic,’ limits the understanding of 
symptom presentation by classifying symptomatic patients as asymptomatic and vice 
versa.     
 Potential symptom confounders.  It has been demonstrated that older adults are 
more likely to become afflicted with PAD (He et al., 2006; Murabito et al., 1997) .  Older 
age also makes it more likely that patients with PAD are afflicted with other age-related 
conditions that could cause or contribute to lower extremity symptoms.  Consideration 
should also be given to PAD severity and its influence on the symptom experience.  
While several researchers have recognized the potential influence of comorbid conditions 
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on symptom presentation (Dolan et al., 2002; He et al., 2006; McDermott, Mehta, & 
Greenland, 1999; McDermott et al., 2001; Newman et al., 2001; Ogren, Hedblad, 
Engstrom, & Janzon, 2005; Ruger et al., 2008; Weinberg, Simovic, Isner, & Ropper, 
2001), the topic has not been thoroughly researched or reported in the literature.  Findings 
from McDermott and colleagues (McDermott et al., 2001) revealed an increased 
prevalence of DM, neuropathy, and spinal stenosis in patients who reported pain on 
exertion and rest.  Similarly, Newman et al. (2001) discovered a higher prevalence of 
arthritis and depression in patients reporting exertional leg pain other than classic 
claudication.  Findings from Bernstein and colleagues (Bernstein, Esterhai, Staska, 
Reinhardt, & Mitchell, 2008) revealed a low prevalence of classic claudication (2%) 
among patients with PAD, half of whom were also diagnosed with degenerative joint 
disease.  Insulin resistance without a diagnosis of DM has also been identified as a factor 
influencing claudication prevalence (Pande et al., 2011). Further support for the effect of 
comorbid conditions came from a study conducted by Weinberg and colleagues 
(Weinberg et al., 2001), indicating that regional neuropathy is commonly associated with 
chronic ischemia and CLI.   
 The neuropathic component of ischemic pain has been examined more closely by 
researchers and the current understanding is that the character of ischemic pain changes 
from nociceptive pain in patients with classic claudication to predominately neuropathic 
pain in patients with CLI (Ruger et al., 2008).  Despite the large numbers of patients 
diagnosed with PAD and reporting neuropathy, the understanding of the role that 
ischemia plays in neuropathic pain remains limited.  Overall, these preliminary results 
suggest that there are differences in the symptoms reported and/or differences in the 
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character of the symptom in the presence of certain comorbid conditions or in those with 
severe PAD (i.e., CLI).  This provides additional evidence that using classic claudication 
as the defining symptom of PAD is insufficient to capture the breadth of symptoms 
experienced, particularly in this patient population.    
 Similarly, differential diagnoses have been described in PAD literature in an 
attempt to clear the blurring of symptom reporting that occurs in the presence of multiple 
comorbidities, but it has not been extensively studied (Abul-Khoudoud, 2006; 
Almahameed, 2006; Jang, Jonathan & Halperin, 2005; Jeon, Han, Chung, & Hyun, 2012; 
Lyden & Joseph, 2006; Meru, Mittra, Thyagarajan, & Chugh, 2006; Weitz et al., 1996).  
An understanding of physiology can allow a clinician to locate the site of arterial 
occlusion based on the location of the symptom(s).  For example, pain or discomfort in 
the calf, ankle, or foot could indicate an obstruction/occlusion in the popliteal or 
superficial femoral arteries (Almahameed, 2006).  Symptoms located primarily in the calf 
or thigh could indicate femoral arteries or their branches, whereas, symptoms in the 
buttock, hip, and thigh indicate higher disease in the aorta or iliac artery.   
 The location of symptoms can serve as a guide, but they do not guarantee the 
presence or location of a lesion with 100% certainty.  Symptoms of a patient with 
claudication may overlap with symptomatology of other conditions, particularly 
neurological and musculoskeletal diseases (Abul-Khoudoud, 2006).  Take for instance a 
patient reporting calf pain.  The pain could indicate claudication secondary to a femoral 
artery occlusion or it could indicate a venous occlusion, chronic compartment syndrome, 
nerve root compression, or a Baker’s cyst (a tight bursting pain/dull ache that worsens on 
standing and resolves with leg elevation) (Abul-Khoudoud, 2006; Dizon-Townson, 
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Nelson, Jang, Varner, & Ward, 1997; Jang & Halperin, 2005; Meru et al., 2006).  The 
presence of any of these conditions could lead a provider to suspect claudication, which 
could be ruled out if the symptom was relieved by a change in position. Symptoms in the 
hip, thigh, or buttock could be related to hip arthritis (Abul-Khoudoud, 2006; Meru et al., 
2006).  However, arthritis is usually a more persistent pain compared to the intermittent 
nature of claudication and typically associated with symptoms in other joints (Abul-
Khoudoud, 2006; Meru et al., 2006).  Spinal cord compression should also be considered, 
particularly when a patient is reporting a history of back pain, with symptoms that worsen 
upon standing, but are relieved by positional changes (Meru et al., 2006).  Patients 
reporting foot symptoms could have an inflammatory condition such as arthritis or 
Buerger’s disease (Abul-Khoudoud, 2006; Weitz et al., 1996).  Current clinician 
recommendations are to conduct a thorough physical exam and symptom assessment that 
includes the location, duration, and intensity (Lyden & Joseph, 2006).  If PAD is 
suspected based on patient symptom report or a patient’s risk factor profile, a 
confirmatory ABI should be performed.    
Summary of Symptom Reporting 
 Claudication questionnaires have been used extensively to assess the presence of 
claudication and subsequently to detect the presence of PAD. Although often highly 
specific, they remain insensitive for the detection and diagnosis of PAD.  Additionally, 
the inconsistent use of one standardized questionnaire, combined with variations in 
sample characteristics, definition of PAD, diagnostic methods, and definition of 
claudication and ‘atypical’ symptoms make comparisons across studies difficult, if not 
impossible.  Although appearing more frequently, the non-specific nature of ‘atypical’ 
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symptoms further complicates clear symptom categorization and necessitates 
classification of ‘atypical’ symptoms as being caused by ischemia or caused by comorbid 
conditions unrelated to ischemia.  Furthermore, age and gender differences may affect the 
reporting of classic claudication and ‘atypical’ symptoms on PAD questionnaires.  
However, the largest confounder of PAD symptom report may be the presence of 
comorbidities, particularly those that affect mobility, as physical limitations may preclude 
manifestation of PAD symptoms and delay necessary diagnosis and treatment.  As the 
role of comorbid conditions becomes more clearly defined, follow-up questions can be 
added to existing questionnaires to eliminate false positives and to capture participants 
who were originally considered false negatives.   
 Additional research is needed to increase the understanding of the role of age, 
gender, race, and comorbid conditions on the symptom experience of patients with PAD.  
The next logical step is to validate subjective symptom report with objective physiologic 
measures that detect ischemia during exercise in an attempt to broaden the current 
understanding of PAD symptom presentation.  Lastly, better understanding and 
differentiation of symptom locations and descriptors that are not consistent with classic 
claudication or ‘atypical’ symptoms caused by ischemia, but rather caused by a comorbid 
condition that is unrelated to ischemia, is essential to further enhance understanding of 
the symptom experience.   
Treadmill Exercise Testing 
 Individuals with PAD experience discomfort during exercise primarily due to the 
presence of ischemia in the calf, thigh, or buttocks (Holm & Bylund‐Fellenius, 1981; 
Zatina, Berkowitz, Gross, Maris, & Chance, 1986).  Subsequently, these exercise-induced 
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ischemic symptoms limit an individual’s ability to exercise and affect oxygen 
consumption during exercise testing (Hiatt, Nawaz, & Brass, 1987; Hiatt, Wolfel, 
Regensteiner, & Brass, 1992).  Thus, treadmill exercise testing is frequently utilized in 
clinical and research settings to assess changes in functional capacity following 
therapeutic interventions or to evaluate PAD disease severity and/or progression.  
 Treadmill testing mainly focuses on the distance at which discomfort begins (i.e., 
initial claudication distance) and the distance at which discomfort becomes so severe that 
it causes an individual to stop walking (i.e., maximal walking distance).  Since walking 
exercise is the primary recommended non-surgical treatment for those suffering from 
PAD, many research studies focus on changes in the aforementioned outcomes (e.g., 
initial claudication distance and maximal walking distance) based on individuals 
participating in supervised exercise programs.  Additionally, treadmill walking is 
considered a more controlled way to elucidate claudication symptoms compared to free- 
living conditions.  In fact, in some circumstances, up to 100% of individuals with PAD 
reported classic claudication under controlled exercise testing (Gardner et al., 2007; 
Gardner et al., 2012; McDermott et al., 2001), while less than 60% had reported classic 
claudication symptoms in everyday living prior to exercise testing (i.e., participants had 
not stopped walking due to calf pain that resolved with subsequent rest).  In light of these 
research findings, one proposed hypothesis is that patients with PAD who do not report 
any claudication symptoms or those who do not report symptoms consistent with classic 
claudication are not walking fast enough and/or far enough to provoke these symptoms 
during everyday activities.         
 Two standard treadmill protocols are primarily used for people with PAD:  graded 
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and constant-load.  During a graded treadmill exercise test, individuals start walking at 2 
miles per hour (mph), at a 0% grade for two (Gardner, Skinner, Cantwell, & Smith, 1991) 
to three (Hiatt, Nawaz, Regensteiner, & Hossack, 1988) minutes.  If walking continues, 
the grade is increased by 2% every 2 minutes (Gardner et al., 1991) or 3.5% every three 
minutes (Hiatt et al., 1988), while the speed is held constant until maximum claudication 
pain is reached.  Compared to the variable workload of a graded test, a constant-load 
treadmill exercise test consists of a single stage, which maintains workload throughout 
exercise testing.  Constant-load testing speed and grade range from 1.5 to 2 mph and 8% 
to 12% grade, respectively.  While a constant-load test may be easier to administer, it 
makes comparing results with a graded test difficult if not impossible.  Additionally, 
since a wide variety of PAD disease severity exists, it is difficult to justify using a single 
stage test for all individuals with PAD.  Regardless of the protocol followed, treadmill 
exercise tests generally focus on individual speed, distance, and in some cases, self-
reported exertion and/or symptom reporting on a numeric scale.           
Simultaneous Evaluation of PAD Symptoms and Calf Tissue Oxygenation 
 Previous PAD studies have combined qualitative and quantitative patient data to 
determine that individuals with PAD suffer from both disease-specific functional 
limitations (e.g., claudication), and more broadly from health-related abnormalities that 
negatively affect QOL (Hirsch, Halverson et al., 2001).  Additionally, functional 
impairment may lead to increased prevalence of depressive symptoms that have been 
observed in patients with PAD (Arseven, Guralnik, O'Brien, Liu, & McDermott, 2001).  
However, mixed methods PAD research has been limited since most of the available 
methods or techniques utilized to objectively assess the presence or severity of PAD are 
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performed mainly in static conditions (Manfredini et al., 2009).  Otherwise, dynamic 
evaluations, such as functional treadmill exercise tests, have been restricted to speed, 
distance, and self-reported exertion and/or symptom rating on a numeric scale.  
Simultaneously collecting subjective symptom reporting (i.e., symptom location and 
description) and objective data during dynamic exercise has the potential to provide new 
symptom locations and/or descriptors that are necessary to consistently and accurately 
detect PAD, thus expanding the currently accepted definition of ‘claudication.’  These 
additional descriptors could be incorporated into existing PAD questionnaires, which 
could enhance the sensitivity of these questionnaires, potentially leading to improved 
detection and treatment of PAD. 
 The role of near-infrared spectroscopy (NIRS).  A recently developed device, 
near-infrared spectroscopy (NIRS), allows for simple, non-invasive, objective study of 
muscle metabolism at rest and under dynamic and post-exercise conditions (Belardinelli, 
Barstow, Porszasz, & Wasserman, 1995; Ferrari, Mottola, & Quaresima, 2004; Mancini 
et al., 1994).  NIRS monitors the key pathophysiological determinant of PAD, oxygen 
delivery to the tissues themselves, as measured by tissue oxygen saturation (StO2).  It is 
designed to allow for an objective assessment of muscle blood flow and oxygenation 
level, enabling assessment of the mismatch between oxygen demand and delivery to 
tissues.  Thus far, NIRS has demonstrated moderate-to-high test-retest reliability 
(Miranda, Figoni, & Castellano, 2010; Miranda et al., 2012) and the degree of muscle 
deoxygenation in the legs correlates well with PAD severity (Manfredini et al., 2009).   
 Unlike the ABI, NIRS has the ability to indirectly measure blood flow.  While 
Doppler ultrasound has similar capabilities (Bernink, Lubbers, Barendsen, & van den 
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Berg, 1982), previous reports have demonstrated that femoral artery flow is not 
sufficiently reliable to assess tissue ischemia (Lewis, Psaila, Morgan, Davies, & 
Woodcock, 1990; Vardi & Nini, 2008).  Magnetic resonance angiography has been 
applied to evaluate PAD (Zatina et al., 1986), but clinical use is limited by high costs and 
lack of availability (Vardi & Nini, 2008).  NIRS on the other hand, has been shown to be 
an inexpensive, non-invasive, accurate, stable, and sensitive tool to study the interactions 
between oxygen delivery and utilization in human skeletal muscle (Wariar, Gaffke, 
Haller, & Bertocci, 2000).  Parameters measured with NIRS can establish PAD presence, 
severity, and response to treatment, and correlate well with ABI (Ferrari et al., 2004; 
Manfredini et al., 2009; Vardi & Nini, 2008). 
 How NIRS works. The electromagnetic spectrum is displayed in Figure 2.  It 
illustrates the range of all possible frequencies and wavelengths of electromagnetic 
radiation.  Regions of the spectrum are divided based on different interactions of 
electromagnetic radiation with matter.  For example, low-frequency, long radio waves 
enable the use of everyday devices such as televisions and mobile phones.  Whereas, 
higher-frequency, shorter waves are utilized in health care to perform x-rays and 
magnetic resonance imaging.  NIRS uses infrared light, specifically near-infrared 
wavelengths to provide information on changes in tissue oxygenation.  Higher-frequency, 
shorter-waves of visible light and ultraviolet light are almost completely absorbed by the 
skin, but near-infrared penetrates much deeper into biological tissues (Van Beekvelt, 
2002).   
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Figure 2.  The Electromagnetic Spectrum.  Adapted from http://lumenistics.com/what-is-
full-spectrum-lighting. 
 
 The near-infrared spectroscopy device used in this research, Artinis Medical 
Systems B.V., PortaMon™, generates near-infrared light at two wavelengths, 760 
nanometers (nm) and 850 nm, from three light emitting diodes (inter-optode distances of 
30, 35, and 40 mm between the receiver and each of the three diodes).  The PortaMon™ 
provides continuous wave NIRS by converting the changes in optical density using a 
modification of the Lambert-Beer Law and spatially resolved spectroscopy (Van 
Beekvelt, Van Engelen, Wevers, & Colier, 2002).  Figure 3 illustrates how the NIRS 
device works.  Near-infrared light penetrates the skin, subcutaneous fat layer, and muscle, 
and is either absorbed or scattered within the tissue.  The transmission of infrared light 
depends upon three properties: reflection, scattering, and absorption (Jobsis, 1977).  The 
light scattering can occur in any direction, but the light detected by the receiving optode 
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is thought to be curvilinear (Cui, Kumar, & Chance, 1991).  The receiving optode 
processes the color of the light that is reflected back and provides output related to tissue 
saturation.  A particular color arises when a molecule absorbs certain wavelengths of 
light and transmits or reflects others.   
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Figure 3.  Measuring tissue oxygenation with the Artinis, PortaMon™ near-infrared spectroscopy (NIRS) device.  Near-infrared light 
is transported into the tissue by three diodes, each emitting two wavelengths of light (760 and 850 nanometers (nm)), at inter-optode 
distances of 30, 35, and 40 millimeters (mm).  Penetration depth is limited to half the inter-optode distance (i.e., 15 to 20 mm).  The 
receiver processes the light reflected back and sends information about tissue oxygenation to a laptop computer via Bluetooth™ 
technology.        
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 A chromophore is the part of a molecule that is responsible for its color (Heller & 
McNaught, 2009). The chromophores that absorb near-infrared light in muscle tissue are 
mainly hemoglobin and myoglobin, and to a lesser extent cytochrome-c oxidase (Van 
Beekvelt, 2002).  Hemoglobin and myoglobin are both iron- and oxygen-binding 
proteins.  Hemoglobin transports oxygen in the blood, has the ability to carry four 
molecules of oxygen, and has a low affinity to oxygen (i.e., affinity gradually increases as 
oxygen concentration increases).  Myoglobin stores oxygen in the muscle, can only carry 
one oxygen molecule, and has a high affinity to oxygen, even in very low oxygen 
concentrations.  Cytochrome-c oxidase is a key enzyme in aerobic metabolism.  It is 
found in human mitochondria and converts one oxygen molecule into two molecules of 
water (Bairoch, 2000).  Concentrations of cytochrome-c oxidase are relatively low in 
muscle tissue, compared to hemoglobin and myoglobin (Van Beekvelt, 2002).  As a 
result, changes in cytochrome-c oxidase are lost within the larger and more obvious 
changes of hemoglobin and myoglobin.  Thus, cytochrome-c oxidase did not constitute a 
significant contribution to this study or to any research that utilizes NIRS technology.   
 Hemoglobin and myoglobin have identical spectral characteristics; therefore 
NIRS cannot distinguish between the two.  However, hemoglobin and myoglobin can be 
divided into two major forms:  oxyhemoglobin(O2Hb) / oxymyoglobin(O2Mb) and 
deoxyhemoglobin(HHb) / deoxymyoglobin(HMb).  Each form has different absorption 
spectra, so using more than one wavelength (the PortaMon™ uses two) allows for 
differentiation of oxygenated and deoxygenated forms of hemoglobin and myoglobin, 
which ultimately provides information about tissue oxygenation (Van Beekvelt, 2002).  
 The information NIRS provides.  NIRS provides information about local tissue 
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oxygen saturation (StO2) during dynamic and static states.  In clinical settings, a more 
familiar and commonly used device that measures oxygen saturation is a pulse oximeter.  
Regardless of the location of the sensor (e.g., fingertip or earlobe), it provides 
information about peripheral saturation of oxygen (SpO2).  While both devices provide 
continuous and immediate information about oxygen saturation in a non-invasive way, 
there are a few distinct differences.  Pulse oximetry is a systemic measure of the oxygen 
saturation of arterial blood, whereas NIRS is a local measure of oxygen saturation; in the 
tissues where the device is located (e.g., calf tissue oxygenation).  Additionally, pulse 
oximeters utilize light-emitting diode technology, sending a combination of visible light 
(specifically red light) and IR wavelengths into the tissue (Ferrari et al., 2004), but NIRS 
relies solely on near-infrared wavelengths.  NIRS measures will fluctuate based on 
changes in the local conditions of oxygen supply and consumption in the tissues; pulse 
oximetry will not.  Lastly, pulse oximetry requires a pulsatile flow, whereas NIRS does 
not.   
 There are four main measures reported by NIRS:  local tissue saturation index 
(TSI), oxygenated hemo/myoglobin (O2Hb/O2Mb), deoxygenated hemo/myoglobin 
(HHb/HMb), and total hemo/myoglobin (tHb/tMb).  TSI is expressed as a percentage 
based on time and reflects the average oxygen saturation of underlying muscle tissue.  
O2Hb/O2Mb, HHb/HMb, and tHb/tMb are reported as change from baseline, as 
measured in micromoles (μM).  In circumstances of total arterial occlusion, THb/TMb 
can be used as a measure of tissue blood volume.  In this paper, the hemoglobin 
abbreviations O2Hb, HHb, and tHb are used to simplify the text.  Note that when these 
abbreviations are used, it is implicitly implied that myoglobin is also being discussed.     
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 Experimental arterial occlusion.  Inflating a BP cuff to 80 millimeters of mercury 
(mmHg) above systolic pressure, blocks both venous outflow and arterial inflow, 
effectively eliminating systemic circulatory changes in the limb.  Without sufficient 
oxygenated blood, muscle metabolism will depend directly on the oxygen available in the 
local capillaries and muscle cells.  In this situation, NIRS illustrates a decrease in O2Hb, 
a concurrent increase in HHb, while tHb remains constant (see Figure 4).  With the 
release of arterial occlusion, a hyperemic response is often observed.  This is due to a 
rapid increase in blood volume, which supplies fresh O2Hb and quickly eliminates HHb.  
Using this method, it is possible to calculate oxygen consumption, re-oxygenation rate, 
and the half-recovery times of the signals during this type of controlled condition.   
Figure 4.  During arterial occlusion, NIRS displays a decrease in oxygenated hemoglobin 
(O2Hb) and a concurrent increase in deoxygenated hemoglobin (HHb), while total 
hemoglobin (tHb) remains constant.  During reperfusion, O2Hb and tHb increase, while 
HHb decreases.      
 
 Arterial insufficiency in patients with PAD during exercise.  The ability of NIRS 
to monitor changes in tissue oxygenation non-invasively and directly in the muscle makes 
it a powerful tool for studying PAD related ischemic changes.  In this population, NIRS 
technology can be used during exercise to objectively assess the degree to which the 
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oxygenated blood supply is being restricted in the calf muscle as a result of arterial 
narrowing and/or blockage (i.e., ischemia).  This can be compared with subjective 
symptom report to provide a more comprehensive description of the PAD symptom 
experience.    
Conceptual Framework 
 This study was guided by current literature related to PAD symptom experiences, 
PAD pathophysiology, and an understanding that variables such as demographic 
characteristics and comorbid conditions may confound the PAD symptom experience.  
Figure 5 presents the conceptual framework that guided this investigation and illustrates 
how a symptom can be classified as ischemic or non-ischemic in three phases: at rest, 
during exercise, and during recovery.  Individuals with PAD have arterial insufficiency.  
During exercise, arterial blood flow to the lower extremities cannot meet the oxygen 
demand of working muscles, leading to skeletal muscle ischemia and causing classic 
claudication and other lesser recognized symptoms.  At rest, prior to exercise, or shortly 
after activity ceases, blood flow is sufficient to prevent or relieve ischemic symptoms.  
However, some individuals report ‘atypical’ symptoms during exertion or report 
discomfort that continues beyond the typical recovery time (McDermott, Mehta, & 
Greenland, 1999; Olson & Treat-Jacobson, 2004).  It is unknown to what extent 
symptoms that fall outside the classic definition of claudication are ‘atypical’ 
presentations of ischemia-dependent symptoms versus ischemia-independent symptoms 
arising from other chronic conditions.  
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Figure 5.  The conceptual framework for the study illustrates how a symptom can be 
classified as ischemic or non-ischemic in three phases: at rest, during exercise, and during 
recovery.  
 
 To determine which symptoms are related to ischemic changes in skeletal muscle 
it is necessary to simultaneously measure subjective PAD symptom reporting and 
objective lower extremity tissue oxygenation during dynamic exercise.  Verbal report of 
symptoms (e.g., location, severity, and sensation) is uncomplicated and can be used to 
subjectively assess the PAD symptom experience.  As previously discussed, recently 
developed techniques, such as NIRS, allow for non-invasive measurement of objective 
changes in calf tissue oxygenation during exercise in individuals with PAD (e.g., 
treadmill walking) (Dolan et al., 2002; McDermott, Mehta, & Greenland, 1999; 
McDermott et al., 2001).  The physiologic data obtained with NIRS can be compared to 
the subjective symptoms reported to determine the relationship.  Both typical and 
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‘atypical’ symptoms that begin after the onset of ischemia, increase in intensity as 
ischemia worsens, and are relieved as ischemia improves, can be distinguished from 
symptoms that do not consistently change with ischemia. This will confirm the exclusion 
of symptoms not related to ischemia and provide support for broadening the definition of 
claudication to include ‘atypical’ ischemia–dependent symptoms.   
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    Chapter 3: Research Method 
Design  
 This was a descriptive, exploratory, longitudinal study designed to 
comprehensively examine the symptom experience of older and younger men and women 
with PAD.  A mixed methods approach, combining qualitative and quantitative 
techniques, was utilized to fully capture the subjective and objective components of the 
PAD symptom experience.  The subjective components consisted of verbal symptom 
report of PAD symptoms at rest and during exercise, while physiologic data related to 
tissue oxygenation during exercise and recovery constituted the objective component.  
Gaining a more comprehensive understanding of the PAD symptom experience is a 
necessary first step towards improving the timeliness and accuracy of diagnosis and 
leading to implementation of the proper treatment to minimize the progression and 
complications associated with this debilitating disease.   
Specific Aims 
 The specific aims of this study were to: 
 1. Understand the symptom experience of older and younger men and women  
  with PAD through in-depth qualitative interviews.   
 2. Simultaneously evaluate calf tissue oxygenation and the self-reported   
  symptoms experienced by older and younger men and women with PAD  
  during  treadmill exercise and throughout recovery. 
Parent Study:  Exercise Training to Reduce Claudication (EXERT) 
 All study participants were recruited from the EXercise Training to Reduce 
Claudication: Arm ERgometry versus Treadmill Walking (EXERT) study.  This study is 
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funded by the National Heart, Lung, and Blood Institute (NHLB) (R01 HL 090854-03, 
PI: Dr. Diane Treat-Jacobson), and examines the efficacy of two forms of supervised 
exercise compared to the usual care provided by a physician for the treatment of PAD.  
Specially, the EXERT study compares aerobic arm exercise and treadmill walking, to 
determine which, if any, form of supervised exercise reduces the symptoms of 
claudication and improves the walking ability in patients with PAD.  Study procedures 
include a screening visit, baseline testing (cardiac exercise stress test, confirmatory ABI, 
etc.), supervised exercise training three times per week or a weekly control visit, and 
follow-up testing at six week increments, until 24 weeks of study participation has been 
completed.   
Pre-Testing 
 Prior to full scale introduction of the main study, two small studies were planned 
and carried out with the goal of positively informing the recruitment, design, procedures, 
and measurements of the main study.  Qualitative and quantitative components were 
assessed on separate occasions.       
 External qualitative pilot study.  A formal and independent preliminary trial of 
the qualitative component of the study was conducted with four volunteers diagnosed 
with PAD and experiencing exercise-limiting symptoms.  The main goals of the pilot 
study were to determine: 1) the feasibility of recruiting and consenting participants, 2) the 
integrity of the qualitative study protocol, and 3) the comprehensiveness and 
appropriateness of the semi-structured interview (see Appendix A) and the PAD 
symptom questionnaire (see Appendix B).   The primary research question was ‘How do 
individuals with PAD describe the symptom experience?’    
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   Design.  The pilot study was a naturalistic study, in which the researcher observed 
and recorded the participants’ descriptions of the PAD symptom experience while 
interfering with participants as little as possible.  To date, no studies have attempted to 
extract symptom descriptors through a combination of a semi-structured interview and 
completion of a PAD symptom questionnaire, and the recent research demonstrated a 
need for a more thorough description of PAD symptoms. 
 A semi-structured, face-to-face, descriptive interview was selected to explore the 
attitudes, beliefs, and perceptions of individuals diagnosed with PAD.  Data obtained 
from interviews were particularly well-suited to answer the research question of interest 
since interviews allowed for a detailed account of the PAD symptom experience in a 
participant’s own words.  Each interview question was designed to be clear, open-ended, 
sensitive, neutral, and targeted towards the participants’ PAD symptom experience, with 
a particular focus on symptoms during exercise.   
 The PAD symptom questionnaire allowed for a visual representation of the 
patients’ symptom location and description; it also served to verify congruence with 
symptom information that was provided during the interview.  It was designed to be a 
comprehensive assessment of all the symptoms a participant experienced during exercise 
and rest, related or unrelated to PAD.  The questionnaire utilized a body diagram and 
color coding to differentiate the location and sensation of each symptom, and to follow its 
course from rest to onset and time to relief.  The primary goal was for participants to first 
describe all of their symptoms in detail, and then target symptoms they believed to be 
directly related to their PAD.    
 Sample.  The population of interest was adults with a diagnosis of PAD who were 
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experiencing exercise-limiting symptoms.  Inclusion criteria were: (a) adults (18+ years), 
(b) people with a diagnosis of PAD, (c) PAD symptoms while exercising, and (d) able to 
read, write, and speak the English language.  Exclusion criteria: (a) children under the 
age of 18.  Participants were not included or excluded based on race, gender, or ethnicity.   
      Ethical considerations.  In accordance with the regulations of the 1996 Health 
Insurance Portability and Accountability Act (HIPAA), and as stipulated by the 
University of Minnesota Institutional Review Board (IRB), the PI was not allowed to 
make the initial contact with potential participants.  The EXERT Study Research 
Coordinator obtained permission from interested individuals at the initial EXERT study 
screening visit to be contacted about this study.   
 If an individual agreed to be contacted, the PI was provided with the potential 
participant’s contact information.  Individuals were then contacted by the PI via 
telephone and provided with more information about the study, prior to asking about their 
willingness to participate.  For individuals who expressed an interest in participation, a 
time was arranged for the investigator and the individual to meet and proceed as 
appropriate.  An information sheet for research was utilized to ensure participants were 
fully aware of the risks and benefits, as well as the burdens of participation (see 
Appendix C).  If after being provided with more information regarding the study, 
individuals did not wish to participate, no further action was taken by the PI.  The 
individuals’ information was then shredded to protect confidentiality. 
 The participants who agreed to participate were each assigned a code name.  Code 
names were used on all questionnaires, field notes, and audio tapes.  Participant names 
with code names were only accessible by the PI and stored in a locked filing cabinet 
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separate from the data with code names.   
 Personal preconceptions.  Since the PI had previously worked with PAD patients 
in the screening, exercise training, and research testing capacity as a graduate assistant on 
the EXERT study, personal preconceptions existed.  The PI had worked with individuals 
with known PAD who had provided PAD symptom descriptors that were not consistent 
with the commonly recognized and hallmark symptom of PAD, classic claudication.  
Therefore, the researcher had a preconceived notion that other valid PAD symptom 
descriptors beyond what was currently being utilized in practice might exist.  
Furthermore, the PI had witnessed an apparent disassociation in the symptom experience 
of men versus women.  For both aforementioned reasons, the PI decided to undertake this 
qualitative pilot study to explore this area in a more detailed and scientific manner.  
Despite the PI’s preconceptions, every attempt was made during data collection and 
analysis to set aside these preconceived notions to see what naturally emerged from the 
data.   
 Data collection procedures.  After obtaining IRB approval from the University of 
Minnesota (see Appendix D), participant recruitment began.  A total of four participants 
were recruited through purposive sampling.  All of the study meetings and activities took 
place on the second floor of the Delaware Clinical Research Unit in room 250, located on 
the University of Minnesota, Minneapolis campus.  To reduce burden, meetings were 
scheduled to take place immediately following supervised exercise training for the 
EXERT study.  The PI met with each participant one time to complete a semi-structured 
interview and the PAD symptom questionnaire (see Appendices A and B).  A printed 
copy of the questionnaire and the information sheet for research were provided prior to 
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the beginning of the visit.   
 All participant responses during the interview and throughout the completion of 
the PAD symptom questionnaire were audio-recorded.  Each interview lasted on average, 
30 to 45 minutes.  Two recorders, a primary and a backup, were started prior to the 
interview taking place, but after participants viewed the information sheet for research 
and agreed to participate.  Both recorders were placed to the side of the table in an 
attempt to reduce measurement reactivity.  However, all participants were informed of 
the audio recording verbally and in writing prior to enrolling in the study. 
 Data analysis.  Conventional content analysis procedures were used to analyze 
the descriptive data gathered during participant interviews (Hsieh & Shannon, 2005; Van 
Manen, 1990).  Initially, the recording unit of analysis was defined by the researcher as 
single words used by the study participants to describe the PAD symptom experience 
(i.e., symptom descriptors).  However, as the analysis began, coding for thematic units 
(Henri, 2012; Van Manen, 1990), also referred to as dynamic units, seemed more 
appropriate to recognize each individual’s PAD symptom experience, as well as to 
uncover a comprehensive group of thematic units in order to understand the phenomenon 
of interest as a whole.  Data were coded for the existence of any descriptors of the PAD 
symptom experience, as opposed to using frequency to determine the validity of a select 
few descriptors.  This was done largely because of a limited sample size (n=4).  
Additional details related to the content analysis of data are detailed in the data analysis 
section under aim one of the main study.    
 Results.  The final sample consisted of four participants afflicted with PAD, two 
males and two females, aged 48 to 79 years.  The following themes were extracted from 
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the participant transcripts:  ache, heavy, weak, Charley horse, cramp, sharp, tight, numb, 
shin involvement, quick dissipation, limiting/adjusting, need for frequent sitting, 
progressive, indescribable, unilateral symptoms, and asymptomatic.   
 Impact on main study.  The pilot study enabled preliminary testing of the 
feasibility of recruiting and consenting participants for the main study.  Based on the 
results of the pilot, the questions on the semi-structured interview form and the PAD 
symptom questionnaire remained unchanged.  Both measurements appeared to be 
comprehensive and appropriate for answering the research question.  However, due to the 
difficulty participants experienced in independently identifying accurate symptom 
locations and following a consistent color coding system on the questionnaire, it was 
decided that the researcher would complete the questionnaire in the main study on the 
behalf of each participant.  This would enhance consistency in reporting and allow for 
more clear comparisons amongst responses in the main study.  It is important to note that 
the focus of the pilot was on testing the administration of the questionnaire, as opposed to 
testing its validity and reliability.  Based on the pilot study results, no other qualitative 
protocol changes were deemed necessary.         
 Initially, a purely qualitative study design was selected and this external 
qualitative pilot study was conducted based on this design.  However, results from the 
pilot study confirmed the results of recently published research citing the existence of 
PAD symptom descriptors beyond those currently recognized in clinical practice 
(McDermott, Mehta, & Greenland, 1999; Tomczyk & Treat-Jacobson, 2009; Treat-
Jacobson et al., 2002).  Despite the recognition of ‘atypical’ ischemia-dependent 
symptoms in the literature, it appeared that relying solely on subjective participant PAD 
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symptom report, while excluding objective physiologic measurement of calf tissue 
oxygenation, would fail to validate any ischemia-dependent symptoms reported, thus still 
limiting the current understanding of the PAD symptom experience. After further 
consideration, a decision was made to incorporate subjective and objective elements into 
the design to comprehensively examine the PAD symptom experience.   
 NIRS feasibility.  Although the information provided by the NIRS feasibility 
evaluation was just as important as the external qualitative pilot study and it was designed 
with similar goals in mind, it was a much less formal evaluation.  The primary goals of 
the NIRS feasibility evaluation were to: 1) assess recently developed quantitative study 
procedures, specifically those focused on NIRS measurement and data acquisition 
following the testing protocol, and 2) refine the application and securing of the NIRS 
device on individual calf muscles, as well as accurately operate the NIRS device to 
ensure effective and adequate data collection during static and dynamic states.     
 Over a two day period, five young, healthy male and female students volunteered 
to participate in the feasibility evaluation.  The evaluation began by covering the NIRS 
device with a thin and transparent layer of clear plastic wrap and placing the device over 
the largest part of the right gastrocnemius muscle (i.e., calf) of the first participant (based 
on the calf circumference obtained with a tape measure while resting in a seated 
position).  The device was secured with 3M™ Coban™ self-adherent wrap, and resting 
baseline values were obtained (i.e., O2Hb, HHb, tHb, TSI, and seated BP).  Next, a large 
adult BP cuff was placed around the upper portion of the right leg.  Participants were then 
asked to begin walking at a slow pace on the treadmill (generally, 2.0 mph, 0% grade).  
During treadmill walking, arterial occlusion was simulated by inflating the upper leg BP 
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cuff to 80 mmHg above the systolic arm pressure value obtained at rest.  Participants 
were asked to numerically rate their discomfort on the NRS (Figure 1) and to provide 
descriptions of the symptom(s) location and sensation.  Treadmill speed and grade were 
increased as tolerated, on an individual basis, in order for each participant to reach 
maximal discomfort (i.e., 5 out of 5 on the NRS).  Testing was stopped when an 
individual reported a rating of 5 on the NRS.  NIRS measurement continued until each 
participant reached full recovery (i.e., a rating of 0 out of 5 on the NRS).   
 All five participants reported symptoms consistent with exercise-induced 
ischemia (e.g., cramp, heavy, tired), that worsened as exercise continued and eventually 
required cessation of physical activity to achieve symptom relief.  The results observed 
were expected to be similar to those of individuals with PAD who were invited to 
participate in the main study.  No major changes to the main study protocol occurred 
based on the feasibility evaluation.  However, to increase the accuracy and completeness 
of descriptive symptom reporting and the timing of NRS ratings, it was decided that the 
treadmill tests for all of the participants in the main study would be audio-recorded. 
Although this evaluation didn’t necessitate major changes in the main study protocol, this 
evaluation increased the PI’s familiarity with the NIRS device to obtain values, mark 
events, and export data, as well as providing exposure to the complexity of 
simultaneously recording participant data and ensuring safety during treadmill exercise.        
Study Population 
 Setting.  Study participants were recruited from the previously described EXERT 
study.  EXERT study staff described this research study to current and future EXERT 
participants.  If a participant expressed interest in this study, the EXERT study staff had 
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the individual complete a study interest form that provided the PI with basic contact 
information.  This information was then given to the PI, at which time the individual was 
contacted and a more detailed study explanation was provided.   
 Additionally, a recruitment letter that was approved by the University of 
Minnesota IRB was sent to all previous EXERT study participants (see Appendices E and 
F).  This letter provided individuals with a brief overview of the proposed study and 
introduced them to potential participation in a non-coercive manner.   
 Sample size.  Given the exploratory nature of the study, some measures and their 
associations had not been previously studied.  Therefore, there were no reliable data on 
which to base a power analysis. The data from this study will allow for these estimates 
and enable conduction of a proper power analysis in future studies.  For the exercise 
testing study component, 40 participants was determined to be a feasible number to 
recruit in the time allotted, and a sufficient number of participants to get estimates of 
effects and a sense of the variability within measurements and between subjects. Sample 
size guidelines for qualitative research were used to provide an estimate of an appropriate 
sample size for the interview component of the study (Guba & Lincoln, 1994).    
 Sample.  It was anticipated that 20 participants would complete the semi-
structured qualitative interview with the anticipation that data saturation would be 
achieved with this number.  The other 20 participants were to complete an abbreviated 
symptom interview in an effort to improve symptom reporting during exercise testing. 
Any English speaking individual aged 21 years or older, with an ABI ≤ 0.90, reporting 
exercise-limiting claudication or ischemia-related symptoms, and deemed safe to exercise 
was considered as a potential participant and screened for eligibility.  See Table 2 for the 
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full list of study inclusion and exclusion criteria.     
Table 2 
Study Inclusion and Exclusion Criteria 
Inclusion Criteria                     Exclusion Criteria 
● ≥ 21 years of age 
● English speaking  
● Exercise limiting claudication  
● ABI of ≤ 0.90 
● Ability to provide informed consent 
● Cleared for exercise via exercise or     
   pharmacological stress test within one year of  
   study enrollment 
● Uncontrolled hypertension (>200 SBP  
    mmHg and/or DBP >100 mmHg) 
● Vascular surgery/procedure within three      
    months of study enrollment 
● Exercise capacity limited by health  
   problems other than claudication (e.g.  
   angina, severe arthritis, or extreme  
   dyspnea on exertion) 
Note.  ABI=ankle-brachial index; SBP=systolic blood pressure; mmHg=millimeters of 
mercury; DBP=diastolic blood pressure.     
 
Variables and Measurements 
 Demographic and medical information.  Data obtained from the medical record 
for this study included primary medical diagnosis, comorbid conditions, previous 
procedures and outcomes related to exercise and PAD, previous ABI values, cardiac 
stress test results, and medications.  Additional data, including age, gender, education, 
ethnicity, and employment were collected with a standard demographic form (see 
Appendix G).  During the consenting visit, participant medications were carefully 
reviewed to ensure that participants were not taking any medications that would be 
affected by exercise (Appendix H).       
 Ankle-brachial index (ABI).  The ABI, a ratio between the ankle and arm 
systolic BP, was utilized to confirm the presence of PAD and to determine disease 
severity at the time of study enrollment.  An ABI ≤ 0.90 is diagnostic of PAD (Aboyans 
et al., 2012; Albert et al., 2013; Coutinho et al., 2011; Tendera et al., 2011).  Participants 
rested quietly in a supine position for 10 minutes prior to the PI obtaining the ABI 
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according to standard procedures (see Appendix I) (Grenon, Gagnon, & Hsiang, 2009; 
Leng et al., 1996; Stoffers et al., 1996). 
 Treadmill familiarization.  This was completed prior to exercise testing to 
ensure participant safety and adequate understanding of treadmill exercise testing 
procedures, and to determine the appropriate speed and grade for exercise testing.  The 
speed during treadmill familiarization began at 1.5 mph at a 0% grade.  Both speed and 
grade were adjusted as necessary to induce ischemia-related discomfort within 3 minutes 
of treadmill walking (see Appendix J).   
 Treadmill test.  The starting speed and grade for treadmill testing was 
individualized and determined by the results of the treadmill familiarization.  Speed and 
grade progression was also individualized to prevent high functioning patients from 
stopping the test due to symptoms other than claudication and to prevent provoking 
discomfort too early in more severely limited participants, which would have potentially 
condensed symptom reporting and prevented the collection of meaningful data.  The 
expected starting speed and grade for most participants was 2 mph and 0% grade, with an 
increase in the grade to 2% at two minutes.  Thereafter, grade was increased by 1% every 
two minutes, maintaining a speed of 2 mph.  If participants continued walking, the speed 
was increased to 2.5 mph at 16 minutes.     
 Subjective symptom reporting.  To gain a better understanding of individual 
perceptions of PAD symptoms, participants were asked to report symptoms during static 
(i.e., seated interview) and dynamic (i.e., treadmill walking) conditions.    
 Semi-structured interview.  Prior to exercise testing, participants were prompted 
to describe all of the symptoms they experience at rest and with exercise, related or 
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unrelated to PAD (see Appendix A for the interview guide).  Interviews were recorded 
and conducted using methods established during the PI’s pilot study. Field notes were be 
taken by the PI as necessary, but kept to a minimum to avoid participant distraction.   
 There was a potential risk that participants would experience emotional distress or 
anxiety while discussing the symptom experience during the interview.  To minimize this 
potential risk, prior to the interview, participants were reminded that their participation 
was voluntary and they could withdraw at any time for any reason without suffering any 
adverse consequences.   
 To minimize response burden, only questions directly related to the study aims 
were utilized during participant interviews.  Additionally, within the timeframe between 
participant consenting and exercise testing, exact timing of interviews was left up to the 
discretion of the individual participant.  This allowed the participant to complete the 
interview and exercise tests when they were least burdensome and according to 
individual stamina.   
 Symptom descriptors.  During the interview, each participant provided a 
comprehensive description of the symptom(s) they experienced during exercise.  
Participants were encouraged to provide the location, sensation, and estimated duration of 
each symptom reported.  Additionally, symptoms were described on the PAD symptom 
questionnaire (Appendix B).  Again, descriptions included location, sensation, and 
duration, for symptoms thought to be related to PAD, as well as those thought to be 
unassociated with the disease.   
 Numeric rating scale (NRS). Participant symptom rating was measured at the 
onset of symptoms and throughout symptom progression during exercise, as well as 
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during recovery, using the NRS (Figure 1).  On this scale, a rating of 0 corresponds to no 
discomfort; whereas a rating of 5 is the maximum ischemia-related discomfort 
experienced.  
 Objective measurement of calf tissue oxygenation.  Calf tissue oxygenation 
was objectively measured via near-infrared spectroscopy (NIRS).  As mentioned 
previously, the PortaMon™ NIRS device provided baseline and continuous-wave 
measurement of tissue oxygenation in the exercising calf muscle to determine the degree 
of calf tissue ischemia during exercise and recovery.  The device was placed, secured, 
and operated using methods established during the NIRS feasibility evaluation.  Instead 
of placing the device on the right leg, as was done with the healthy participants in the 
feasibility evaluation, the device was placed on the calf muscle of the more symptomatic 
leg as reported by each study participant, regardless of disease severity (which was 
determined by the confirmatory ABI).  If participants reported equal symptom severity in 
both legs, the device was placed on the leg with the higher disease severity (i.e., lower 
ABI).  Equilibration, as well as baseline and continuous measurements were obtained 
following methods consistent with previous PAD NIRS studies (Gardner et al., 2009; 
Hamaoka, McCully, Quaresima, Yamamoto, & Chance, 2007; Manfredini et al., 2009; 
Van Beekvelt, Colier, Wevers, & Van Engelen, 2001) and the PI’s previously conducted 
feasibility evaluation.   
 Safety measures.  Exercise testing carries a small risk (1 in 10,000) of heart 
attack or death.  Potential risks to participants included exercise related risks such as a 
change in BP, heart rate (HR), and/or rhythm.  Other potential risks included physical 
discomfort from inflation of the BP cuff, disclosure of protected health information, and 
48 
 
response burden.  The likelihood of potential risks was believed to be minimal and the 
following procedures were in place to decrease the potential risks that have been 
described.   
 Blood pressure (BP).  BP was taken pre- and post-exercise, while seated and 
standing, as a safety measure before, during, and after exercise.  During the evaluation of 
BP function, if a participant felt that the discomfort from the inflation of the BP cuff was 
more than they could tolerate, they were instructed to inform the researcher and their 
study participation would be terminated for safety reasons.   
 Heart rate (HR).  A Polar™ HR monitor strap was placed across the participants’ 
chest and a baseline HR was obtained.  Participants were informed of their maximal HR 
based on the stress test results provided during study enrollment.  HR was monitored 
continuously during exercise and recovery.  If HR exceeded 85% of the maximum HR 
achieved during cardiac or pharmacological stress testing, the treadmill speed and grade 
were to be reduced.  If HR remained elevated, the exercise test would be stopped.   
 Blood glucose.  Any individual with a confirmed diagnosis of DM, type 1 or 2, 
received blood glucose testing before and after exercise (obtained via glucometer).  If 
blood sugar levels were low, participants were provided with an appropriate snack and 
testing continued until the participants blood glucose returned to a normal level to ensure 
their safety after completing the study visit. 
Procedure 
 After obtaining informed consent and HIPAA authorization (see Appendices K 
and L), data were collected from each participant’s medical record. Participants then 
completed the treadmill familiarization.  Next, participants verified their medical record, 
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filled out the demographic form, and completed the semi-structured interview.  Following 
the completion of these procedures, the 10 minute rest period for the baseline ABI was 
initiated.  After 10 minutes of rest, the ABI was obtained, recorded, and reported to the 
participant. The Polar™ HR monitor was placed around the participant’s chest and the 
baseline HR was obtained.  Next, the NIRS device was covered with a thin and 
transparent layer of clear plastic wrap to protect it from perspiration and placed on the 
inner aspect of the appropriate calf muscle at the area of largest circumference (consistent 
with the pilot study, the largest circumference was determined prior to testing with a tape 
measure while the participant rested in a seated position with both feet flat on the floor).  
The device was secured with 3M™ Coban™ self-adherent wrap and paired via Bluetooth 
with the study dedicated laptop computer.  The participant was asked to remain in a 
seated position while baseline values (e.g., O2Hb, HHb, tHb, TSI, HR, and seated BP) 
were obtained.  During this time, a repeated explanation of study procedures was 
provided and participants were offered another opportunity to ask any study related 
questions prior to the start of exercise testing.     
 Each treadmill test was started at the speed and grade that was determined during 
the treadmill familiarization.  Participants were asked to descriptively (e.g., left calf ache) 
and numerically (on the NRS) report the onset of symptoms (e.g., 1 out of 5) and the 
progression of symptom intensity, at whole integers on the NRS, until the maximum 
discomfort level was achieved (i.e., 5 out of 5 on the NRS).  Symptom report was 
recorded on a data collection form (see Appendix M), as well as audio-recorded for the 
purposes of data verification.  After reaching a rating of 5 on the NRS, the treadmill 
speed and grade were reduced slowly until the participant was able to safely stop walking 
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on the treadmill.  At that point, they were assisted off of the treadmill and into a seated, 
resting position in a chair.   
 At the beginning of the recovery period, post-exercise BP and HR were obtained 
and recorded on the data collection form.  Throughout recovery, subjective (e.g., 
symptom descriptions and ratings on the NRS) and objective (e.g., NIRS measures) data 
collection continued.  Full recovery was reached when participants reported a rating of 0 
on the NRS, and HR and BP returned to or fell below baseline values.        
 Two additional exercise tests were performed during the same session, following 
the same procedures as the first test.  During the second and third exercise tests, 
participants again reported the onset and acceleration of symptoms, in addition to 
providing verbal descriptors of their symptoms throughout exercise.  To ensure safety, 
continuous HR monitoring and periodic BP monitoring continued throughout the 
remainder of the study visit.      
Ethical Considerations  
 Protection against potential risks.  Because of the risks associated with exercise 
testing, several procedures were in place to minimize the risks to study participants.  
These procedures are described in the safety measures section.     
 Data management and security.  Consistent with the external qualitative pilot 
study, numeric codes were used on all data collection forms and de-identification was 
ensured.  Participant names with numeric codes were kept in a locked cabinet separate 
from the data with numeric codes and remains only accessible by the PI.  All study data 
were kept in a secured locked file cabinet in the PI’s office.  Electronic databases were 
password protected and stored on a secure desktop computer.  A codebook was 
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developed and revised for all of the study procedures and variables.  The PI was solely 
responsible for the storage, entry, auditing, and analysis of all data.   
Data Analysis 
 Data were collected during semi-structured interviews, and during the resting, 
exercise, and recovery phases of three consecutive treadmill tests with adequate rest 
periods in between.  The data were analyzed using content analysis, descriptive statistics, 
graphing individual growth trajectories, and multi-level modeling (MLM).  Lastly, the 
data were evaluated as a whole to provide a more comprehensive understanding of the 
PAD symptom experience.  SPSS version 21 was used for descriptive statistics, 
SigmaPlot version 10.0 was used to graph individual growth trajectories, and R version 
2.15.2 was used for estimating exercise and recovery models over time. 
 Aim 1:  Content analysis of the PAD symptom experience.  The semi-
structured interview transcripts were analyzed using qualitative content analysis, which is 
the interpretation of data through the systematic identification of patterns or themes 
(Hsieh & Shannon, 2005).  This coding method provides simplification and organization 
of large amounts of text (Holsti, 1969) in order to discover meaningful patterns that are 
descriptive of a particular phenomenon (Auerbach & Silverstein, 2003; Van Manen, 
1990).  The analysis procedures followed were consistent with conventional content 
analysis guidelines (Hsieh & Shannon, 2005; Van Manen, 1990), and were identical to 
those utilized when analyzing the transcripts of the previously mentioned external 
qualitative pilot study.  The recording unit of analysis was dynamic units, also referred to 
as thematic units (Henri, 2012; Van Manen, 1990).  Consistent with the analysis of the 
pilot study data, all descriptions of the PAD symptom experience were coded, regardless 
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of their frequency.     
 Transcripts were generated from the audio taped interviews.  Each transcript was 
reviewed three times for verification of authenticity and to capture any emotional content 
in the recording that was not evident in the written transcripts.  Transcript review was 
followed by preliminary analysis.  This consisted of reading through every transcript 
once to understand each interview in its entirety, writing memos throughout as necessary 
to note emerging themes.  The primary goal of the preliminary analysis was to get a sense 
of the whole and understand the essential features of each interview (Sandelowski, 1995).   
 Next, the emerging codes were listed and additional memos were taken 
throughout the duration of analysis.  Connections between the codes were identified, and 
codes were clustered together as necessary to capture the essence of the PAD symptom 
experience.  The final result was multiple categories that reflected topics appearing in all 
of the data.  Verbatim quotes representative of each theme were extracted from the 
transcripts, as appropriate.  The content of each category was analyzed to ensure that 
there were no subcategories that could be merged into a higher category.  Lastly, 
descriptive statistics were calculated as appropriate to analyze the data for the consistency 
of symptom descriptors amongst age group and gender.    
 Reliability.  According to Lederman (1991), there are three types of reliability 
relevant to content analysis:  stability, reproducibility, and accuracy.  Stability and 
reproducibility were addressed through the use of two human coders with experience in 
qualitative research methods.  The first coder was the PI and the second coder was Dr. 
Cynthia Peden-McAlpine, an expert in qualitative research methodology who reviewed 
the transcripts and verified the codes.  Intercoder reliability was further increased by 
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providing the second coder with the PI’s content analysis steps with ambiguous words 
being clearly and consistently defined throughout, in addition to providing memos and 
field notes that detailed reactions, biases, and thought processes throughout data 
collection and analysis. 
 Accuracy was assessed by test coding pieces of text extracted from the transcripts.  
This aspect of rigor is reached when the investigator can provide a full range of lived 
experiences and fully capture the phenomenon.  The PI used memoing, as well as written 
and spoken data while performing content analysis to gain a comprehensive 
understanding of the PAD symptom experience.  Another method that increased data 
accuracy was human coding, as opposed to relying on a computer to identify, code, and 
cluster the emerging themes.  Computer content analysis may be superior to human 
coding in large projects or in coding that focuses on analyzing specific words or verbatim 
phrases (Popping, 2000).  However, in this research, computer coding would not have 
provided specific detail on how final codes were decided upon, as well as specify the 
steps involved in the process; which gives further support to human coding and recording 
memos.   
 Validity.  Validity of the content analysis was assessed through confirmability and 
transferability, also referred to as generalizability.     
 Aim Two:  Modeling the PAD symptom experience.  Multilevel modeling 
(MLM) was used to determine:  1) how TSI changed from baseline to onset, during the 
progression of symptoms, and during recovery, and, 2) whether characteristics such as 
gender, age, and disease severity were related to particular patterns of change in TSI over 
time.  The first component is descriptive and characterizes each individual’s pattern of 
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change over time (Singer & Willett, 2003).  This question was addressed through 
graphing individual growth trajectories to examine how TSI changed over time.  The 
second question is relational and examines the associations between predictors and 
patterns of change (Singer & Willett, 2003).  The second question was addressed by 
examining groups of smoothed individual growth trajectories for similarities and 
differences and utilizing MLM to estimate the associations between predictors and 
particular individual patterns of change during the exercise and recovery phases.   
 Individual graphical trajectories.  Individual patterns of change were explored by 
graphing the trajectories of TSI and discomfort ratings throughout the exercise and 
recovery phases of three consecutive treadmill tests for each participant.  These graphs 
enabled the selection of a functional form by assessing the intra-individual variation in 
the outcome variable (i.e., TSI) over time.  Graphs were smoothed via loess and 
comparisons were made between groups, with a particular focus on age and gender.             
 Multilevel model for change. Building a multi-level model allowed for 
examining the associations between predictors and patterns of change.  Specifically, 
MLM characterized change within individuals (level-1) and between individuals (level-2) 
over time.  Each participant completed three treadmill tests, which created multiple 
waves of data (i.e., repeated measures).  Repeated measures increased the flexibility for 
MLM with less restrictive assumptions compared to two wave studies (Singer & Willett, 
2003).     
 Data were organized in a person-level data set and structured hierarchically; 
repeated observations were nested within individuals.  The outcome variable was TSI, 
expressed as a percentage and recorded continuously over time.  Individual level 
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predictors included baseline TSI, exercise time, recovery time, exercise rating, recovery 
rating, disease severity as measured by ABI, age, body mass index (BMI), gender, race, 
smoking status, and the presence of comorbid conditions such as DM and neuropathy.      
 Unconditional means model.  The unconditional means model (equations 2 
through 4), tested two null hypotheses: (1) no change over time (i.e., within-person 
variation), and (2) no variation between participants (i.e., between-person variation).  In 
other words, this model tested whether there was sufficient variation in the outcome 
variable, TSI, to warrant further analyses.  If TSI did not change significantly over time 
within individuals and variation in TSI did not significantly vary from individual to 
individual, no further analysis would be necessary.  However, it was expected that there 
would be sufficient variation, at least between-person variation, thus a more complex 
model (introducing predictors) would be required to explain the intra- and inter-
individual change in TSI over time.     
 
Level-1 model: 
 үij = π0i + ε ij        [2] 
 
Level-2 model: 
 π0i = γ00 + ζ0i         [3] 
үij = tissue saturation index (TSI) for participant i at time j 
π0i = true initial status of individual i when time j = 0   
ε ij = level-1 (within-person) residual for individual i at time j, assuming ε ij ῀ N (0, σ2/ ε)   
γ00 = grand mean TSI across individuals and occasions 
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ζ0i = person specific mean for individual i at time j = 0, assuming ζ0i ῀ N (0, σ2/0)           
N = normal distribution    
σ2/ ε = within-person variance 
σ2/0 = between-person variance 
 
The composite model:  
 үij = γ00 + ζ0i  + εij        [4] 
 
 Unconditional growth model.  The unconditional growth model (equations 5 
through 8), introduced the predictor, TIME, into the level-1 sub-model.  Variation in this 
model was partitioned across individuals and time.  This model estimated how much 
variation in TSI was attributable to linear TIME.  However, it was expected that sufficient 
variation would remain after accounting for TIME, meaning that a conditional growth 
model that includes time-invariant level-2 predictors would be warranted.  This model 
served as a baseline model for change over time.     
 
Level-1 model: 
 үij = π0i + π1iTIMEij  + εij     [5] 
 
Level-2 model: 
 π0i = γ00 + ζ0i       [6]    
 π1i= γ10 + ζ1i       [7] 
үij = tissue saturation index (TSI) for participant i at time j 
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π0i = true initial status of individual i when time j = 0   
π1i TIMEij = true rate of change per unit of TIME (second) for individual i  
εij = portion of individuals i’s TSI unexplained on occasion j, assuming εij ῀ N (0, σ2/ε)   
γ00 = population average initial status when time j = 0 
ζ0i = level-2 residuals for individual i at time j = 0, assuming ζ0i ῀ N (0, σ2/0)           
γ10 = population average true rate of change    
ζ1i = level-2 residuals of individual i from the average rate of change  
N = normal distribution    
σ2/ε = within-person variance 
σ2/0 = between-person variance 
 
The combined equation is: 
 үij = γ00 + γ10 TIMEij + [ζ0i + ζ1i TIMEij  + εij]    [8] 
  
 Conditional growth model.  The conditional growth model introduced level-2 
predictors that had the potential to explain some of the variation in TSI over time.  With 
MLM, two types of effects can be modeled, fixed effects and variance components (also 
referred to as random effects).  The following equation [9] illustrates the full mixed 
model for the change in TSI during exercise based on multiple individual-level 
predictors:     
 үije = γ00 + γ01ExerciseTimeij + γ02BaselineTSIij +   [9] 
        γ03ExerciseRatingj + γ04ABIj + γ05Agei +  
                   γ06BMIj + γ07Diabetesj + γ08Genderj + 
58 
 
        γ09Neuropathyj + γ010Racej + γ011SmokingStatusj +  
        [ζ0i + ζ1i TIMEij  + εij]    
үije = tissue saturation index (TSI) for participant i at time j during exercise e 
γ00 = population average initial status when time j = 0  
γ01ExerciseTimeij = individual intercept based on exercise time of individual i at time j   
γ02BaselineTSIij = individual intercept based on baseline TSI of individual i at time j 
γ03ExerciseRatingj = mean intercept for group based on exercise rating 
γ04ABIj = mean intercept for group based on ABI category 
γ05Agei = individual intercept based on the age of individual i 
γ06BMIj = mean intercept for group based on BMI category 
γ07Diabetesj = mean intercept for group based on diagnosis of diabetes 
γ08Genderj = mean intercept for group based on gender 
γ09Neuropathyj = mean intercept for group based on diagnosis of neuropathy  
γ010Racej = mean intercept for group based on race  
γ011SmokingStatusj = mean intercept for group based on smoking status 
ζ0i = level-2 residuals for individual i at time j = 0, assuming ζ0i ῀ N (0, σ2/0)  
ζ1i = level-2 residuals of individual i from the average rate of change  
εij = portion of individuals i’s TSI unexplained on occasion j, assuming εij ῀ N (0, σ2/ε)   
 
The following equation [10] illustrates the full mixed model for the change in TSI during 
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recovery based on multiple individual-level predictors:    
         
 үijr = γ00 + γ01RecoveryTimeij + γ02BaselineTSIij +   [10] 
                γ03RecoveryRatingj + γ04ABIj + γ05Agei +  
                   γ06BMIj + γ07Diabetesj + γ08Genderj +  
        γ09Neuropathyj + γ010Racej + γ011SmokingStatusj +  
        [ζ0i + ζ1i TIMEij  + εij]    
үijr = tissue saturation index (TSI) for participant i at time j during recovery r 
γ00 = population average initial status when time j = 0  
γ01RecoveryTimeij = individual intercept based on recovery time of individual i at time j  
 
γ02BaselineTSIij = individual intercept based on baseline TSI of individual i at time j 
γ03RecoveryRatingj = mean intercept for group based on recovery rating 
γ04ABIj = mean intercept for group based on ABI category 
γ05Agei = individual intercept based on the age of individual i 
γ06BMIj = mean intercept for group based on BMI category 
γ07Diabetesj = mean intercept for group based on diagnosis of diabetes 
γ08Genderj = mean intercept for group based on gender 
γ09Neuropathyj = mean intercept for group based on diagnosis of neuropathy  
γ010Racej = mean intercept for group based on race  
γ011SmokingStatusj = mean intercept for group based on smoking status 
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ζ0i = level-2 residuals for individual i at time j = 0, assuming ζ0i ῀ N (0, σ2/0)  
ζ1i = level-2 residuals of individual i from the average rate of change  
εij = portion of individuals i’s TSI unexplained on occasion j, assuming εij ῀ N (0, σ2/ε)  
  
 
 Model selection criteria.  Statistical significance for the final results of all 
analyses was considered at p<.05.  Since no overall fit index has been developed for use 
with general multilevel models, two commonly used ‘penalized’ model selection criteria 
served as the foundation for model selection: Akaike’s information criterion (AIC) and 
Bayesian information criterion (BIC).  Ideally, the final model would be favored by both 
criteria.  However, if the AIC and BIC disagree, more consideration was given to the 
model favored by BIC in an attempt to balance good fit with parsimony (i.e., selecting a 
model with fewer parameters to estimate, therefore more degrees of freedom for error).  
Other model selection criteria included residual analysis and ease of interpretability.   
 Mixed methods research.  This research combined qualitative and quantitative 
data (i.e., mixed methods) in an attempt to comprehensively examine the symptom 
experience of individuals with PAD.  This approach is also referred to as methodological 
triangulation, in which more than one method is used to gather data with a goal of 
providing a more detailed and balanced picture of a situation (Altricher, Feldman, Posch, 
& Somekh, 2007) or to more fully explain the richness and complexity of human 
behavior (Cohen, Manion, & Morrison, 2011).  Integration of methods occurred at the 
data collection and data analysis phases.   
 Semi-structured interviews conducted prior to treadmill exercise, allowed 
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participants to describe their PAD symptom experience in detail.  Subsequent treadmill 
testing enabled subjective reporting of the PAD symptom experience through numeric 
ratings (using the NRS to rate the level of discomfort) and symptom descriptions (using 
words to describe the location and sensation of discomfort).  The evaluation of calf tissue 
oxygenation via NIRS during treadmill testing allowed for an objective evaluation of the 
PAD symptom experience.  Obtaining data from both perspectives (subjective and 
objective) of the PAD symptom experience and determining the level of congruence was 
thought to be a principle step towards improving the detection, diagnosis, and treatment 
of this painful and life-limiting disease.           
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     Chapter 4:  Results 
Sample 
 A purposive sample of 40 participants was recruited from the EXERT study and 
enrolled in this study over an eight month period (August 11, 2011 through March 2, 
2012).  The sample consisted of adults who were experiencing lower extremity symptoms 
during exercise due to underlying PAD.   
 General summary.  Based on the positive feedback received during the pilot 
study, the investigator attempted to conduct an interview and complete a symptom 
questionnaire with each participant who enrolled in the study.  Although there was no 
attrition during the study, two male participants were unable to conduct the symptom 
interview due to time constraints on the day of their study visit.  Both of these 
participants declined to come back for another study visit to complete the interview.  
Thus, interviews were conducted with 38 out of 40 participants who enrolled in the study 
(95%).  Following the content analysis procedures previously outlined, data saturation 
was reached after analyzing 27 out of 38 interviews.      
 All of the study participants walked to a five out of five on the NRS during three 
consecutive treadmill tests with the exception of one male participant.  This participant 
was limited by shortness of breath on the day of his study visit, thought to be related to 
deconditioning from a recent hospital stay.  It is important to note that although this 
participant only reached a four out of five on the NRS during exercise, his symptoms did 
progress in intensity during exercise, were not present at rest (i.e., prior to exercise), and 
were relieved within the typical recovery time.  Therefore, all of his information was 
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included in the final analysis.  The missing NRS ratings and corresponding TSI values 
were considered to be missing at random. 
 Throughout the entire course of the study, there were no unanticipated or adverse 
events.  At the participant’s request, each interview took place on the same day as 
exercise testing, with the exception of two individuals (one male and one female) who 
were interviewed during their participation in the pilot study, prior to implementation of 
the full study.  During the interviews, no participant exhibited anxiety or distress that 
required stopping the interview.  Likewise, none of the exercise tests were terminated due 
to abnormal circumstances outlined in the method section (e.g., elevated BP, HR, or 
angina). 
 Demographics.   Characteristics of the 40 participants appear in Table 3.  The 
average age of participants was 67.55 years (SD 9.18).  Participants were predominately 
Caucasian males (80%).  Thirty percent of participants were aged 65 years and older, 
retired, and living with a spouse or partner at the time of study participation.  Overall, it 
was a highly educated group, with over three quarters of the participants completing 
some college or graduate school.   
 Medical variables.    Table 4 summarizes participant baseline disease status (i.e., 
ABI), BMI category, smoking status, medical diagnoses, and commonly used 
medications and supplements at the time of study enrollment.  The average ABI indicated 
mild disease severity (M=0.81, SD=0.27).  However, a mode ABI between 0.50 and 0.69 
indicated that the largest percentage of participants had a moderate level of disease.  The 
average BMI was 28.25 (SD=4.78), which falls into the overweight category.  The 
majority of participants were overweight or obese with a history of smoking.   
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 Medical diagnoses included risk factors for PAD (e.g., hypertension and 
hyperlipidemia), and comorbid conditions thought to confound the PAD symptom 
experience (e.g., neuropathy, OA, and spinal stenosis).  Not surprisingly, the most 
frequently diagnosed medical conditions among participants were hypertension and 
hyperlipidemia, both of which are risk factors for the development of PAD.  The majority 
of study participants were taking medications to control these conditions, with nearly 
83% (n=33) taking a cholesterol-lowering medication and an anti-platelet agent, and 70% 
(n=28) taking a cholesterol-lowering medication, an anti-platelet agent, and an anti-
hypertensive medication.  Supplements were frequently used in this sample, with half of 
the participants taking a multivitamin and nearly one-third taking fish oil.       
 
Table 3  
Characteristics of the Study Sample (N=40)      
Characteristic Category n   (%) 
Age 49 – 64 years 17 (42.5) 
 65 – 83 years 23 (57.5) 
Gender Male 35 (87.5) 
 Female 5 (12.5) 
Ethnicity Caucasian 36 (90.0) 
 African American 2 (5.0) 
 Native American 2 (5.0) 
Education High school diploma 9 (22.5) 
 Some college 16 (40.0) 
 College degree 10 (25.0) 
 Graduate school 5 (12.5) 
Employment Full time 5 (12.5) 
 Homemaker 1 (2.5) 
 Part time 8 (20.0) 
 Retired 26 (65.0) 
Marital Status Married/Living with partner 23 (57.5) 
 Divorced 9 (22.5) 
 Widowed 2 (5.0) 
 Single 6 (15.0) 
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Table 4 
Summary of Study Sample Medical Variables (N=40) 
Variable Category n    (%) 
ABIa Non-compressible (>1.40) 1 (2.5) 
 Normal (1.00-1.40)   9 (22.5) 
 Borderline abnormal (0.91-0.99) 5 (12.5) 
 Mild disease (0.70-0.90)  6 (15.0) 
 Moderate disease (0.50-0.69)     15 (37.5) 
 Severe disease (≤ 0.49) 4 (10.0) 
BMIb Underweight (<18.50) 1 (2.5) 
 Normal weight (18.50-24.99)  10 (25.0) 
 Overweight (25.00-29.99) 18 (45.0) 
 Obese (≥ 30.00) 11 (27.5) 
Smoking status History 7 (75.0) 
 Current 30 (17.5) 
 Never smoked 3 (7.5) 
Diagnoses Hypertension  37 (92.5) 
 Hyperlipidemia  36 (90.0) 
 Osteoarthritis 12 (30.0) 
 Diabetes   
      Type 1 2 (5.0) 
      Type 2 8 (20.0) 
 Neuropathy 3 (20.0) 
 Rhythm disturbance 7 (17.5) 
 Cancer history 4 (10.0) 
 Depression 4 (10.0) 
 Metabolic syndrome 3 (7.5) 
 Anemia history 2 (5.0) 
 Rheumatoid arthritis 2 (5.0) 
 Spinal stenosis 1 (2.5) 
Medications Anti-hypertensive 35 (87.5) 
 Anti-platelet 34 (85.0) 
 Cholesterol-lowering 36 (90.0) 
Supplements Multivitamin 20 (50.0) 
 Fish oil 12 (30.0) 
 Iron 2 (5.0) 
Note. ABI=ankle-brachial index; BMI=body mass index. 
a Categorization based on “Measurement and Interpretation of the Ankle-Brachial Index:  
A Scientific Statement from the American Heart Association,” by V. Aboyans, M. 
Criqui, P. Abraham, M. Allison, M. Creager, … & D. Treat-Jacobson, 2012, 
Circulation, 126(24), pp. 2890-2909.  
b Categorization based on World Health Organization classification. 
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 Summary of treadmill exercise and recovery phases.  Treadmill exercise 
testing protocols varied based on individualized treadmill familiarizations.  The majority 
of participants (n=31, 78%) started walking at 2 mph and 0% grade.  A summary of the 
treadmill speed and grade, as well as the performance during the exercise and recovery 
phases is presented in Table 5.  On average, participants walked 6 minutes and 44 
seconds, and required 6 minutes and 4 seconds to fully recover from exercise-induced 
ischemic symptoms.       
Table 5 
Summary of Treadmill Exercise Performance and Recovery 
Variable           
M 
  (SD) Mdn    Minimum   Maximum 
Starting Speed (mph) 1.99 (0.26) 2.00 1.00 3.00 
Starting Grade (%) 0.58 (1.92) 0.00 0.00 9.00 
Maximum Speed (mph) 2.15 (0.43) 2.00 1.00 4.00 
Maximum Grade (%) 7.54 (3.96) 8.50 0.00 14.00 
Exercise Time (s) 644.26 (288.57) 619.00 117.00 1740.00 
Recovery Time (s) 364.49 (250.15) 297.50 51.00 1401.00 
Note. mph=miles per hour; s=seconds. 
Aim 1:  Description of the PAD Symptom Experience 
 Description provided during interviews.  Information obtained from the semi-
structured interviews provided a foundational understanding of the PAD symptom 
experience.  The interviews not only allowed participants to share their symptom 
experiences, but it allowed them to formulate the vocabulary they subsequently used to 
describe their symptom experience during treadmill walking.  Following the content 
analysis procedure previously described, six themes emerged from 27 participant 
interviews: symptom descriptors, maintaining equilibrium, temporal fluctuations, the role 
of exercise, the perceived impact on QOL, and disease presence and treatment. 
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 Theme 1: Symptom descriptors.  Twenty-four symptom descriptors in 10 lower 
limb locations were provided during the semi-structured interviews (Tables 6 and 7).   
The average number of descriptors provided during the interviews was 3.41 (SD=1.72, 
Range=1-8), whereas the average number of locations provided was slightly less 
(M=2.96, SD=1.26, Range=1-7).  Some individuals used the same word (e.g., ache) to 
describe symptoms that were present in multiple locations, while others had distinct 
vocabulary for each lower extremity location (e.g., aching calf and burning buttock).  
Even when symptoms were restricted to one location, participants used different 
vocabulary to describe their discomfort as it progressed and subsided.  All of the 
combinations of symptom locations and descriptors reported during the interviews appear 
in Table 8.   
 
Table 6 
Symptom Descriptors provided during Interviews (N=27) 
Ache Hard   Pain Tight 
Burn Heavy Pressure Tingling 
Charley horse Hurt/Tender Prickly Tired/Fatigue 
Cramp Jammed Pulling Twinge 
Grinding/Rubbing Knot Sore Warm 
Gripping Numb Stiff Weak 
Note. Descriptors in bold are those commonly associated with classic claudication.   
Table 7 
Symptom Locations provided during Interviews (N=27) 
Ankle Calf Groin Hip Quadriceps 
Buttock Foot Hamstring Knees Shin 
Note. Locations in bold are those commonly associated with classic claudication.   
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Table 8 
Symptom Location and Descriptor Combinations Provided during Interviews (N=27) 
Location        n    (%) Descriptor                             n      (%) 
Calf              25 (92.6) Tight 10 (40.0) 
 Ache 8 (32.0) 
 Pain 8 (32.0) 
 Cramp 5 (20.0) 
 Sore 5 (20.0) 
 Charley horse 4 (16.0) 
 Tired/Fatigue 2 (8.0) 
 Weak 2 (8.0) 
 Burn 1 (4.0) 
 Hard 1 (4.0) 
 Heavy 1 (4.0) 
 Knot 1 (4.0) 
 Pressure 1 (4.0) 
Hip               10 (37.0) Ache 5 (50.0) 
 Grinding/Rubbing 3 (30.0) 
 Pain 2 (20.0) 
 Gripping 1 (10.0) 
 Heavy 1 (10.0) 
 Hurt/Tender 1 (10.0) 
 Pulling 1 (10.0) 
 Stiff 1 (10.0) 
 Tight 1 (10.0) 
Foot               9 (33.3) Numb (foot & heel) 4 (44.4) 
 Tingling (foot & toes) 3 (33.3) 
 Pain (heel & toes) 2 (22.2) 
 Burn 1 (11.1) 
 Jammed (toes) 1 (11.1) 
 Pressure 1 (11.1) 
 Prickly 1 (11.1) 
 Sore (heel) 1 (11.1) 
 Warm 1 (11.1) 
Buttock          8 (29.6) Ache 4 (50.0) 
 Pain 2 (25.0) 
 Burn 1 (12.5) 
 Gripping 1 (12.5) 
 Heavy 1 (12.5) 
 Tired 1 (12.5) 
Hamstring      6 (22.2)  Ache 3 (50.0) 
 Burn 1 (16.7) 
 Gripping 1 (16.7) 
 Hurt/Tender 1 (16.7) 
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Table 8 – Continued. 
  
   
 Tingling 1 (16.7) 
 Tired/Fatigue 1 (16.7) 
 Twinge 1 (16.7) 
 Weak 1 (16.7) 
Shin               6 (22.2) Sore/Tender 3 (50.0) 
 Burn 2 (33.3) 
 Pain 2 (33.3) 
 Cramp 1 (16.7) 
 Tight 1 (16.7) 
Quadriceps    6 (22.2) Ache 2 (33.3) 
 Pain 2 (33.3) 
 Charley horse 1 (16.7) 
 Numb 1 (16.7) 
 Sore 1 (16.7) 
 Tired/Fatigue 1 (16.7) 
Knees             3 (11.1) Ache 2 (66.7) 
 Pain 1 (33.3) 
 Stiff 1 (33.3) 
 Weak 1 (33.3) 
Ankle               2 (7.4) Sore 1 (50.0) 
 Tight 1 (50.0) 
Groin               1 (3.7) Pain 1  (100.0) 
Note. Twenty-four symptom descriptors in 10 lower extremity locations provided during 
27 interviews for a total of 64 location-descriptor combinations.    
 
 Gender.  The most common symptom location reported by men was the calf.  
Table 9 provides the frequencies for each of the 12 calf descriptors provided by 21 men 
during the interviews.  Conversely, the most commonly reported symptom location for 
women was the hip, followed closely by the calf.  Although all of the women interviewed 
reported hip discomfort as being part of the symptom experience, no two individuals used 
the same word to describe it.  The seven hip descriptors provided by women during the 
interviews can be found in Table 10.  The frequencies of the six calf descriptors are 
provided in Table 11.  As noted in Table 12, females reported symptoms in more 
locations compared to males, but both genders provided a similar number of symptom 
descriptors (Table 13).        
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Table 9 
Frequency of Calf Descriptors provided by Men during Interviews (N=21) 
Descriptor n (%) 
Pain 8 (38.1) 
Tight 8 (38.1) 
Ache 7 (33.3) 
Sore 5 (23.8) 
Cramp 4 (19.0) 
Charley horse 3 (14.3) 
Tired/Fatigue 2 (9.5) 
Burn 1 (4.8) 
Heavy 1 (4.8) 
Knot 1 (4.8) 
Pressure 1 (4.8) 
Weak 1 (4.8) 
Note. Of the 22 male interviews included in the content analysis, 21 men described calf 
symptoms.  Fourteen men provided more than one calf descriptor, so percentages do not 
add up to 100%.    
 
Table 10 
Frequency of Hip Descriptors provided by Women during Interviews (N=5) 
Descriptor n  (%) 
Ache 1 (20.0) 
Grind 1 (20.0) 
Gripping 1 (20.0) 
Hurt 1 (20.0) 
Pain 1 (20.0) 
Stiff 1 (20.0) 
Tight 1 (20.0) 
Note. All five women interviewed described hip symptoms.  None of the women reported 
the same symptom descriptor and two women provided two descriptors, so percentages 
do not add up to 100%.   
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Table 11 
Frequency of Calf Descriptors provided by Women during Interviews (N=4) 
Descriptor n (%) 
Tight 2 (50.0) 
Ache 1 (25.0) 
Charley horse 1 (25.0) 
Cramp 1 (25.0) 
Hard 1 (25.0) 
Weak 1 (25.0) 
Note.  Of the five female interviews included in the content analysis, four women 
described calf symptoms.  Two women provided more than one symptom descriptor, so 
percentages do not add up to 100%.   
 
Table 12 
Summary of Interview Symptom Locations by Gender 
Category n M (SD) Minimum Maximum 
Male 22 2.73 (1.03) 1 4 
Female 5 4.00 (1.73) 3 7 
 
 
Table 13 
 
Summary of Interview Symptom Descriptors by Gender 
 
Category n M (SD) Minimum Maximum 
Male 22 3.23 (1.48) 1 6 
Female 5 4.20 (2.59) 1 8 
  
 Age.  The younger age group (<65 years old) comprised seven males and one 
female, whereas four females and fifteen males were included in the older age group (≥ 
65 years old).  The calf was the most frequently reported symptom location among 
younger and older participants during the interviews.  Tables 14 and 15 summarize the 
descriptors provided by each age group.  On average, older individuals provided one 
symptom location more than younger participants (Table 16), while the number of 
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symptom descriptors provided by individuals in each age group appeared to be similar 
(Table 17).              
 
Table 14 
Frequency of Calf Descriptors provided by Participants < 65 Years Old during 
Interviews (N=7) 
Descriptor n   (%) 
Pain 4 (57.1) 
Tight 3 (42.9) 
Ache 2 (28.6) 
Charley horse 2 (28.6) 
Sore  2 (28.6) 
Weak 1 (14.3) 
Note.  Of the eight younger participant interviews included in the content analysis, seven 
described calf symptoms.  Five younger participants provided more than one symptom 
descriptor, so percentages do not add up to 100%.   
 
Table 15 
 
Frequency of Calf Descriptors provided by Participants ≥ 65 Years Old during  
 
Interviews (N=18) 
 
Descriptor N   (%) 
Tight 7 (38.9) 
Ache 6 (33.3) 
Cramp 5 (27.8) 
Pain 4 (22.2) 
Sore 3 (16.7) 
Charley horse 2 (11.1) 
Tired/Fatigue 2 (11.1) 
Burn 1 (5.6) 
Hard 1 (5.6) 
Heavy 1 (5.6) 
Knot 1 (5.6) 
Pressure  1 (5.6) 
Weak 1 (5.6) 
Note.  Of the 19 younger participant interviews included in the content analysis, 18 
described calf symptoms.  Eleven older participants provided more than one symptom 
descriptor, so percentages do not add up to 100%.   
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Table 16 
 
Summary of Interview Symptom Locations by Age 
 
Category n M (SD) Minimum Maximum 
< 65 years old 8 2.25 (1.04) 1 4 
≥ 65 years old 19 3.26 (1.24) 2 7  
Table 17 
Summary of Interview Symptom Descriptors by Age 
Category n M (SD) Minimum Maximum 
< 65 years old 8 2.88 (0.83) 2 4 
≥ 65 years old 19 3.63 (1.89) 1 8 
 
 Overall.  Irrespective of gender and age, a subset of participants reported 
symptoms that were consistent with the descriptors associated with classic claudication 
(e.g., aching, cramping, painful, and tired).  Participants provided the following ‘classic’ 
descriptions during interviews:     
 
     “I get a cramping in the left calf.” 
     “My legs get tired.  I can feel it in my thighs.”   
     “I get a strong pain in the right buttock, it’s a painful throbbing.” 
     “I start having pain in my calf.  And the further I go, it keeps going up my leg.”  
     “Originally, it’s a feeling of tiredness, but then it develops into a pain.”  
  
 Other participants provided symptom descriptors in ‘atypical’ locations, symptom 
descriptors that differed by location, and symptom descriptors that extended beyond the 
aching, cramping, painful, and tired description of the classic and most commonly 
recognized symptom, claudication.      
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      “My feet get kind of tingly…like they’re sleeping.” 
     “My legs start to hurt and my calves will get real hard.” 
     “It’s like a knot, and it’s in my calf.  If I’m walking up the stairs, it goes to my   
 shin, and that’s a burning sensation.”   
     “My left calf and heel get sore.  Even after a couple hours, it feels like I’ve   
 already put a full day on it.”   
 
Additionally, symptom descriptors varied based on the intensity and duration of exercise, 
as well as the treadmill grade.    
 
     “I have to walk really far to get it to go to the shin.  It’s kind of dull, unless I push 
 it, then it gets to be a sharper pain as I go on.” 
     “The faster or the steeper on that thing [treadmill] I go, the quicker it comes on.”       
 
 Theme 2: Maintaining equilibrium.  Participants described different tactics that 
enabled them to prevent symptoms from occurring or to maintain symptoms at a tolerable 
level once they had begun.  This theme consisted of three sub-categories, all with a 
common element of control:  controlling the pace, controlling the environment, and 
controlling the elements of recovery.   
 Control the pace.  Participants described deliberately controlling the pace of their 
walking to prevent or delay the onset of ischemic symptoms and/or prevent further 
symptom progression. 
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     “I don’t walk at a pace that’s enough [to bring about symptoms].” 
     “I regulate my pace so that it doesn’t bother me.”  
     “I compensate for the pain by slowing down.”   
     “It depends completely on how hard I walk.  If I walk very slowly, I can go many,  
 many blocks, more than a dozen, or so.  If I walk aggressively, I can start   
 to feel something in maybe two blocks.”     
     “[My husband] will walk with me, but then we have to hold hands so he doesn’t  
  get ahead.” 
  
 Control the environment.  Maintaining equilibrium for some individuals involved 
asking walking companions to slow down or simply catching up with them later.  For 
others, this meant avoiding situations in which they knew they would have to walk faster 
or further than they were comfortable doing.    
   
   “I walk at a pace where I’m not holding anybody up, or I just tell them ‘I’ll catch  
 up.’” 
     “We try not to have to keep up to somebody.  My wife has rheumatoid arthritis, so  
 she is limited too.  We went to Alaska a couple of years ago with our   
 neighbors, and they are younger people, a little younger than we are.  We   
 just let them go where they wanted to go, and we went where we wanted   
 to, because it was just too difficult to keep up all the time.”   
     “I’ll drive a block and a half over to the Y.  I can’t get there without taking a time- 
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 out on  the way.” 
     “Like going to the Mall of America.  I usually decline to join in that because it’s  
 just too much walking.  It’s going to be way too much walking.  [It’s] the same 
 with Walt Disney World.”   
     “Any hiking or anything like that, I just don’t attempt to do.” 
     “I usually shy away from places where I won’t be able to sit down and rest.” 
 
Many individuals identified self-imposed limits and activities that were avoided because 
of having PAD.  However, several individuals described being able to walk through the 
discomfort in certain situations.      
 
     “Sometimes I can walk through it, and then other times I have to stop and rest.” 
     “I just tend to ignore the pain.  I just keep going and attempt to push through it.   
 I’m used to the pain, so I don’t stop.” 
     “I don’t baby it, I just keep on going.” 
 
 Control the elements of recovery.  The last element of control involved 
manipulating the recovery position and utilizing specific techniques participants believed 
to aid in recovery.  Some described achieving complete symptom relief from stopping the 
activity and simply standing still.  However, the vast majority of participants preferred to 
recover in a seated position.    
 
     “I prefer to sit down, but if I stand it will eventually go away.  It goes away faster  
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 if I’m sitting.”   
     “I sit and lean against a wall and take all the pressure off my leg.”  
     “I can stand during all of this stuff.  It’s not that type of pain or anything.  I just  
 casually walk around a little bit and it will go away.” 
     “I’ll massage the shin, trying to get the blood flow back up to snuff.” 
     “I’ll massage my leg, and it gets warmer.” 
     “I just wiggle [my leg] around for a couple of minutes.” 
     “If I stretch it out and kind of move the muscle around, then I can recover quicker.” 
 
 Theme 3: Temporal fluctuations.  Participants described the influence of time on 
the symptom experience and described day to day fluctuations in their symptoms.  This 
included fluctuations based on exercise duration and the amount of time spent in 
recovery.  
 
     “Every day is a little different.”  
     “It’s really odd, because some days I have it worse than others.  Lately, I’m not  
 having it as bad, but it seems like I always have some in my calves---it varies. 
   Sometimes I can only walk five minutes, sometimes eight.  I notice [the 
 variation], especially when I’m on the treadmill” 
     “Even the time of day will change a lot for me, or if I’ve exercised a lot.” 
     “It changes not only day to day, but hour to hour.  I’m not really sure what controls it, 
 but some days I just feel much better than other days.” 
     “I have a longer recovery if I’ve pushed harder.” 
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     “In some cases, you have to be at a 5, and you have to keep going before you can  
 stop.  In those cases, it can take 5, 6, or 7 minutes to really recover.” 
 
Participants also reported fluctuations in symptoms based on the walking surface or 
incline, as well as the influence of various medical conditions and medications.  
 
     “The harder [the surface] the worse [the pain]…the softer the better.” 
     “You have more resistance with hard pavement.  You have more absorption with  
 a softer grass or something like that.  The treadmill seems to be in the middle of 
 all that.  Most of my walking around the home is on tar, so I’m stuck with that.  I 
 can’t walk on people’s lawns…” 
     “I think the tile is really hard to walk on.  Carpet seems good and the treadmill is 
 good.  But, hard, ceramic floor; it seems like it bothers you more.” 
     “I could walk as much as 14 minutes at one time, but I was ‘cheating’ because the  
 platform was flat. So when they lifted it to 0.6%, then the best I could do was 
 three to four minutes.” 
     “I normally walk either on the treadmill or on asphalt.  I try to avoid concrete or grass, 
 for that matter, because of the unevenness of it.”    
     “It’s bad when you’re working on a ladder where you’re almost on your toes.  The  
 forward part of your foot is on a tread, which is tensing the calf muscle.” 
     “My hemoglobin makes a big difference in how my legs feel.” 
     “I have sore legs when [my blood] sugars are high.” 
     “If [my blood sugar is] a little over 250, the legs ache.” 
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  Participants described a blurring of symptoms that made it difficult to decipher 
the cause of their discomfort at certain points in time.  Some felt that the symptoms they 
were experiencing during exercise were a direct result of PAD, for some they thought the 
symptoms were a result of another medical condition, and for others, it was thought to be 
a combination of both.     
 
     “For me it’s hard to distinguish. Is it the PAD totally or is it the medication?  As  
 soon as they took me off of the Effexor is when I saw a major improvement in my 
 leg symptoms.” 
     “The number one thing I can’t do is walking and running, and this may be partly 
 related  to the multiple sclerosis.” 
     “I can’t run.  That’s PAD and knee related, at the same time.  It hurts a lot.  I have 
 weak ankles too.”   
     “It’s easier to go up than down [stairs], and I’m wondering if that isn’t the 
 neuropathy.” 
     “Sometimes I have to sit down to recover.  I’m not sure if it’s because of the   
 buttock pain or if it’s the neuropathy in my feet.  I have a hard time distinguishing 
 there.  If my feet are doing okay, then I think I stand and wait.” 
     “It feels like I don’t have a lot of movement in the hip.  You know, it’s real tight,  
 but that may be because of the bursitis too.” 
   
 Theme 4: The role of exercise.  Participants described the effects of repetitive 
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exercise on the symptom experience, in addition to the cumulative effects.   
  
     “Yesterday I probably overdid it a little, and this morning I had to stop much more 
 than I normally do.”   
     “The further I walk, the worse the pain and the more frequently I will have to stop.” 
     “It seems if I continue walking again, I won’t be able to walk as far.  The distance  
 decreases.” 
     “One thing I have noticed is that if I’ve walked hard enough to develop pain and then 
 have it go away, I don’t have to go as far to have it come back. It will start 
 coming back sooner than the first time.” 
 
Some individuals also reported experiencing a post-exercise pain spike after stopping 
activity.   
  
     “After I get off of the treadmill and I come to sit down, I’ve got maybe 5 to 15   
 seconds, then I’ll just hit a streak of it, it just goes up.” 
     “When I stop walking and sit down, it will be even more severe.  More severe after I  
 stop walking than when I was doing the actual walking.” 
 
 A separate, but related sub-category in the role of exercise theme was the progress 
that individuals perceived they were making because of their commitment to an ongoing 
exercise program.   
     “I’ve made progress [on the treadmill], but it doesn’t always correlate to walking on  
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 the ground.” 
     “I work through the pain.  Now I can go quite a ways.” 
     “In the beginning, it was about two minutes [of recovery time] after seven or eight  
 minutes of walking.  Now I can walk up to 15 minutes, but then I need about 
 four minutes of recovery.  If I only go seven or eight minutes, then two minutes  
 [of recovery] is fine.”    
     “I kept working at it, walking around Normandale Lake, which has lots of inclines. 
 At first, I would have to take frequent breaks, but I kept working at it to where I 
 was finally able to go around without having to stop.” 
     “The more exercise I do, the better off I feel.”  
 
 Theme 5: The perceived impact on quality of life (QOL).  Having a diagnosis of 
PAD and living with the disease on a daily basis impacted participants in different ways.  
For some, the biggest impact was personal.  Having PAD negatively affected their self-
esteem and their outlook on life.  For others, the impact of the disease on their QOL was 
relative to their advanced age or to a medical condition that they perceived as being more 
severe (e.g., cancer).  Despite the perceived personal and relative impact on QOL, most 
individuals had defined limits in place and spoke fondly of their “old life” and described 
a variety of activities they used to enjoy.      
 
     “When I swim, I don’t feel a thing.  It’s only when I’m walking that prevents me from 
 having a normal life.  Walking, which is very important to my wife, she loves 
 to walk and I hate to walk.” 
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     “I get angry, at myself, I guess, because I don’t like being restricted.  I used to walk  
 for miles and miles.” 
     “It’s definitely affected walking and anything that associated with walking more than 
 a block or two.  And I’m embarrassed, so I don’t tell anybody, and then I just 
 say, ‘No, I can’t do that.  No, I’m not up to that,’ and I don’t say why.”   
     “My brother asked us to go to Italy again, and we’re not.  They walk around faster 
 than we do, so it’s just not fair to keep them kind of slowed down.” 
     “I can’t go for a walk or go on a picnic and take a hike, and I used to like doing that 
 stuff.  I’m embarrassed that I don’t have the energy or the ability to do it and I 
 don’t want to hold them back.” 
     “Well, considering my age, I don’t do as much running, or that kind of behavior.  I 
 was pretty active working with kids as a teacher for 40 years.  I was able to move 
 around pretty much as I wished, but I’m slower now and I just don’t do as much. I 
 must be getting older.” 
     “I will go [grocery shopping], but not often.  I usually send my husband, and I didn’t 
 even think about that.  It’s kind of unconscious that you just don’t do things 
 anymore.  I used to be very, very active, and I can see that I’ve just slowed down, 
 but I figure that’s the age.”   
     “I love to dance.  I can’t do that.  Bending down, housework, I don’t do a lot of that 
 just because it hurts so much to bend down.  I can’t go on picnics and walks and  
 stuff with my grandkids like I normally would in the summer because I can’t walk 
 that far, and I can’t walk that fast.”   
     “I have to stop and think about when I was diagnosed with PAD and what kind of 
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 symptoms I was having.  That wasn’t the number one thing in my life because 
 I’ve been dealing with cancer since 1991.”   
     “I think it has limited me from doing 85 to 90% of things.  Fishing, I can’t do that, not 
 the way that I would like to do it.  Basically just going places and walking.  It 
 limits my range of operation, I’d put it that way.” 
     “I had to give up my job as a fireman because of PAD.  I knew I couldn’t keep doing 
 what I was doing.  The more intense it was, I had to stop.  And I thought, this 
 could be trouble if I were on a scene or something, so I quit.”   
     “I can’t run, just run because it felt good.  I can’t do it anymore.  I can’t go hill 
 climbing or anything…or hiking is something I would like to do.” 
     “The last 2 years, my husband has gone to the fair alone because he doesn’t want to 
 have to meet me every half hour somewhere if I’m sitting around.  And so with 
 walking at the fair, I don’t really enjoy that anymore.”   
     “I think it’s just a matter of becoming limited in what you’re going to do.  You just 
 don’t move around as much as you used to.  And that’s basically the whole extent 
 of what it’s done to me. 
 
 Theme 6: Disease presence and treatment.  Participants described their 
awareness of the disease and subsequent treatment to prevent further disease progression 
to varying degrees.  Some individuals provided accurate physiological descriptions of the 
disease and appropriate lifestyle modifications in hopes of preventing disease progression 
and avoiding an increased chance of having a heart attack or stroke.  While others 
expressed having knowledge of what they needed to do or should be doing, but 
84 
 
acknowledged that they were unable or unwilling to change their behavior (e.g., quitting 
smoking).  Some individuals were able to articulate the symptoms they experienced 
better than others.  A few individuals struggled to describe their symptoms beyond “pain” 
or “hurt.”  However, most of the individuals interviewed were able to provide very 
specific symptom descriptors that appeared to fully encompass the symptoms 
experienced by all 40 participants during treadmill walking.    
 
     “It’s like a cramp.  The legs are hollering because they’re not getting sufficient 
 oxygen.” 
     “I’ll stop and lean on the fence for a minute just because the legs are talking to  me.” 
     “I always visualize a closure of a path that there’s not enough blood circulating and 
 then the body is signaling starvation.” 
     “The doctor said ‘If you keep smoking, you’re going to have to redo [the surgery]’ so 
 I started wearing support hose.  But being a blockhead, I decided not to give up 
 smoking yet.” 
     “The doctor kept saying, ‘Quit smoking, quit smoking,’ which I never did, so the  
 stents re-occluded.” 
     “I saw an ad in the paper for PAD, and I thought, well, I don’t even know what PAD 
 is.  Why don’t I do that?  Maybe I’ll find out more about what PAD is.  I had been 
 diagnosed with it, but I was just stunned that it hurt so badly.  I kept trying to 
 walk, but everybody had to rest with me.  I didn’t know that was part of PAD.”  
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 Description provided during treadmill exercise.  Interestingly, the majority of 
the symptom descriptors provided during interviews and all of the symptom locations 
reported during interviews (a static state) were also reporting during treadmill walking (a 
dynamic state) (see Tables 18 and 19).  Based on this evidence, the symptom descriptors 
and locations provided by the individuals included in the content analysis (n=27) appear 
to be representative of the whole group (n=40), since there weren’t any symptom 
descriptors or locations provided during treadmill walking that weren’t originally 
described by the 27 participants interviewed.  The average number of descriptors 
provided during exercise was three (SD=1.75), whereas the average number of locations 
provided during treadmill walking was slightly less (M=2.50, SD=1.32).  Similar to the 
interview results, some individuals used only one word to describe symptoms in multiple 
locations, while others used a different word for each lower extremity location that was 
affected during exercise.  Table 20 summarizes all of the location and descriptor 
combinations provided by all 40 participants during treadmill exercise.        
 
Table 18 
Symptom Descriptors provided during Exercise (N=40) 
Ache Knot Sore Gripping 
Burn Numb Tight Hard 
Charley horse Pain Tingling Hurt/Tender 
Cramp Pressure Tired/Fatigue Jammed 
Grinding/Rubbing Prickly Twinge Stiff 
Heavy Pulling Warmth Weak 
Note. Descriptors in bold are those commonly associated with classic claudication.  
Italics denotes symptom descriptors that were only described during the interviews 
(n=27) and not reported during subsequent treadmill walking by any of the 40 study 
participants.   
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Table 19 
 
Symptom Locations provided during Exercise (N=40) 
 
Ankle Calf Groin Hip Quadriceps 
Buttock Foot Hamstring Knees Shin 
Note. Locations in bold are those commonly associated with classic claudication.  
 
Table 20 
Symptom Location and Descriptor Combinations provided during Exercise (N=40) 
Location        n    (%) Descriptor n   (%) 
Calf              39 (97.5) Ache 19 (48.7) 
 Tight 18 (46.2) 
 Cramp 11 (28.2) 
 Pain 9 (23.1) 
 Tired/Fatigue 8 (20.5) 
 Burn 5 (12.8) 
 Sore 5 (12.8) 
 Heavy 3 (7.7) 
 Knot 3 (7.7) 
 Tingling 3 (7.7) 
 Charley horse 2 (5.1) 
 Pressure 2 (5.1) 
 Warm 2 (5.1) 
 Discomfort 1 (2.6) 
 Sensitive 1 (2.6) 
 Stretch 1 (2.6) 
Hamstring†  15 (37.5)  Ache 5 (33.3) 
 Burn 3 (20.0) 
 Tight 3 (20.0) 
 Tired/Fatigue 3 (20.0) 
 Sore 2 (13.3) 
 Pain 1 (6.7) 
 Pull  1 (6.7) 
Buttock        10 (25.0) Ache 3 (30.0) 
 Pain 3 (30.0) 
 Burn 2 (20.0) 
 Tight 2 (20.0) 
 Sore 1 (10.0) 
 Twinge 1 (10.0) 
 Warm 1 (10.0) 
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Table 20 – Continued.      
    
Foot‡             8 (20.0) Sore (foot & heel) 2 (25.0) 
 Burn 1 (12.5) 
 Cramp (toes) 1 (12.5) 
 Pain (heel) 1 (12.5) 
 Pressure (toes) 1 (12.5) 
 Numb (toes) 1 (12.5) 
 Prickly 1 (12.5) 
 Tingling 1 (12.5) 
 Wet 1 (12.5) 
Hip                 8 (20.0) Ache 6 (75.0) 
 Warm 2 (25.0) 
 Burn 1 (12.5) 
 Grind 1 (12.5) 
 Pain 1 (12.5) 
 Pull 1 (12.5) 
 Sore 1 (12.5) 
 Tight 1 (12.5) 
Quadriceps    7 (17.5) Tired/Fatigue 3 (42.9)  
 Tight 2 (28.6) 
 Pain 2 (28.6) 
 Ache 1 (14.3) 
 Sore 1 (14.3) 
 Tingling 1 (14.3) 
 Warm 1 (14.3) 
Shin††           6 (15.0)  Burn 3 (50.0) 
 Ache 1 (16.7) 
 Discomfort 1 (16.7) 
Knees             5 (12.5) Ache 3 (60.0) 
 Burn 1 (20.0) 
 Sore 1 (20.0) 
 Tight 1 (20.0) 
 Warm 1 (20.0) 
Note. Twenty-two descriptors in eight locations provided by 40 participants during 
exercise for a total of 62 location-descriptor combinations.  
† One male participant reported discomfort in the hamstring, but did not report a 
descriptor.    
‡ Location only reported by men. 
†† One male participant reported discomfort in the shin, but did not report a descriptor.   
 
  
 
 
88 
 
 Gender.  For males, the most common symptom location reported at any point 
during treadmill exercise was the calf (n=34, 97%).  For 68% of those males (n=23), the 
calf was the limiting location for all three treadmill tests.  For an additional 9% (n=3) of 
male participants reporting calf discomfort, the calf was the limiting symptom location 
for at least one treadmill test.  Table 21 summarizes the 16 calf symptom descriptors 
provided by males during treadmill exercise.  Table 22 provides a breakdown of the 
exercise limiting symptom location for all 40 men in the study.  Other exercise limiting 
locations included the hamstring, buttock, foot, quadriceps, hip, and shin. 
 
Table 21 
Frequency of Calf Symptom Descriptors provided by Men at any point during Treadmill 
Exercise (N=34) 
Descriptor n (%) 
Ache 18 (52.9) 
Tight 15 (44.1) 
Cramp 10 (29.4) 
Pain 8 (23.5) 
Tired/Fatigue 7 (20.6) 
Sore 5 (14.7) 
Burn 4 (11.8) 
Knot 3   (8.8) 
Charley horse 2 (5.9) 
Heavy 2 (5.9) 
Pressure 2 (5.9) 
Tingling 2 (5.9) 
Warm 2 (5.9) 
Discomfort 1 (2.9) 
Sensitive 1 (2.9) 
Stretching 1 (2.9) 
Note. All but one male reported calf symptoms; twenty-three provided more than one calf 
descriptor, so percentages do not add up to 100%. 
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Table 22 
 
Exercise Limiting Symptom Locations for Males 
 
Location 3 Exercise Tests (%) 2 Exercise Tests (%) 1 Exercise Test (%) 
Calf 65.7% 4.0% 1% 
Quadriceps 8.6% --- 1% 
Hip 5.7% --- 1% 
Buttock 3.0% --- 1% 
Foot 3.0% --- --- 
Hamstring 3.0% --- --- 
Heel 3.0% --- --- 
Note. Percentages are based on N=105 since each of the 35 male participants completed 
three treadmill exercise tests. 
 
 The calf was also the most frequently reported symptom location among female 
study participants (n=5, 100%).  Two female participants were limited by the calf for all 
three treadmill tests (40%), while two more were limited by the calf during at least one 
treadmill test (40%).  Although all five women experienced symptoms in the calf during 
exercise, the only descriptor reported by more than one individual was “tight.”  Table 23 
lists the seven calf symptom descriptors provided by women during exercise.  All of the 
locations that limited women during treadmill walking are listed in Table 24.  Compared 
to men, none of the female participants were limited during exercise by symptoms in the 
shin, heel, foot, or buttock.  However, both genders reported a similar number of 
symptom locations and symptom descriptors during treadmill exercise (see Tables 25 and 
26).   
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Table 23 
Frequency of Calf Symptom Descriptors provided by Women at any point during 
Treadmill Exercise (N=5)  
Descriptor n (%) 
Tight 3 (60.0) 
Ache 1 (20.0) 
Burn 1 (20.0) 
Cramp 1 (20.0) 
Pain 1 (20.0) 
Tingling 1 (20.0) 
Tired/Fatigue 1 (20.0) 
Note. All five women reported calf symptoms; three provided more than one calf 
descriptor, so percentages do not add up to 100%.    
 
Table 24 
Exercise Limiting Symptom Locations for Females 
Location 3 Exercise Tests (%) 2 Exercise Tests (%) 1 Exercise Test (%) 
Calf 40.0% 13.3% 6.7% 
Hamstring 20.0% --- --- 
Hip --- 13.3% --- 
Quadriceps --- --- 6.7% 
Note. Percentages are based on N=15 since each of the five female participants completed 
three treadmill exercise tests. 
 
Table 25 
Summary of Exercise Symptom Locations by Gender 
Category N M (SD) Minimum Maximum 
Male 35 2.37 (1.26) 1 6 
Female 5 3.40 (1.52) 1 5 
 
Table 26  
Summary of Exercise Symptom Descriptors by Gender 
Category n M (SD) Minimum Maximum 
Male 35 3.06 (1.83) 1 8 
Female 5 2.60 (1.14) 1 4 
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 Age.  Despite the differences reported during interviews, the calf was the most 
frequently reported symptom location among younger and older study participants during 
exercise.  A complete list of the calf symptom descriptors reported by each age group 
during exercise appears in Tables 27 and 28.  Moreover, the calf was the most common 
exercise limiting symptom location among both age groups.  Tables 29 and 30 provide a 
complete list of exercise limiting symptom locations for participants in each age group.       
 
Table 27 
Frequency of Calf Descriptors provided by Participants < 65 Years Old at any point 
during Treadmill Exercise (N=16) 
Descriptor n    (%) 
Tight 8 (50.0) 
Ache 7 (43.8) 
Tired/Fatigue 5 (31.3) 
Cramp 4 (25.0) 
Pain 4 (25.0) 
Sore 3 (18.8) 
Burn 2 (12.5) 
Knot 2 (12.5) 
Charley horse 1 (6.3) 
Discomfort 1 (6.3) 
Heavy 1 (6.3) 
Pressure 1 (6.3) 
Stretching 1 (6.3) 
Tingling 1 (6.3) 
Note.  All but one younger participant reported calf symptoms: eleven provided more 
than one calf descriptor, so percentages do not add up to 100%.     
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Table 28 
Frequency of Calf Descriptors provided by Participants ≥ 65 Years Old at any point 
during Treadmill Exercise (N=23) 
Descriptor n   (%) 
Ache 12 (52.2) 
Tight 10 (43.5) 
Cramp 7 (30.4) 
Pain 5 (21.7) 
Burn 3 (13.0) 
Tired/Fatigue 3 (13.0) 
Heavy 2 (8.7) 
Sore 2 (8.7) 
Tingling 2 (8.7) 
Warm 2 (8.7) 
Charley horse 1 (4.3) 
Knot 1 (4.3) 
Pressure  1 (4.3) 
Sensitive 1 (4.3) 
Note. All older participants reported calf symptoms; fifteen provided more than one calf 
descriptor, so percentages do not add up to 100%.    
 
 
Table 29 
 
Exercise Limiting Symptom Locations for Participants < 65 Years Old  
 
Location 3 Exercise Tests (%) 2 Exercise Tests (%) 1 Exercise Test (%) 
Calf 58.8% 3.9% --- 
Quadriceps 17.6% --- --- 
Buttock 5.9% --- --- 
Foot 5.9% --- --- 
Heel 5.9% --- --- 
Hamstring --- --- 2.0% 
Note. Percentages are based on N=51 since each of the 17 participants under the age of 65 
years completed three treadmill exercise tests. 
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Table 30 
Exercise Limiting Symptom Locations for Participants ≥ 65 Years Old  
Location   3 Exercise Tests (%) 2 Exercise Tests (%) 1 Exercise Test (%) 
Calf 65.2% 5.8% 2.9% 
Hip 8.7% 2.9% 1.4% 
Hamstring 8.7% --- --- 
Buttock --- --- 1.4% 
Quadriceps --- --- 1.4% 
Shin --- --- 1.4% 
Note. Percentages are based on N=69 since each of the 23 participants aged 65 years and 
older completed three treadmill exercise tests; percentages do not add up to 100% due to 
rounding.   
 
As illustrated in Tables 31 and 32, there were no apparent differences in the number of 
symptom locations or symptom descriptors provided by younger versus older 
participants.       
 
Table 31 
Summary of Exercise Symptom Locations by Age 
Category N M (SD) Minimum Maximum 
< 65 years old 17 2.12 (1.05) 1 4 
≥ 65 years old 23 2.78 (1.44) 1 6 
 
 
Table 32 
 
Summary of Exercise Symptom Descriptors by Age 
 
Category N M (SD) Minimum Maximum 
< 65 years old 17 3.00 (1.90) 1 8 
≥ 65 years old 23 3.00 (1.68) 1 8   
 
Aim 2:  Modeling the PAD Symptom Experience 
 The information obtained from the semi-structured interviews informed and 
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guided treadmill exercise data collection.  Subjective data in the form of NRS scores, 
symptom descriptors, and symptom locations were combined with objective data 
obtained from the NIRS (i.e., TSI values) to provide a comprehensive understanding of 
the PAD symptom experience.  Individual change trajectories were explored to get a 
preliminary understanding of the data before proceeding with general multilevel 
modeling of the repeated measures.  The loess method for smoothing was used for all of 
the individual and group trajectories.        
 Overview of the dataset.  Three treadmill tests were conducted with each of the 
40 participants for a total of 1,264 observations during 120 treadmill tests.  The number 
of observations varied based on exercise and recovery times, as well as the number of 
NRS ratings provided during each phase.  More than half (60%) of the observations 
occurred during exercise (n=762), with the remaining 502 observations occurring during 
recovery.  Each observation had a TSI value and a corresponding numeric symptom 
rating based on the NRS.  Table 33 provides a summary of observations based on the 
exercise and recovery phases.  The average number of observations per participant during 
exercise was slightly less than the average number reported during the recovery phase.   
 
 
 
 
 
Table 33 
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Summary of Observations: Total Number and Average per Individual throughout 
Treadmill Exercise Testing and Recovery 
Category   N      M (SD) Minimum Maximum 
Exercise Observations 762 19.05 (3.08) 12 30 
Recovery Observations 502 12.48 (2.67) 7 16 
Note.  Each observation had a tissue saturation index value and a corresponding numeric 
symptom rating based on the numeric rating scale.  
 
 TSI values.  Calf muscle tissue oxygenation, as measured by TSI values obtained 
via NIRS, was recorded prior to the start of each test, and throughout the exercise and 
recovery phases.  A summary of the TSI values obtained during all three phases is 
presented in Table 34.  As expected, the average TSI of participants at baseline was 
higher than the average TSI during both the exercise and recovery phases.  Figure 6 
illustrates that baseline TSI values followed a relatively normal distribution (M=62.24, 
Mdn=62.32), whereas TSI values throughout exercise and at peak exercise (i.e., NRS=5) 
exhibited a slightly negatively skewed distribution as shown in Figure 7 and 8 (M=49.72, 
Mdn=52.57, and M=46.74, Mdn=49.25, respectively).  Figures 9 and 10 illustrate 
similarly skewed distributions of TSI values obtained throughout the recovery phase 
(M=58.13, Mdn=61.92), as well as when participants reported full recovery (i.e., NRS=0; 
M=63.73, Mdn=66.93).  However, since the skewing of the exercise and recovery TSI 
values was minimal, the mean was the primary measure of central tendency reported.      
 
 
 
Table 34 
Summary of Tissue Saturation Index (TSI) values  
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Variable n     M         (SD)     Minimum     Maximum 
Baseline TSI (%)  120 62.24 (8.24) 30.46 77.95 
Overall exercise TSI (%) 762 49.72 (14.62) 0.00 77.95 
Peak exercise TSI (%) 120 46.74 (13.62) 0.00 64.42 
Overall recovery TSI (%) 499 58.13 (16.51) 0.00 88.49 
Full recovery TSI (%) 120 63.73 (12.36) 16.84 81.48 
Note.  Values for baseline TSI, peak exercise TSI, and full recovery TSI were recorded 
once during each of the 120 treadmill tests.    
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Figure 6.  Histogram of baseline tissue saturation index (TSI) values. 
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Figure 7.  Histogram of tissue saturation index (TSI) values during exercise.  
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Figure 8.  Histogram of tissue saturation index (TSI) values at peak exercise (NRS=5). 
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Figure 9.  Histogram of tissue saturation index (TSI) values during recovery.  
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Figure 10.  Histogram of tissue saturation index (TSI) values at full recovery (NRS=0).   
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 NRS ratings.  The NRS ratings provided during exercise and recovery are 
summarized in Tables 35 and 36.  The total number of NRS ratings during exercise 
equaled 723, which didn’t match the total number of exercise observations reported in 
Table 34 (n=762).  This inequity arose from circumstances in which participants reported 
discomfort in a location other than the primary and exercise limiting location or when 
participants reported an NRS rating in another location, but did not provide a NRS rating 
for the primary, exercise limiting location.  This situation occurred 39 times during 
exercise.  Likewise, the 498 NRS ratings reported during recovery didn’t equal the total 
number of recovery observations (n=502).  This discrepancy occurred due to individuals 
not reporting a NRS rating for the exercise limiting symptom location when they 
provided a NRS rating for another symptom location.  This situation occurred four times 
during recovery.   
   
Table 35 
Summary of Numeric Rating Scale (NRS) Ratings Reported during Exercise 
NRS Rating Frequency 
0 120 
1 114 
2 110 
3 129 
4 133 
5 117 
Note.  If every individual had reported all six NRS ratings on each treadmill test, the 
frequency for each NRS rating would have been 120.  
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Table 36 
 
Summary of Numeric Rating Scale (NRS) Ratings Reported during Recovery 
 
NRS Rating Frequency 
5+a 3  
5 12 
4 65 
3 100 
2 87 
1 101 
0 130 
Note.  If every individual had reported all six NRS ratings during each recovery period, 
the frequency for each NRS rating would have been 120.  The frequency of a NRS rating 
of zero exceeded 120 due to circumstances in which the exercise limiting symptom 
location had fully recovered, but another symptom location had not.   
a A rating of 5+ reflects a post-exercise spike in pain.     
 
Combining TSI values and NRS ratings.  One of the unique aspects of this study 
was the comparison between subjective symptom reporting and objective changes in calf 
tissue oxygenation during exercise and throughout recovery.  Figure 11 illustrates that the 
most rapid decline in TSI values during exercise took place between the start of exercise 
and the onset of discomfort (i.e., between NRS 0 out of 5 and 1 out of 5).  Overall, the 
decline in TSI values between the onset of discomfort and peak discomfort (i.e., NRS 5 
out of 5) was relatively minimal.  A different relationship was observed during recovery 
(see Figure 12).  After participants stopped walking, TSI values steadily increased from 
the maximum discomfort (i.e., NRS 5 out of 5) and full recovery (i.e., NRS 0 out of 5).             
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 Figure 11.  Tissue saturation index (TSI) values by numeric rating scale (NRS) rating during exercise.   
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Figure 12.  Tissue saturation index (TSI) values by numeric rating scale (NRS) rating during recovery.  A NRS rating of 0 signifies 
full recovery.     
103 
 
 Individual graphical trajectories.  Although each individual trajectory during 
the exercise and recovery phases was unique, several common patterns were identified.  
Patterns were separated into the exercise and recovery phases, with distinctive groupings 
identified in each phase.  However, a subset of individuals either walked for a short 
period of time or had a great deal of variability in their trajectories that precluded them 
from fitting into any of the identified patterns.  One individual case is provided as an 
example for every pattern.  All 40 of the participants grouped according to exercise and 
recovery patterns appear in Appendices N and O.      
 Exercise.  Six patterns emerged from the individual exercise trajectories.  The 
most common pattern (n=10) was an initial rapid decline in TSI, followed by slowly 
declining or relatively unchanged TSI values throughout the rest of exercise (see Figure 
13).  Figures 14 and 15 illustrate the next two patterns identified, which were 
exponentially declining (n=8) and relatively unchanged (n=8) TSI values during exercise.  
The fourth most common pattern (n=7), depicted in Figure 16, was a gradual decline in 
TSI values throughout the exercise phase.  The last identifiable pattern appears in Figure 
17.  The two individuals in this group illustrated a nearly quadratic change in their TSI 
values during treadmill walking; TSI values decreased at the beginning of exercise 
testing, but then started increasing prior to the termination of the test.             
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Figure 13.  The exercise trajectory for participant #9.  This participant exhibited an initial rapid decline in TSI values, followed by 
relatively unchanged TSI values throughout the rest of treadmill exercise.   
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Figure 14.  An exponentially declining TSI trajectory exhibited by participant #29 during exercise testing.   
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Figure 15.   Participant #11 illustrated a relatively unchanged TSI trajectory during treadmill exercise.   
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Figure 16. A gradually declining TSI trajectory was identified during exercise for participant #39.   
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Figure 17.  Participant #19 demonstrated a quadratic change in TSI values during treadmill exercise testing.   
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 Of the five remaining individuals, three walked for less than six minutes, which 
complicated cross comparison with other study participants who walked longer. When 
the time scale for these individuals was condensed, two of the participants, #4 and #5, fell 
into the relatively unchanged TSI pattern, whereas participant #10 fit more closely into 
the gradually declining TSI group.  The remaining two participants, #21 and #36, 
followed a cubic change in TSI values during exercise, with the latter participant 
experiencing a more severe decline in TSI at the beginning of exercise compared to the 
more prolonged decline in TSI experienced later in the exercise phase for participant #21 
(see Figure 18).  Appendix P provides a numeric summary of the exercise phase for each 
individual.          
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Figure 18.  Individual exercise trajectories for participant #36 exhibiting a cubic change in TSI values.    
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 Recovery.  TSI recovery patterns were more diverse compared to TSI exercise 
patterns.  Eight patterns emerged from the individual recovery trajectories.  The most 
common pattern was a peak in TSI during recovery (n=11).  Three individuals reached a 
peak TSI rapidly, followed by a gradual decline in TSI values (Figure 19), whereas the 
other eight participants had a slower TSI recovery, with a less pronounced peak in TSI 
before values started declining again (Figure 20).  Figures 21 and 22 illustrate the next 
two recovery patterns identified, which were an exponential recovery (n=6) and a cubic 
recovery (n=6).  The cubic recovery patterns were further broken down into a rapid initial 
TSI recovery (Figure 22) and a slower (i.e., flatter) TSI recovery at the beginning of the 
recovery phase (Figure 23).   
 The next most common recovery pattern (n=5), depicted in Figure 24, was a 
slightly flat TSI recovery, indicating that TSI values remained relatively unchanged 
throughout the recovery phase compared to the other patterns identified.  The next two 
patterns, a linear recovery (n=4) and a rapid full recovery (n=4), are shown in Figures 25 
and 26.  During the initial exploratory analysis, the rapid full recovery pattern appeared to 
be a vertical line.  However, when the x-axis was condensed, the true form emerged.  The 
last pattern identified was a quick initial TSI recovery, similar to the rapid full recovery, 
but this group did not reach full recovery for some time after the initial spike in TSI, and 
TSI values gradually declined throughout the recovery period (n=3) (see Figure 27).  
Figure 28 illustrates the unique recovery pattern exhibited by participant #19.  TSI values 
for this individual appeared to decline initially, then peak mid-recovery, followed by 
another decline and finally reaching the highest TSI at the end of the recovery phase.  
Numeric recovery phase summaries for each individual are listed in Appendix Q.              
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Figure 19.  A rapid peak in tissue saturation index (TSI), followed by a decline exhibited by participant #23 during recovery.   
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Figure 20.  Participant #5 illustrated a less pronounced peak in tissue saturation index (TSI), followed by a gradual decline during 
recovery.   
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Figure 21.  An exponential tissue saturation index (TSI) recovery trajectory was identified for participant #24.   
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Figure 22. Participant #1 demonstrated a steep cubic tissue saturation index (TSI) trajectory during recovery.   
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Figure 23.  A less pronounced cubic tissue saturation index (TSI) recovery trajectory was exhibited by participant #28.   
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Figure 24.  Participant #6 exhibited relatively unchanged tissue saturation index (TSI) values throughout the recovery phase. 
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Figure 25.  A linear tissue saturation index (TSI) recovery trajectory was identified for participant #40.   
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Figure 26.  The individual recovery trajectory for participant #36, exhibiting a rapid and full recovery of tissue saturation index (TSI).   
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Figure 27.  The recovery trajectory for participant #15.  This individual exhibited a rapid initial recovery, followed by gradually 
declining tissue saturation index (TSI) values.   
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Figure 28.  Participant #19 had a tissue saturation index (TSI) recovery trajectory unlike any other study participant.   
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 Grouping graphical trajectories.  Individual TSI values during exercise and 
recovery were grouped together and subsequently explored from multiple perspectives.  
Again, the exercise and recovery phases were split, mainly because of the inflection point 
that appeared to separate the entire trajectory into two distinct phases.  The initial focus 
was on grouping trajectories based on each of the three exercise tests.  Additional 
exploration included grouping trajectories based on several PAD risk factors (e.g., ABI, 
DM, smoking status, and age), comorbid conditions that could potentially confound the 
PAD symptom experience (e.g., neuropathy and OA), and other potentially influencing 
factors (e.g., gender, BMI, and ethnicity).  Some of the more interesting group 
trajectories are presented.  However, all of the graphical trajectories for each group 
during the exercise and recovery phases appear in Appendices R and S.    
 Exercise test.  Interestingly, TSI values for the entire group remained relatively 
unchanged from test to test.  The nearly identical loess lines depicted in Figure 29 
demonstrates how similar the TSI values were in the first, and subsequent two exercise 
tests.  Similarly, Figure 30 illustrates the stability in TSI values among the three recovery 
phases.  The stability in TSI values during both the exercise and recovery phases 
indicated that individuals fully recovered between tests, and eliminated the need to 
control for exercise tests in multilevel modeling, which simplified the interpretation of 
the final model results.         
 
 
123 
 
Figure 29.  Stability in TSI values during exercise for each treadmill test.    
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n = 120 
n = 120 
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 Figure 30.  Stability in TSI values during recovery for each treadmill test. 
 
 PAD risk factors.  Graphical trajectories based on ABI, DM, smoking status, and 
age were explored during the exercise and recovery phases.  According to baseline ABI 
measurements, the majority of participants (n=15) were considered to have a moderate 
form of PAD (i.e., ABI 0.50-0.69).  Those with borderline disease (i.e., ABI=0.91-0.99) 
or those with a normal ABI (i.e., 1.00-1.40) had trajectories that appeared relatively 
unchanged throughout exercise (see Figure 31).  Individuals with the most severe PAD 
(i.e., ABI ≤ 0.49) had the most pronounced decline in TSI, followed by individuals with 
non-compressible arteries (i.e., ABI >1.40).  Those with mild (i.e., ABI = 0.70-0.90) to 
moderate disease, appeared to experience an initial decline in TSI values, followed by a 
n = 120 
n = 120 
n = 120 
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steady decline throughout the rest of exercise.  Figure 32 suggests that individuals with 
non-compressible arteries recovered the quickest, while those with mild to moderate 
disease experienced an initial increase in TSI, followed by a steady stabilization of TSI 
values throughout the duration of recovery.  Individuals with normal or borderline ABI 
values followed similar patterns in which TSI values remained relatively unchanged 
throughout the recovery phase.   
  The presence of DM or metabolic syndrome did not appear to influence TSI 
values during the exercise or recovery phases.  All four groups exhibited similar 
trajectories during exercise and recovery, except that individuals with Type 2 DM had a 
more pronounced dip in TSI values mid-exercise compared to the other three groups.  
Likewise, no apparent differences in the group trajectories based on smoking status were 
observed.  During exercise, current smokers appeared to exercise longer and reach lower 
TSI values compared to non-smokers and those with a history of smoking.  Longer 
recovery times were observed for individuals with a smoking history, and again, lower 
TSI values were exhibited by current smokers.                
 As illustrated in Figure 33, younger adults appeared to have a less steep initial 
decline in TSI values compared to individuals aged 65 years and older.  However, the 
TSI values of younger participants continued to decline throughout the duration of 
exercise.  Since younger adults, as a group, walked longer than their counterparts, it’s 
difficult to conclude that older adults wouldn’t have followed a similar pattern if they had 
similar exercise times.  Comparable trajectories were followed during recovery (see 
Figure 34), with older participants having an earlier and more pronounced recovery of 
TSI values compared to their younger counterparts.   
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 Figure 31.  TSI values during exercise based on ABI category. 
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Figure 32.  TSI values during recovery based on ABI category. 
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Figure 33.  TSI values during exercise in younger versus older participants. 
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 Figure 34.  TSI values during recovery in younger versus older participants. 
 
 Comorbid conditions.  Regardless of a diagnosis of neuropathy, individuals 
experienced similar exercise and recovery patterns.  At the start of exercise, both groups 
demonstrated a comparable drop in TSI, followed by stabilization of TSI values mid-
exercise, and an eventual decline in values until exercise ceased.  Both groups 
experienced a similar recovery, but those without a diagnosis of neuropathy had a more 
pronounced TSI recovery at the beginning of the recovery phase.  Additionally, a 
diagnosis of OA did not appear to affect TSI values during exercise (see Figure 35).  
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However, even though individuals without a diagnosis of OA walked longer and 
recovered quicker, they exhibited lower TSI values compared to those diagnosed with 
OA.  Figure 36 illustrates that both groups experienced similar recovery patterns with a 
few individuals with OA experiencing a prolonged recovery.  Similar to individuals with 
neuropathy, those with a diagnosis of OA had a more pronounced TSI recovery at the 
beginning of the recovery phase compared to individuals without OA.      
 
Figure 35.  TSI values during exercise based on diagnosis of osteoarthritis. 
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Figure 36.  TSI values during recovery based on diagnosis of osteoarthritis.   
 
 Other factors.  Figure 37 indicates that males walked longer and reached lower 
TSI values during exercise compared to females.  However, only five females 
participated in the study.  Both groups exhibited similar recovery times, but females had 
higher TSI values at the beginning of recovery, with a subsequent decline (see Figure 38).  
On the other hand, men exhibited a slower initial recovery, but were able to maintain 
higher TSI values throughout the rest of the recovery period.   
 BMI may influence TSI values during exercise and recovery, but there were a 
limited number of individuals that fell into each category.  Viewing Figure 39, 
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individuals with a normal ABI appeared to walk the longest, but exhibited a similar 
exercise trajectory as those in the overweight group.  The individuals in the obese 
category exhibited relatively stable TSI values during exercise and recovery (see Figure 
40), with a slight dip in TSI mid-exercise.  However, the average ABI in the obese 
category was 0.92, a borderline normal value, which may be the underlying explanation 
for stabilization in TSI values during both phases.            
 Trajectories based on ethnicity were difficult to interpret, particularly since only 
four individuals were not Caucasian.  Based on the study sample, African Americans 
appeared to have relatively unchanged TSI values during exercise and recovery.  
Caucasians exhibited a gradual decline in TSI, whereas Native Americans had a sharp 
initial decline, followed by a partial increase in TSI values, and an eventual decline.  
During recovery, Caucasians experienced an initial TSI recovery, followed by 
stabilization of TSI values throughout the recovery phase.  Native Americans exhibited a 
more gradual TSI recovery, followed by a gradual decline. 
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Figure 37.  TSI values during exercise based on gender. 
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Figure 38.  TSI values during recovery based on gender. 
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Figure 39.  TSI values during exercise based on BMI category. 
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Figure 40.  TSI values during recovery based on BMI category. 
 
 Multilevel modeling.  In conjunction with the rest of the data analyses, multilevel 
modeling was divided into two phases: exercise and recovery.  Based on the within-
person data correlation, a compound symmetry covariance structure was selected.  
Restricted maximum likelihood was the estimated method utilized since it accommodated 
for data that was missing at random.  Lastly, the residual degrees of freedom were 
divided into between-subject and within-subject portions.   
 Individual growth curves during the exercise phase for a random subset of 12 
study participants were examined (see Figure 41).  They appeared to have varying 
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intercepts, but all exhibited a negative, linear slope as exercise discomfort increased; 
some were more flat than others (i.e., less change, smaller slope).  Similarly, graphical 
analysis of the recovery data for another random subset of 12 study participants (see 
Figure 42) revealed a positive and linear slope throughout recovery; thus a linear growth 
model was selected for both phases; exercise and recovery.  Despite the apparent 
difference in slopes, including the slope as a random effect greatly increased the number 
of estimated parameters; and with a sample size of 40, including random slopes had the 
potential to overwhelm model estimation.  Additionally, the slope estimates for exercise 
and recovery were both very small and arguably wouldn’t have added a meaningful 
contribution to the model (e.g., a change of 0.05% TSI for every 5 minutes of exercise, 
and a change of 0.07% TSI for every 5 minutes of recovery).  Considering that the 
average walking time was less than 11 minutes, and the average recovery time was 
roughly 6 minutes, the inclusion of random slopes during either phase was not justified.  
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Figure 41.  A random subset of 12 study participants illustrated a negative, linear slope during exercise, but varying intercepts at the 
start of exercise.    
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Figure 42.  A random subset of 12 study participants illustrated a positive, linear slope throughout recovery, but varying intercepts at 
the beginning of the recovery phase.      
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 Exercise.  The first model constructed was the unconditional means model.  This 
model partitioned the total variation in the outcome variable, TSI, in a meaningful way.  
The within-person variation (σ2/ε = 69.95), was smaller than the between-person 
variation (σ2/0=132.30).  To determine the relative magnitude of the variance 
components, the intraclass correlation coefficient (ICC) was calculated.  The ICC, 
denoted as ρ, describes the proportion of the total outcome variation that lies “between” 
people (Singer & Willet, 2003).  For the exercise data, 65% of the variation in TSI was 
attributable to individual differences (ρ=0.65).  These results indicated that sufficient 
variation existed and that the analysis should continue.     
 The next model built was the unconditional growth model (see Table 37).  This 
model was constructed to determine if the relationship between the predictor, time, and 
the outcome variable, TSI, was the same for all individuals, or if the regression 
coefficient varied from participant to participant.  The results indicated that the 
relationship between time and TSI varied by participant (p<.001), and that 71% of the 
variation in TSI was attributable to additional individual differences (ρ=0.71).  These 
results suggested that a “random effect” needed to be added to the model in an attempt to 
account for the variation that remained after including exercise time.      
 Linear and quadratic growth curve models were considered, as well as models 
centering time, models including treadmill test as a covariate, and models taking pack 
year smoking history into consideration.  Additionally, variables were treated as 
continuous and categorical for consideration in the model.  Interactions were tested 
throughout, but none were detected.  The final three models (Table 37) included exercise 
time, baseline TSI, and exercise rating as covariates. Using BIC criteria (Table 38), the 
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final model for the exercise phase was selected.  Compared to the full model, the final 
model had a 14 point decrease in BIC, which provided very strong evidence to support 
choosing it as the final model (Raftery, 1995).  The final model included exercise time, 
baseline TSI, NRS exercise rating, ABI category, and BMI category as covariates.  
Intercepts were allowed to vary by individual, but the slope was held constant.     
 The final exercise model revealed a significant grand mean intercept and 
significant intercepts for each NRS exercise rating.  Only three ABI categories were 
significantly predictive of TSI during exercise, which suggested that having a “normal” 
ABI (0.91-1.40) or an ABI that indicates mild disease (0.70-0.90), didn’t influence TSI 
variability during exercise.           
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Table 37 
Fixed Effects Estimates (Top), Random Parameter Estimates (Middle), and Summaries for Models of the Predictors of Tissue Saturation Index  
(TSI) during Exercise 
Parameters            Growth Model |p|              Partial Model |p|                 Full Model |p|                Final Model |p| 
  Fixed effects   
Intercept  56.93 (1.79) |*| 39.66 (3.59) |*| 51.55 (16.98) |.003|    43.21 (4.73) |*| 
Exercise time (minutes)   -1.08 (0.06) |*|                 -0.84 (0.12) |*|              -0.84   (0.12)      |*|                 -0.84 (0.12) |*| 
Baseline TSI −  0.37 (0.05) |*|          0.35   (0.05)      |*|   0.35 (0.05) |*| 
NRS exercise rating     
    Rating 0 (baseline)   − 0             0 0 
    Rating 1 −   -9.67 (0.95) |*|              -9.62   (0.95)      |*| -9.58 (0.95) |*| 
    Rating 2 − -9.41 (1.06) |*|             -9.36   (1.06)      |*| -9.315 (1.06) |*| 
    Rating 3 −   -8.17 (1.14) |*|              -8.10   (1.15)      |*| -8.04 (1.14) |*| 
    Rating 4 −    -7.26 (1.28)|*|              -7.18   (1.29)      |*| -7.1027 (1.28) |*| 
    Rating 5 −    -6.82 (1.44)|*|              -6.72   (1.45)      |*| -6.33 (1.44) |*| 
ABI category     
    ABI 1.00-1.40 − −             0 0 
    ABI 0.91-0.99 − −              1.45    (5.48)   |.79|            0.223 (4.29) |.96| 
    ABI 0.70-0.90 − −             -6.23    (4.57)  |.19|              -8.097 (4.05) |.05| 
    ABI 0.50-0.69 − −             -7.23    (4.08)  |.09|              8.97 (3.31) |.01|        
    ABI ≤ 0.49 − −           -10.11    (7.31)  |.18|             -14.97 (4.75) |.004| 
    ABI > 1.40 − −           -17.89 (10.13)   |.09|           -21.87 (8.29) |.01| 
Age − −             -0.002  (0.19)  |.99| − 
BMI category     
    Normal − −            0 0 
    Underweight − −            -7.79    (13.19) |.56|              0.23 (8.07) |.98| 
    Overweight − −              4.74     (3.84) |.23|              4.00 (3.21) |.22| 
    Obese − −              9.05     (4.18) |.04|              7.07 (3.56) |.06| 
Diabetes − −              0.12     (1.64) |.94| − 
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Table 37 – Continued.   
 
Gender category 
    Male − −            0 − 
    Female − −              1.96     (4.93) |.70| − 
Neuropathy − −             -3.17     (3.98) |.43| − 
Race category     
    Caucasian − −            0 − 
    African American − −             9.22    (9.92)   |.36| − 
    Native American − −            -8.31    (8.52)   |.34| − 
Smoking category     
    Never − −            0 − 
    Current smoker − −            -5.43      (8.08) |.51| − 
    History of smoking − −            -7.60      (5.72) |.20| − 
     
  Random parameters   
Residual (within) 49.91  (7.06) 35.64 (5.97)            35.62      (5.97) 35.63 (5.97) 
Intercept (between)   119.67 (10.94)  86.16 (9.28)            60.78      (7.80)       55.85 (7.47)  
     
  Model summary   
AIC 5310 4806 4738 4760 
BIC 5329 4852 4856 4842 
Number of parameters 4 10 26 18 
Note.  Standard errors are in parentheses.  NRS = numeric rating scale; ABI = ankle-brachial index; BMI = body mass index; AIC = Akaike 
information criterion; BIC = Bayesian information criterion.  Significant at the p<.05 level.   
* p < .001. 
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Table 38 
Interpreting differences in Bayesian Information Criteria (BIC) across Models 
Decrease in BIC Level of evidence 
0 to 2 points Weak 
2 to 6 points Positive 
6 to 10 points Strong 
>10 points Very strong 
Note.  Criteria adapted from “Bayesian Model Selection in Social Research,” by A. 
Raftery, 1995, Sociological Methodology, 25, p. 139.      
 
 Recovery.  Modeling of the recovery phase followed a similar process as the 
exercise phase modeling.  The first model constructed was the unconditional means 
model.  Within-person variation (σ2/ε =89.41) was smaller than the between-person 
variation (σ2/0=170.70) and 66% of the variation in TSI was attributable to differences 
between individuals (ρ=.66).  The next model, the unconditional growth model, 
illustrated that the relationship between time and TSI varied by participant during 
recovery (p<.001) (see Table 39).  Additional models that included linear and quadratic 
growth curves were constructed, but a linear model was deemed the most appropriate.  
Similar to the modeling process outlined for the exercise phase, other model construction 
included treating variables as continuous and categorical, as well as the inclusion of other 
covariates.  There was evidence to suggest an interaction between recovery time and 
recovery rating, as well as an interaction between baseline TSI and NRS recovery rating.  
Both interaction terms were included in the full and final models (see Table 39). 
 The final recovery model illustrated a significant grand mean intercept and 
significant intercepts for each NRS recovery rating (p<.001).  Other significant covariates 
included both interactions, ABI’s indicative of non-compressible arteries (ABI>1.40) and 
ABI’s indicating the presence of moderate and severe disease (ABI 0.50-0.69 and ABI ≤ 
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0.49).  Even though none of the BMI categories were significant, BMI was included in 
the final model for two reasons.  First, it improved the overall fit of the final model, and 
second, because the p-value of the underweight category decreased when included in the 
final model.  BMI was explaining variation in the final model that wasn’t explained by 
the other covariates already included the model.  Comparing the BIC of the full and final 
models, there was a 6 point decrease.  Using the modeling selection criteria that were 
used in the exercise model selection (Table 38), the decrease in BIC provided positive to 
strong evidence of choosing the final model over the full model (Table 39).             
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Table 39 
Fixed Effects Estimates (Top), Random Parameter Estimates (Middle), and Summaries for Models of the Predictors of Tissue Saturation Index  
(TSI) during Recovery 
Parameters            Growth Model |p|              Partial Model |p|                  Full Model |p|           Final Model |p| 
                   Fixed Effects   
Intercept  53.79 (2.19) |*| 31.94 (5.73) |*| 32.37 (22.46) |.15|            18.89 (9.07) |.04| 
Recovery time (minutes)    1.20 (0.12) |*|              0.12 (0.18)   |.58|               -0.10  (0.18)  |.61|              -0.06 (0.18)  |.72| 
Baseline TSI −  0.10 (0.08) |.18|                -0.03 (0.10)  |.76|           -0.01 (0.09) |.94| 
NRS exercise rating     
    Rating 5 (maximum)   − 0             0                            0 
    Rating 4 −                12.09 (2.58) |*|             16.17   (3.10)      |*|        16.10 (3.10) |*| 
    Rating 3 − 14.85 (2.54) |*|             22.73   (4.41)      |*|        22.62 (4.41) |*| 
    Rating 2 −  21.22 (2.61) |*|              32.92   (6.00)      |*|        32.77 (6.00) |*| 
    Rating 1 −                22.57 (2.61) |*|             39.10  (7.72)      |*|        38.94 (7.72) |*| 
    Rating 0 −                24.49 (2.69) |*|             46.71   (9.54)      |*|        46.52 (9.55) |*| 
Time*rating − −               0.01 (.002) |.004|                0.01 (.002)  |.003| 
Baseline TSI*rating − −               0.061 (.03)   |.03|                0.06 (.03)    |.03| 
ABI category     
    ABI 1.00-1.40 − −             0 0 
    ABI 0.91-0.99 − −            -3.10    (7.54)   |.69|           -1.44   (5.80)  |.81| 
    ABI 0.70-0.90 − −             5.21     (6.32)  |.42|             1.89  (5.48)  |.73| 
    ABI 0.50-0.69 − −             -7.33    (5.65)  |.21|           -9.97   (4.47)  |.03|        
    ABI ≤ 0.49 − −             -7.07  (10.10)  |.49|         -19.14   (6.39)  |.005| 
    ABI > 1.40 − −           -24.14  (14.06)  |.01|         -25.27 (11.29)  |.03| 
Age − −             -0.12    (0.25)  |.64| − 
BMI category     
    Normal − −            0 0 
    Underweight − −            -21.42  (18.16) |.25|         -12.79 (10.84)  |.25| 
    Overweight − −              6.63     (5.28) |.22|            6.11    (4.32) |.17| 
    Obese − −              11.39   (5.72) |.06|            9.50    (4.77) |.06| 
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Table 39 – Continued.       
     
Diabetes − −              1.14     (2.26) |.62| − 
Gender category     
    Male − −            0 − 
    Female − −              2.13     (6.78) |.76| − 
Neuropathy − −             -0.77     (5.49) |.89| − 
Race category     
    Caucasian − −            0 − 
    African American − −             8.80  (13.63)   |.52| − 
    Native American − −            -17.15  (11.70) |.16| − 
Smoking category     
    Never − −            0 − 
    Current smoker − −            -11.90  (11.16) |.30| − 
    History of smoking − −            -8.75       (7.89)|.28| − 
  Random parameters   
Residual (within) 76.39   (8.74) 58.15   (7.63)               56.85   (7.54) 56.90  (7.54) 
Intercept (between)   175.37 (13.24)  161.97 (12.73)            114.12 (10.68)                100.14 (10.01)  
  Model summary   
AIC 3727 3569 3498 3524 
BIC 3744 3611 3614 3608 
Number of parameters 4 10 28 20 
 Note.  Standard errors are in parentheses.  NRS = numeric rating scale; ABI = ankle-brachial index; BMI = body mass index; AIC = Akaike 
information criterion; BIC = Bayesian information criterion.  Significant at the p<.05 level.   
* p < .001.
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Chapter 5:  Discussion 
 The purpose of this study was to obtain a comprehensive understanding of the 
PAD symptom experience, beyond classic claudication, including symptom reporting and 
changes in calf tissue oxygenation during exercise and recovery.  The specific aims of the 
study were to: (1) understand the symptom experience of younger and older men and 
women with PAD through in-depth qualitative interviews; and (2) simultaneously 
evaluate calf tissue oxygenation and the self-reported symptoms experienced by 
individuals with PAD during treadmill exercise and throughout recovery.  This research 
was designed and conducted based on review of the literature, which identified a gap in 
regards to understanding the frequency and presentation of ‘atypical’ claudication.  
Furthermore, experiences in clinical practice suggested that ‘atypical’ symptoms existed 
and that they may be more prevalent that what was currently being recognized.    
 Both qualitative and quantitative methodologies were utilized to characterize the 
symptom experience of individuals with PAD.  Semi-structured interviews included 
completing a PAD symptom questionnaire and providing a detailed description of the 
symptoms experienced at rest and during exercise (e.g., location, sensation, and 
duration).  Individuals were given another opportunity to descriptively as well as 
numerically report PAD symptoms during three successive treadmill exercise tests.  
NIRS provided an objective measurement of calf tissue oxygenation via TSI values.  
Content analysis revealed six themes of the PAD symptom experience, while graphing 
the individual and group trajectories visually depicted the patterns of change in TSI 
during exercise and recovery based on particular characteristics and baseline status.  
Lastly, general MLM was utilized to explore the relationship between particular 
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characteristics, baseline values, and symptom ratings with TSI during the exercise and 
recovery phases. This chapter provides a summary and discussion of the results by aim, 
the study limitations, and the implications for future research and vascular disease 
practice.     
Aim 1:  Description of the PAD Symptom Experience 
 Although a variety of vocabulary and phrases were provided during interviews, 
responses were categorized into six main themes: symptom descriptors, maintaining 
equilibrium, temporal fluctuations, the role of exercise, the perceived impact on QOL, 
and disease presence and treatment.  These six themes were closely aligned with the 
themes identified in a broader exploration of the PAD experience and its perceived 
effects on health-related QOL (Treat-Jacobson et al., 2002).  Participant characteristics of 
the two studies were similar, but Treat-Jacobson and colleagues (2002) included a larger 
percentage of females and conducted open-ended interviews with participants from two 
geographical locations.  Participants in the Treat-Jacobson et al. (2002) study provided 
similar descriptions of the symptom experience (e.g. cramping, aching, burning, 
cramping, and tired/fatigue), but provided a less exhaustive list compared to the 
participants in this study.  Additionally, participants in the Treat-Jacobson et al. (2002) 
study only reported claudication in classic locations (e.g., calf, thigh, and buttock), as 
opposed to the broader list of locations (i.e., typical and ‘atypical’) provided by 
participants in this study.  Similar to the participants in this study, individuals described 
the limitations in their physical and social functioning, including the loss of activities 
they used to enjoy.  Additionally, participants expressed feelings of social isolation, and 
described the burden of the disease on their family.  Participants addressed these 
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limitations by being flexible and adjusting, but also expressed a degree of uncertainty and 
fear as to what to expect in the future.  The aspects of adjusting and uncertainly, closely 
aligned with the maintaining equilibrium and temporal fluctuations themes identified in 
this study.  In these two themes, participants reported exerting control over their pace, the 
environment, and the elements of recovery, as well as expressing uncertainly regarding 
day to day fluctuations in symptom onset, severity, and progression.  Individuals 
described their unsuccessful attempts to identify patterns in physical functioning, which 
led to further frustration and uncertainty.  However, unlike the Treat-Jacobson et al. 
(2002) study, participants in this study did not express fear regarding the loss of a limb or 
more significantly, death as a result of the disease.  This could be reflective of the more 
moderate disease severity of the sample in this study compared to the broad range of 
PAD severity in the Treat-Jacobson et al. (2002) study, which included individuals with 
rest pain and non-healing wounds.     
 Study findings also resembled the themes identified by a qualitative study 
conducted in 2005 that investigated the experience of living with PAD and the influence 
of the disease on activities of daily living (Wann-Hansson, Hallberg, Klevsgård, & 
Andersson, 2005).  Participants described PAD as being physically, socially, and 
emotionally burdensome.  Yet again, participants talked about the consequences of the 
disease and specific coping strategies designed to relieve the burden and gain control in 
daily life.  This theme closely aligned with the maintaining equilibrium theme of this 
study and the adaptation theme of the Treat-Jacobson et al. (2002) study.  Participants in 
the Wann-Hanson et al. (2005) study also talked about accepting and adapting to the 
burden, and discussed particular limitations in daily life because of the disease, which 
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again closely aligned with themes identified in both of the aforementioned studies.       
 Symptom descriptors provided by study participants during the interviews were 
consistent with the descriptors that typically indicate classic claudication (e.g., ache, 
cramp, pain, and tired/fatigue).  The calf was the most commonly reported location of 
pain or discomfort, which is consistent with the classic definition of claudication.  Many 
described the sensation as a pain, which is also consistent with classic claudication.  
However, nearly half described calf discomfort as tight.  In fact, this was the most 
frequently reported descriptor among men, women, and older participants, and the second 
most frequently reported descriptor among younger participants.  Aside from the other 
classic claudication descriptors reported by participants (e.g., cramp, ache, and 
tired/fatigue), calf discomfort was described as sore, a Charley horse, weak, burning, 
hard, heavy, knotting, and pressure.   
 During interviews, participants reported discomfort in the two other commonly 
recognized locations, the buttock and the quadriceps.  However, participants also reported 
discomfort in ‘atypical’ locations.  The second most commonly reported location during 
interviews was the hip, followed by the foot. Other ‘atypical’ locations included the 
hamstring, shin, knee, ankle, and groin.  Again, classic descriptions in ‘typical’ and 
‘atypical’ locations were provided (e.g., ache, pain, and tired), but were not exhaustive.  
Similar to the calf, participants described the sensation as burning, tight, grinding, 
tingling, pulling, pressure, numb, prickly, and a twinge.  Burning has previously been a 
descriptor of the PAD symptom experience (Ruger et al., 2008; Tomczyk & Treat-
Jacobson, 2009; Treat-Jacobson et al., 2002), as well as tingling, numbness, throbbing, 
and shooting.    
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 Interestingly, the descriptions of lower extremity claudication that participants 
provided were nearly identical to the early descriptions of ischemic heart pain (i.e., 
angina) from the initial Rose Questionnaire (Rose, 1962).  In the Rose study (1962), 
participants described chest pain as, gripping, occasionally sharp, burning, sharp, 
shooting, kind of pricking, pins and needles, and like something pressure.  Even on early 
surveys, ischemic heart pain descriptors such as tight, heavy, constricting, crushing, 
numbing, and burning, with the ability to radiate to other locations were recognized as 
being associated with angina.  Lower extremity ischemia is a similar physiological 
process, but it occurs in a different body location.  Even without the provision of further 
objective evidence, these descriptions and qualities should also be more commonly 
accepted descriptions of ischemia occurring in the lower extremities.   
 Classic claudication rates reported during exercise were lower than those reported 
in other PAD studies (Gardner et al., 2007; Gardner et al., 2012; Leng & Fowkes, 1992; 
Makdisse et al., 2007; Ogren et al., 2005).  Only 62.5% of study participants (23 men and 
two women) were limited by discomfort in the calf during all three treadmill tests.  Even 
fewer provided a classic calf descriptor (e.g., ache, cramp, pain, or tired/fatigue) at the 
time that discomfort became so severe they had to stop walking (i.e., NRS rating 5 out of 
5).  Other calf descriptors included tight, burn, tingling, sore, knot, Charley horse, heavy, 
pressure, warm, sensitive, and stretching.  The calf was the most common exercise 
limiting symptom location for both genders, as well as younger and older participants.  
Ache, tight, and cramp were the calf symptom descriptors most frequently reported by 
both age and gender groups.  
 Unlike the findings from Gardner and colleagues (Gardner et al., 2007; Gardner et 
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al., 2012), all study participants did not report symptoms consistent with classic 
claudication under controlled exercise testing conditions.  During exercise, participants 
were limited by symptoms in typical locations (e.g., calf, quadriceps, and buttock), as 
well as ‘atypical’ locations (e.g., hamstring, hip, foot, and heel).  Some individuals 
provided symptom descriptions consistent with the definition of classic claudication (e.g., 
ache, cramp, pain, and tired/fatigue), while others reported lesser recognized descriptors 
(e.g., tight or burning).  These results serve as evidence to challenge the theory that all 
individuals with PAD will experience classic claudication under controlled exercise 
testing conditions.  In this study, symptom onset and progression were provoked by 
individualized speed and grade increases during treadmill exercise, but individuals 
reported symptoms other than classic calf claudication that were related to ischemic 
changes in calf muscle tissue and limited their ability to continue exercising.   
 In addition to the descriptions of the PAD symptom experience that participants 
provided while in a static state (i.e., semi-structured interviews), they also provided this 
information during a dynamic state (i.e., treadmill exercise).  Several similarities and 
differences between the two states were identified.   
 The symptom descriptors provided during exercise were similar to those reported 
during the interviews, but the frequencies of descriptors based on gender and age groups 
changed slightly.  Again, the most commonly reported location during exercise was the 
calf, most frequently described as a discomfort, ache, tight, cramp, pain, and 
tired/fatigue.  Calf discomfort was also described as burning, sore, heavy, knotting, 
tingling, Charley horse, pressure, warm, sensitive and stretching.  Tightness remained the 
most common descriptor reported by women, but the second most common among men 
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and older participants during exercise.  Younger participants primarily described calf 
discomfort as tight during exercise, as opposed to pain described during interviews.  Ache 
was the most frequently reported descriptor by men and older participants, and the second 
most common descriptor reported by younger participants.  Similar to findings from other 
studies (Gardner et al., 2007; Gardner et al., 2012; McDermott et al., 2001), a larger 
percentage of participants reported calf discomfort during exercise (n=39, 97.5%), 
compared to the 92.6% (n=25) who reported calf discomfort during the interviews.     
 The other symptom locations reported during exercise were consistent with those 
provided during interviews, with the exception of the groin and ankle.  Exercise limiting 
locations included all three typical locations (i.e., calf, quadriceps, and buttock), but also 
included locations considered to be ‘atypical’ presentations of claudication (i.e., 
hamstring, hip, foot, and heel).  Interestingly, although all five female participants 
described hip discomfort during the interview, the hip was the exercise limiting location 
during only two female exercise tests.  On the other hand, only five men reported hip 
discomfort during interviews, but seven male exercise tests were stopped due to pain in 
this location.  Another apparent gender difference was revealed when comparing the 
number of descriptors provided by men and women under static and dynamic conditions.  
On average, women provided more descriptors than men during interviews, but during 
exercise it was the inverse.  The number of symptom locations and descriptors provided 
by younger and older participants during interviews was similar, with consistency in 
reporting under static and dynamic conditions for both groups.  Similar to the findings in 
patients with angina, these preliminary results suggest that symptom reporting may differ 
by gender.  However, additional research should be conducted in order to confirm these 
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findings to determine whether PAD screening and education should be individualized 
based on gender.       
Aim 2:  Modeling the PAD Symptom Experience 
  Exploration of individual trajectories revealed that TSI values during exercise and 
recovery were varied.  However, several distinct patterns were identified during each 
phase.  This preliminary and informal analysis indicated that the most common pattern of 
change in TSI during exercise was an initial rapid decline in TSI, followed by slowly 
declining or relatively unchanged TSI values throughout the rest of exercise.  Some 
individuals stopped at the point of minimum TSI, while others were able to continue 
exercising after the minimum TSI was reached.  The resiliency exhibited by some 
individuals was in direct contrast to those who had to stop exercising as soon as TSI 
declined to a specific point.  It is unknown whether there a specific compensatory 
mechanism that some individuals have that allowed them to continue exercising despite 
low TSI values, or that enabled TSI values to increase above the minimum TSI obtained 
despite the progression of exercise intensity and duration.   
 Recovery patterns were similar to the patterns identified during exercise, but more 
numerous.  The most common pattern was a peak in TSI, either during a rapid recovery, 
or more commonly in this sample, a slower initial recovery of TSI values.  Some 
individual’s symptoms resolved fully once peak TSI was reached, whereas others had 
TSI values that continued to decline even though symptom discomfort was lessening.  
Individual recovery patterns produced similar questions to those raised during the 
exercise phase.  It has yet to be determined whether some individuals recover more 
quickly than others based on specific characteristics such as gender or age, and why some 
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individuals report a full recovery as soon as TSI peaks, while others don’t report a full 
recovery until TSI starts to decline.   
 The most notable findings from this study are in regards to the relationship 
between symptom rating and TSI values during exercise and recovery.  All of the 
symptom rating categories were significant for both the exercise and recovery models.  
During exercise, the most severe decline in TSI was observed between the start of 
exercise and the onset of pain (i.e., NRS 1 out of 5).  TSI continued to decline slightly 
throughout the duration of exercise until the maximum discomfort was reached (i.e., NRS 
5 out of 5).  The recovery model told a similar story in which TSI values were at their 
lowest point when participants were still experiencing maximum discomfort (i.e., NRS 5 
out of 5) and then steadily increased until full recovery was achieved (i.e., NRS 0 out of 
5).  These patterns were depicted clearly in the group trajectories during both phases. 
 Findings similar to these have not been reported in the literature. Researchers 
have collected data on perceived exertion while measuring oxygenation with NIRS, but 
have not collected data on symptom descriptions or provided analysis comparing tissue 
oxygenation to the perceived exertion data collected.  Miranda and colleagues (Miranda 
et al., 2012) collected data on perceived exertion every minute during rest and exercise, 
but provided no results comparing oxygenation values to perceived exertion.  Similarly, 
Collins et al. (2012) tracked perceived exertion during exercise, but only reported a mean 
rating of 5.04 at peak exercise on the Borg scale in the final presentation of study 
findings.  To the authors’ knowledge, this study is the first of its kind to analyze the 
relationship between subjective and objective PAD symptom reporting.       
 To explore the potential relationships of TSI values and specific characteristics, 
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individual trajectories were grouped based on several PAD risk factors, and comorbid 
conditions that could influence the PAD symptom experience, as well as gender and 
BMI.  Further exploration involved model construction for the exercise and recovery 
phases using general MLM.  Due to a relatively homogenous sample, the group trajectory 
patterns identified, and the exercise and recovery models constructed cannot be 
generalized to the PAD population.  Generalizability of these findings could be 
strengthened by a larger, more diverse sample.   
 Based on the preliminary data, individuals with the lowest ABI (≤ 0.49) had the 
most pronounced oxygen desaturation during exercise, followed by individuals with non-
compressible vessels; whereas fixed effects coefficients of the exercise model suggested 
the reverse.  These two groups, as well as the mild and moderate disease categories were 
all significant terms included in the final exercise model.  TSI recovery was gradual for 
all of the ABI groups, except those with non-compressible vessels who exhibited a 
slightly erratic recovery pattern.  On the other hand, individuals with a borderline or a 
normal ABI had trajectories that remained relatively unchanged throughout the exercise 
and recovery phases. This was confirmed by non-significance in the recovery model.  
However, non-compressible, moderate, and severe disease categories were all statistically 
significant, indicating that differing TSI recovery patterns were present.  These findings 
aren’t surprising since individuals with borderline or normal ABI’s have less arterial 
narrowing, which allows for a quicker restoration of blood flow once activity ceases.  
Furthermore, research supports the correlation of NIRS measures with disease severity 
(i.e., ABI) and recovery times.   
 Age was a non-significant predictor of TSI in both the exercise and recovery 
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models.  Although no interaction was detected, ABI may have influenced the apparent 
relationship between oxygenation and age during exercise and recovery; particularly 
since age in healthy individuals has been shown to have no effect on saturation values 
(Miranda et al., 2010).  Older participants appeared to have a quicker and more 
pronounced recovery, which could have been a result of an uneven distribution of disease 
severity among both age groups.  If the older participants were less diseased overall, they 
could have exhibited quicker recovery times as a result of less arterial narrowing instead 
of another mechanism.      
 Similar imbalances in gender led to inconclusive results.  Overall, male 
participants walked longer, but they exhibited lower TSI values.  This directly contrasts 
the saturation patterns identified in healthy subjects based on gender in which women had 
a 15% lower baseline tissue saturation compared to men; with women maintaining lower 
values throughout exercise compared to males (Miranda et al., 2010).  However, in the 
Miranda et al. study (2010), calf skinfold was 107% higher in women compared to men, 
and calf skin temperature of women was 3% lower.  Adipose tissue thickness has been 
identified as a factor that influences oxygenation values (Van Beekvelt, Borghuis, Van 
Engelen, Wevers, & Colier, 2001), while the role of skin temperature is less understood.  
Since neither were measured and accounted for in this study, the lack of both measures 
could have compounded the difficulty to conclude the existence of true gender 
differences.  The conclusions of group trajectories were supported by the exclusion of 
both groups in the final exercise and recovery models.   
 Group trajectories based on DM suggested that individuals with type 2 DM 
experienced a more pronounced tissue oxygen desaturation mid-exercise and a post-
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exercise delay in oxygen saturation recovery.  Individuals without a diagnosis of DM and 
those with type 1 DM displayed similar oxygen desaturation and re-saturation patterns.  
Changes in TSI during exercise and recovery were expected in individuals with either 
type of DM based on the physiology of the disease and on recent research findings.  
Arterial calcifications are more prevalent and more severe in patients with DM than in 
non-diabetics (Morrison & Bogan, 1929) and even in the absence of PAD (i.e., normal 
ABI), individuals with DM have been shown to have reduced skeletal muscle capillary 
blood volume expansion during exercise (plantar flexion and treadmill walking), as 
measured by NIRS (Mohler, Lech, Supple, Wang, & Chance, 2006).   Even after 
combining both types of DM into one category, DM was not a significant predictor of 
TSI in the final model for either phase.   
 The non-significance of any smoking category could have resulted from the fact 
that the majority of participants had a history of smoking.  Based on the group 
trajectories, current smokers appeared to have an initial oxygen desaturation during 
exercise that wasn’t present in non-smokers or in those with a history of smoking.  
Similarly, less conclusive study results about the role of ethnicity and BMI could have 
primarily been caused by an unbalanced design.  Additionally, there is some debate about 
ethnicity being an independent risk factor for PAD after adjusting for atherosclerotic risk 
factors (Collins et al., 2005).  If the disease affects all ethnicities equally, perhaps similar 
patterns of tissue oxygenation would be observed as well.  The non-significance of any of 
the BMI categories except obesity in the full exercise model, suggests that there is no 
relationship between BMI and calf tissue oxygenation during exercise.  However, the 
categories were unbalanced and BMI was included in both final models (i.e., exercise and 
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recovery) because it explained variation that wasn’t explained by any of the terms already 
included in the model.  Based on these findings, it is conceivable that significant effects 
would be observed with a larger, more diverse sample.  The apparent protective effect of 
obesity on calf tissue oxygenation during exercise could be due to the fact that many 
individuals who smoke tend to have lower BMI’s than those who do not.  However, this 
did not hold true for the seven smokers in this study, who on average had a BMI of 26.7, 
which falls into the overweight category.   
Limitations 
 Study limitations included issues related to measurement, the study sample, and 
model selection.  The NIRS device used to collect calf tissue oxygenation data could not 
account for factors such as collaterals, cardiac function, inotropic and chronotropic 
response to therapeutic agents, vessel wall stiffness, and the presence of comorbid 
conditions that could have influenced calf tissue oxygenation during exercise (Manfredini 
et al., 2009).  Additionally, the subcutaneous layer can vary considerably among 
individuals due to differences in adipose tissue thickness, which may confound NIRS 
measurements (Matsushita, Homma, & Okada, 1998; Niwayama et al., 1999; Van 
Beekvelt et al., 2001).  Calf skin temperature has also been measured in similar research 
conducted with healthy adults (Miranda et al., 2010).  Calf adipose tissue thickness and 
skin temperature were not measured in this study.  Furthermore, no data on ambient 
temperature or humidity levels in the exercise testing room were collected.  However, all 
exercise testing took place in the same room, at roughly the same time of day for all study 
participants.  Individualized testing protocols were selected to guide individuals through 
symptom progression, while attempting to avoid stopping exercise for any other reasons.  
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The lack of a standardized exercise testing protocol may limit the comparison of study 
findings with future research studies.   
 The sample in this study was small and relatively homogenous.  In addition, all of 
the study participants were recruited from a single parent study in one geographical 
location.  The lack of heterogeneity in this study could have impacted the ability to 
construct stronger, more accurate exercise and recovery models, which limits 
generalizability of the study findings to other individuals with PAD.  Another limitation 
of the study sample is that all of the study participants were volunteer research subjects, 
which could have potentially introduced a response bias.  Perhaps individuals with PAD 
that do not volunteer for research would report distinctly different PAD symptom 
experiences. Collecting data from individuals in a variety of geographical locations with 
more diverse backgrounds and a spectrum of disease severity will strengthen 
generalizability of study findings.   
 Likewise, a small and homogenous sample placed limitations on model selection. 
If the study sample was larger and more diverse, other functional forms (i.e., non-linear) 
may have been more apparent.  Models based on a larger and more heterogeneous sample 
could have included different characteristics based on more or less statistically significant 
findings.  However, this was an exploratory study and the primary purpose was to 
summarize the data of the study sample, describe individual and group trajectories, and 
gain an initial understanding of the relationship between symptom reporting and calf 
tissue oxygenation during exercise and recovery.    
Implications for Research 
 The results of this research add further evidence to support more comprehensive 
162 
 
PAD assessment.  Classic claudication is widely accepted and well understood.  
Therefore, research that supports the existence of and more clearly describes the 
presentation of ‘atypical’ claudication (e.g., location, sensation, and duration) is needed.  
Based on the research conducted to date, there is a particular need for research studies 
that include a larger number of participants, with a balanced number of individuals with 
respect to age, gender, ethnicity, and disease severity categories.  This research would 
enable further exploration of the effect, if any, of PAD risk factors, baseline 
characteristics, and comorbid conditions on calf tissue oxygenation during exercise and 
recovery. 
 This study is foundational for future research to determine patterns of calf tissue 
oxygenation, their relationship to symptom reporting, and potential changes with 
therapeutic interventions.  Future research should focus on longitudinal studies to 
evaluate patterns in calf tissue oxygenation throughout disease progression, pre-and post-
intervention, and perhaps most importantly, pre- and post-supervised exercise programs, 
since this is the number one recommended treatment for individuals with PAD.  
 Insufficient research has been conducted to evaluate the impact of supervised 
exercise programs on calf tissue oxygenation during exercise and recovery; study 
findings are inconclusive thus far.  Not surprisingly, researchers have found that exercise 
improved the maximal treadmill exercise time (Collins et al., 2012; Figoni et al., 2009), 
but the impact of a program of exercise on calf tissue oxygenation remains unclear.  
Collins et al. (2012) found no obvious differences in calf tissue oxygenation pre- and 
post-exercise program, but found a lengthened time to reach minimum calf tissue 
oxygenation values during exercise.  Miura and colleagues (Miura, McCully, & Chance, 
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2003) found that exercise training reduced calf tissue saturation recovery half-time by 
17% in individuals with PAD, whereas Figoni et al. (2009) found no significant 
improvement in recovery times after participating in a three month supervised exercise 
program.  A recently conducted NIRS study illustrated promise for extending PAD 
exercise programs into the home (Manfredini et al., 2012).  Manfredini et al. (2012) 
observed hemodynamic and functional improvements for 31 individuals that participated 
in a 34 week home-based exercise program at a prescribed walking pace, compared to 
individuals with PAD walking at a free pace and a healthy control group performing 
usual activities.  Revisiting the parallels between heart disease and PAD, Gerovasili and 
colleagues (Gerovasili et al., 2009) discovered that physical exercise improved the 
peripheral microcirculation, as measured by NIRS, after three months of supervised 
cardiac rehabilitation.  These results highlight the need for additional research to clarify 
the relationship between individual characteristics and calf tissue oxygenation, as well as 
the need to establish abnormal cutoff values based on specific oxygen demands for 
inadequate calf tissue oxygenation at rest and during exercise that could be used to detect 
individuals at a higher risk for developing PAD and those in the early stages of the 
disease.   
Implications for Practice 
 The knowledge gained from this study has significant implications for the 
improvement of PAD detection and diagnosis by broadening currently accepted symptom 
descriptors to provide a more clear and comprehensive symptom presentation of the 
disease.  Unlike the results published in other studies, participants were limited by 
symptoms in ‘atypical’ locations (e.g., hip, hamstring, and shin) and/or they used 
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uncommonly recognized vocabulary to describe the sensation (e.g., tight, burning, and 
numb).  These results suggest that in clinical practice, patients may be confused by the 
language used by their providers to describe the locations and sensations experienced by 
individuals with PAD.  Similarly, providers may assume that the symptoms being 
reported by their patients are attributable to another medical condition since they don’t 
mirror the definition of classic claudication.  In this study, participants reported ‘atypical’ 
symptoms in ‘atypical’ locations, but experienced similar changes in calf tissue 
oxygenation as those who reported symptoms consistent with classic claudication.  
Although they were reported less frequently than classic calf claudication, a greater 
emphasis should be placed on broadening the current understanding of factors related to 
‘atypical’ symptom presentation.   
 The results of this study emphasize the importance of a more comprehensive 
assessment to detect PAD before it progresses, or even to identify individuals at-risk 
before the disease develops (i.e., borderline disease; ABI 0.90-0.99).  For example, 
individuals with borderline ABI values or those in an early stage of the disease may 
report symptoms in ‘atypical’ locations and/or use vocabulary less familiar to clinicians 
to describe the sensations related to the disease.  These ‘atypical’ descriptions may not 
trigger clinicians to perform the simple, yet necessary testing to diagnosis the disease 
(e.g., ABI).  Clinicians should encourage patients who are already diagnosed with PAD 
to share their symptom experiences.  This would: 1) allow clinicians to better appreciate 
the diversity of disease presentation, 2) enable individuals to gain insight into the disease, 
and 3) provide therapeutic relief through the sharing of symptom experiences since 
chronic disease can cause a tremendous amount of stress in one’s life.   
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 Lastly, clinicians should continue to educate patients with PAD, as well as the 
general public about the typical and the less commonly recognized symptoms of the 
disease.  Education regarding pain and pain management should be ongoing, as the 
causes and treatments of the disease are commonly misunderstood.  For example, two 
participants in this study were taking opioids to relieve their claudication.  Claudication is 
caused by ischemic conditions and by definition it is intermittent in nature, thus it should 
not be treated with medications designed to alleviate acute and/or chronic pain.  Pain 
education should include regular evaluation of all sources of pain and the appropriate 
pain management for each affected site based on the primary cause of discomfort.  
 Clinicians should also continue providing education regarding the role of exercise 
and the risks associated with worsening of the disease.  Not all of the participants in this 
study understood the importance of regular physical activity and none expressed 
knowledge of the implications of disease progression.   Once the relationship between 
individual characteristics and their effects on calf tissue oxygenation are more clearly 
understood, patients should be individually assessed and provided with their information 
about calf tissue oxygenation during exercise and recovery.  This information has the 
potential to increase an individual’s insight into the symptoms they experience and enable 
them to distinguish PAD symptoms from symptoms related to other comorbid conditions.   
Conclusion 
 This study provides a unique perspective and a preliminary understanding of the 
relationship between subjective symptom reporting and calf tissue oxygenation with a 
variety of PAD risk factors and individual characteristics.  At rest, during exercise, and 
during recovery, participants provided typical and ‘atypical’ symptom locations and 
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descriptors to describe the PAD symptom experience.  During exercise, the most severe 
oxygen desaturation took place between the start of exercise and the initial onset of 
symptoms.  Oxygen desaturation continued throughout exercise to a lesser extent and to 
varying degrees.  When the recovery phase began, blood flow was restored to the lower 
extremities.  During this phase, the majority of individuals experienced an initial re-
saturation of oxygen in calf tissue, but the increase in oxygenation did not provide 
immediate symptom relief.   
 Continued research simultaneously comparing subjective symptom reporting with 
objective physiologic changes during exercise is necessary to validate ‘atypical’ 
participant symptom reporting and broaden the currently accepted PAD symptom 
locations and descriptors.  Despite the under-reporting of ‘atypical’ symptoms compared 
to classic claudication, they do exist and they are no less important for the early 
detection, diagnosis, and treatment of PAD to minimize the impact of this painful, 
debilitating, and deadly disease.   
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     Appendix A 
  Peripheral Artery Disease (PAD) Semi-Structured Symptom Interview 
 
Questions: 
 
1.  Please describe in as much detail as possible the symptoms you experience while 
exercising.  This can include activities such as walking, gardening, shoveling, etc. 
 
2.  When does this symptom come? 
 
3.  How does it feel?  What words would you use to describe it? 
 
4.  If you rest (stand still, sit or lie down) how long does it take to go away? 
 
5.  Do you experience any other pain or discomfort while exercising or resting?     
  
6.  If you got up to walk right now what would happen? 
 
7.  Does your ability to exercise change from day to day?   
  
Sample Interviewer Prompts:  
…Tell me more about that.  
…Can you elaborate a little on that? 
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     Appendix B                                             
  Peripheral Artery Disease (PAD) Symptom Questionnaire 
 
1.  On the diagram below, shade in the areas where you experience symptoms while 
exercising (walking, gardening, shoveling, etc).   Use a different color for each type of 
pain, for example use red to shade the calf area for an ache and use blue to shade the foot 
for numbness.    
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2.  Following the same directions as above, shade in the areas where you continue to 
experience symptoms after you stop exercising (standing still, sitting or lying down).  
  
 
 
     
 
3.  If any or all of your symptoms go away when you rest, please write below an estimate 
for how long you have to rest for each symptoms to go away. 
 
Symptom location: ________Time at rest for symptom to go away: ___________minutes   
Symptom location: ________Time at rest for symptom to go away: ___________minutes   
Symptom location: ________Time at rest for symptom to go away: ___________minutes 
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4.  Continuing to follow the initial directions, shade in the areas you experience 
symptoms at different times of the day, not related to exercise.  For example, while 
sitting in your recliner chair you get a shooting pain along your thigh.  
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                 Appendix C 
                      Information Sheet for Research 
   Exploring Peripheral Artery Disease (PAD) Symptoms 
 
You are invited to be in a research study of the description of symptoms people with 
PAD experience while resting and with activity.  You were selected as a possible 
participant because you have been given a diagnosis of PAD by a doctor or nurse and 
expressed an interest to participate in this study while attending a screening visit for the 
EXERT study.  We ask that you read this form and ask any questions you may have 
before agreeing to be in the study.   
 
This study is being conducted by:  Erica Schorr, BSBA, BSN, RN, Graduate Student of 
the University of Minnesota School of Nursing.   
 
Procedures: 
 
If you agree to be in this study, we would ask you to do the following things: 
Complete a brief questionnaire about your symptoms, then describe your symptoms in 
more detail to the principal investigator (PI), Erica Schorr, during a voice taped 
interview.  This will take approximately 45 to 60 minutes of your time.  There is a slight 
risk you may become emotionally upset discussing the pain you experience, however the 
risk is small and is minimized by you sharing only what you feel comfortable with during 
the interview.  You will not receive any compensation for your participation. 
 
Confidentiality: 
 
The records of this study will be kept private.  In any sort of report we might publish, we 
will not include any information that will make it possible to identify a subject.  Research 
records will be stored securely and only researchers will have access to the records.  Only 
the PI will have access to the audio recordings.  They will be erased at the completion of 
the study or within four years, whichever occurs first.   
 
Voluntary Nature of the Study: 
 
Participation in this study is voluntary.  Your decision whether or not to participate will 
not affect your current or future relations with the University of Minnesota.  If you decide 
to participate, you are free to no answer any question or withdraw at any time without 
affecting those relationships.   
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Contacts and Questions:   
 
The researcher(s) conducting this study (are):  Erica Schorr and Cynthia Peden-
McAlpine.  You may ask questions you have now.  If you have questions later, you are 
encouraged to contact them at Erica Schorr 120 Dinnaken Office Building, 925 
Delaware Street, Minneapolis, MN 55455, (612) 381-4449, scho0828@umn.edu.  
Cynthia Peden-McAlpine, 6-109 Weaver-Densford Hall, 308 Harvard Street SE, 
Minneapolis, MN 55455, (612) 624-0449, peden001@umn.edu.   
 
If you have any questions or concerns regarding this study and would like to talk to 
someone other than the researcher(s), you are encouraged to contact the Research 
Subjects’ Advocate Line, D528 Mayo, 420 Delaware St. Southeast, Minneapolis, 
Minnesota 55455; (612) 625-1650.  
 
  You will be given a copy of this information to keep for your records.   
 
195 
 
     Appendix D 
    Pilot Study IRB Approval
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     Appendix E 
          IRB Approval for the Main Study 
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     Appendix F  
            Recruitment Letter 
 
«Month» «Day» «Year» 
 
 
«Title» «FirstName» «LastName» 
«Address1», «Address2» 
«City», «State» «PostalCode» 
 
Dear «Title» «LastName»: 
 
As a previous participant in the EXERT study I thought you might like to know about a 
new study I am conducting at the University of Minnesota to learn more about the 
peripheral artery disease (PAD) symptom experience.   
 
This study would involve completing an interview about your symptoms and walking on 
a treadmill to test a new device to measure the amount of oxygen in your calf muscle 
during exercise.  The technology is near-infrared spectroscopy (NIRS) and it allows for 
pain free measurement to obtain this valuable information.     
 
If you have any questions regarding this study, or would like more information about 
enrollment, please do not hesitate to contact me at 612-381-4449.  If you would like more 
information about why you were contacted or how this relates to your participation in the 
EXERT study please contact the EXERT study coordinator, Laura Kirk at 612-626-4687.  
Thank you for your time and consideration.   
 
Sincerely, 
 
 
 
Erica Schorr, R.N. 
Principle Investigator  
University of Minnesota School of Nursing 
(612) 381-4449 
scho0828@umn.edu 
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Appendix G 
Demographic Information Form 
 
 
 
 
 
Sex:  Male     Female    
 
Age:        
 
Date of Birth:     
 
Marital Status: 
 Single ___________ 
 Married/Living with Partner   __  
 Divorced    
 Widowed    
 
Race (Please check all that apply): 
 American Indian or Alaskan Native    
 Asian    
 Black or African American    
 Native Hawaiian or Pacific Islander    
 White    
 
Ethnicity:  
 Hispanic or Latino    
 Non-Hispanic or Non-Latino    
 
Education: 
 Less than High School Diploma  ____ 
 High School Diploma    
 Some College ____________ 
 4 year College Degree    
 Graduate School    
 
Employment Status: 
 Full-Time Employed ____________ 
 Part-Time Employed ____________ 
 Homemaker  __________ 
 Retired  _____ 
 
Previous Occupation:          
 
 
 
Participant Namecode ______________               Visit Date  ___/___/___ 
Participant ID _____________________       
Visit: Consent 
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Appendix H                                                         
Medication List 
 
 
 
 
Previous Medications 
 
Name Dose Reason 
   
   
   
   
   
   
   
   
   
   
   
 
 
Current Medications 
 
Name Dose Reason 
   
   
   
   
   
   
   
   
   
   
   
 
 
 
 
 
 
 
 
Participant Namecode ______________                 Visit Date  ___/___/___ 
Participant ID _____________________   
Visit: Consent 
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 Appendix I  
                                                        Resting ABI Measurement Form 
 
     
 
    ABI MEASUREMENT 
 
Right Arm        Left arm 
Systolic pressure (mmHg)      Systolic pressure (mmHg) 
 
_____________________      ___________________ 
 
 
Right ankle         Left ankle 
Systolic pressure (mmHg)      Systolic pressure (mmHg) 
Posterior Tibial (PT)       Posterior Tibial (PT) 
 
_________________       ____________________ 
 
Dorsalis Pedis (DP)       Doralis Pedis (DP) 
 
________________       ___________________ 
 
 
Right ABI equals ratio of: 
 
Higher of the right ankle pressures (PT or DP).  ____________mmHg 
 
           DIVIDED BY  =_____________ 
 
Higher arm pressure (left or right arm).              _____________mmHg 
 
 
Left ABI equals ratio of: 
 
Higher of the left ankle pressures (PT or DP).    ___________mmHg 
 
           DIVIDED BY  =______________ 
 
Higher arm pressure (left or right arm).              ___________mmHg 
 
 
 
 
 
 
Participant Namecode: _______________   Visit Date: ___/___/___   
Participant ID  ______________    
Rest start time __________  
ABI start time_________ 
Visit: Consent 
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 Appendix J            
 Treadmill Familiarization Form                                           
 
 
 
TREADMILL and TESTING PROCEDURE FAMILIARIZATION 
 
Prior to completing the treadmill familiarization, participants will have the opportunity to 
examine the discomfort scale (0-no discomfort to 5-maximal discomfort).  Explain the meaning 
of the scale and its use during subsequent testing.  Explain that he/she will be walking briefly on 
the treadmill and that he/she will be asked to mimic the testing procedures, verbally reporting a 
number between 0 and 5 to indicate their level of discomfort and providing symptom descriptors 
during exercise. 
 
The treadmill familiarization should begin at a slow treadmill speed of 1.0 mph and 0% grade. 
Increase speed and grade until claudication discomfort is reached within 3 minutes.  The walking 
bout should only last until the appropriate speed and grade to induce claudication is determined, 
but may be repeated if needed. 
 
 1.  Have the participant straddle the treadmill belt and step on it once it is fully up to  
  speed at between 1.0 and 2.0 mph.  Participant should walk for a minimum of two 
  separate bouts of walking.  Additional bouts of walking may be repeated as  
  necessary. 
2.  During familiarization, the participant should walk on the treadmill in as normal a  
  manner as possible.  Make sure they are using a normal stride and not doing a  
  shortened stutter or shuffle step.  They should be instructed to walk with their  
  back straight and looking forward instead of looking down at the belt.   
3.  Ensure that participants walk on the treadmill with their hands resting lightly on the 
 handgrips at the front of the treadmill to help with balance only. 
4.  Have participant walk at 1.5 mph for 3 minutes.  Assess discomfort at 30 second 
 intervals. 
5.  Have participant walk at 2.0 mph for 3 minutes.  Again, assess discomfort at 30 
 second intervals.   
6.  If participant did not experience claudication discomfort, additional bouts may be 
 performed until the appropriate speed and incline for treadmill testing has been 
 determined. 
 
(Note: Stop treadmill if participant is unsteady or reporting discomfort >1). 
 
□ Treadmill explained 
□ Discomfort scale explained 
□ NIRS probe placement explained 
□ Patient Verbalizes Understanding 
Visit: Consent 
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 Appendix J            
 Treadmill Familiarization Form                                           
 
 
 
  
 Assess gait, noting any gait instability. Describe:       
            ______ 
 
Treadmill Walking Trial: 
Trial 30 
Second 
Rating 
  
60 
Second 
Rating 
 
90 
Second 
Rating 
 
120 
Second 
Rating 
 
150 
Second 
Rating 
 
180 
Second 
Rating 
 
1.5 
MPH 
 
0.0% 
Grade 
      
2.0 
MPH 
 
0.0% 
Grade 
      
 
_____ 
MPH 
 
_____ 
Grade 
      
 
 
From Treadmill Familiarization (please check one): 
 
 _______ 2.0 MPH is appropriate beginning testing speed 
 
 _______ 1.5 MPH is appropriate beginning testing speed 
 
 _______ Other (specify speed achieved and duration) 
 
 
Notes from TM Familiarization: ____________________________________________ 
 
______________________________________________________________________   
 
______________________________________________________________________  
Visit: Consent 
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     Appendix K 
          CONSENT FORM 
 Characterization of the Peripheral Artery Disease (PAD) Symptom Experience 
 
You are invited to be in a research study exploring the way people diagnosed with 
peripheral artery disease (PAD) describe the symptoms they experience.  You will be 
asked to describe your symptoms during an interview and while walking on a treadmill.  
You were selected as a possible participant because a doctor or nurse has given you a 
diagnosis of PAD, you are a current participant in the EXercise Training to Reduce 
Claudication: Arm ERgometry versus Treadmill Walking (EXERT) study, and you 
expressed an interest to participate in this study to an EXERT staff member.   
 
We ask that you read this form and ask any questions you may have before agreeing to be 
in the study.   
 
Erica Schorr, RN of the University of Minnesota School of Nursing, is conducting this 
study.  It is funded by a grant received from the Nursing Research Section at the National 
Institutes of Health.   
 
Study Purpose 
 
The purpose of this study is to gain a comprehensive understanding of the PAD symptom 
experience in older and younger men and women beyond classic claudication, including 
the quality, duration, and intensity of symptoms.  We also want to know if there is a 
relationship between how much oxygen is getting to your leg muscles and the symptoms 
you are reporting.  You will verbally report your symptom(s) using words to describe 
what you are feeling and giving each symptom a numerical rating on a scale of 0 to 5.   
 
Study Procedures 
 
You have been cleared to exercise by a qualified cardiovascular clinician based on the 
EXERT study protocol.   
 
If you agree to participate in this study, you will meet one time with the Principle 
Investigator (PI) for approximately two hours.  Your visit will include the following:   
 
PAD Questionnaire 
You will be asked to complete a two-page questionnaire with the help of the PI.  This 
form will ask you to identify the location of all of your symptoms (while exercising, 
immediately after, and at rest) on a body diagram.  For symptoms that go away or lessen 
with rest, you will be asked to give an estimate of how long it takes your symptoms to go 
away after stopping exercise.     
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Symptom Interview 
You will be asked to describe all of your symptoms (related or unrelated to PAD) in more 
detail during a voice-recorded interview.  You will be asked to describe your diagnosis of 
PAD, your symptoms, and how you feel they affect your life.    
 
Ankle-Brachial Index (ABI)  
The ABI is a test that compares the blood pressure in your arms to the blood pressure in 
your legs.  During this procedure, blood pressure cuffs will be placed around your upper 
arms and ankles, and a small amount of gel will be placed over the artery being 
measured.  A Doppler probe attached to a small speaker will be placed on the gel and you 
will hear a loud pulsing sound.  The cuffs will be inflated individually until the sound is 
no longer heard and then slowly released.  A resting ankle-brachial index (ABI) will be 
taken prior to walking on the treadmill and four times immediately after your first 
exercise test (immediately after stopping exercise, 2 minutes after stopping exercise, 5 
minutes after stopping exercise, and 10 minutes after stopping exercise).  These intervals 
could change based on how quickly the blood flow in your legs improves according to a 
piece of equipment called near-infrared spectroscopy (NIRS).  It is a painless procedure 
that involves placing a small patch (optode) over your calf muscle.  The patch will be 
placed at rest and will remain on your calf until all three exercise tests have been 
completed.       
 
Treadmill Familiarization  
You will review a discomfort scale (0-no discomfort to 5-maximal discomfort).  We will 
explain how it will be used during testing.  Next, you will walk briefly on a treadmill to 
imitate the testing procedures.  The treadmill speed will begin at 1.5 mph and 0% incline.  
The speed and incline will be increased until discomfort is reached (1 out of 5) within 3 
minutes. You will also describe your leg discomfort in words during exercise.  The 
treadmill will be stopped if you are unsteady or reporting discomfort >1.       
 
Treadmill Testing 
You will be asked to walk on a treadmill three separate times, with at least 10 minutes of 
rest in between to allow the blood flow in your legs to return to normal.  The treadmill 
will start at the speed and incline determined during your treadmill familiarization.  The 
amount of oxygen in your leg muscles will be measured by NIRS.  You will walk on the 
treadmill reporting a number from 0 to 5 that corresponds to your discomfort, as well as 
reporting words that describe your symptoms.  The test will be stopped as soon as you 
report a discomfort level of 5 out of 5.   
 
Risk of Study Participation 
 
The study has the following risks:   
 
The risks associated with this study are primarily related to exercise.  For safety reasons, 
before study testing, you will be placed on a treadmill and asked to walk at a slow speed 
to determine an appropriate speed for testing.   
 
Version Date: 04/18/11        Page 2 of 5 
207 
 
   
 
Exercise testing carries a small risk (1 in 10,000) of heart attack or death.  To minimize 
this risk, you will only be allowed to participate if you do not have severe heart disease.  
Your risk is also minimized by being cleared for exercise through your participation in 
the EXERT study.   
 
We will check a resting ABI before the test.  Your blood pressure will be taken before 
and after exercise, while seated and standing.  You may experience discomfort in the leg 
and arm when the blood pressure cuff inflates.  If you feel the discomfort is too much, 
please tell the researcher and the study will be stopped immediately.  You heart rate will 
be monitored continuously with a strap placed around your chest and a watch on your 
wrist.  If you have diabetes, a pre- and post-exercise blood sugar with be taken with a 
glucometer.  These measures will be taken to ensure that it is safe to perform exercise on 
the treadmill.   
 
Trained staff and the necessary equipment will be available should anything unusual 
happen while you are exercising.  The treadmill will be stopped if you have shortness of 
breath or chest pain that makes it uncomfortable for you to continue.  The treadmill will 
also be stopped anytime that you ask it be stopped.  If you are suspected of having a 
cardiac event, 911 will be called immediately and the emergency protocols of the facility 
will be followed.     
 
There is a slight risk that you may become emotionally upset discussing the experience of 
your symptoms during the interview, particularly those that cause you a great deal of 
pain.  However, the risk is small and is minimized by you sharing only what you feel 
comfortable with during the interview.   
 
Benefits to Study Participation 
 
The benefits to study participation are:   
 
There is no direct benefit to you for participating in this study.   
 
This research has potential benefit for current and future patients with PAD.  This study 
will provide information on the assessment, evaluation, and diagnosis of PAD based on 
age, gender, and symptoms reported.    
 
Alternatives to Study Participation 
 
Choosing not to participate in this study will not affect treatment for your PAD in any 
way.  If you choose not to participate, your participation with the EXERT study will not 
be affected.   
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Study Costs/Compensation 
 
All care provided as part of this study will be provided to you at no charge.  A parking 
permit will be provided for your visit.  There is no other compensation provided to you 
for participation in this study.    
 
Research Related Injury 
 
In the event that this research activity results in an injury, treatment will be available, 
including first aid, emergency treatment, and follow-up care as needed. Care for such 
injuries will be billed in the ordinary manner to you or your insurance company. If you 
think that you have suffered a research related injury, let the principle investigator know 
right away. 
 
Confidentiality 
 
The records of this study will be kept private. In any publications or presentations, we 
will not include any information that will make it possible to identify you as a study 
participant.  Your research records will be stored securely and only study investigators 
and staff will have access to the records.  Study records may be subject to review by the 
NIH and the FDA. There are also departments at the U of MN with appropriate 
regulatory oversight which may review your records. 
 
Protected Health Information (PHI)  
Your PHI created or received for the purpose of this study is protected under the federal 
regulation known as HIPPA.  Please refer to the attached HIPPA authorization for details 
concerning the use of this information.   
 
Voluntary Nature of the Study 
 
Your decision whether or not to participate in this study is strictly voluntary.  Your 
decision will not affect your current or future relations with your regular doctor or the 
University of Minnesota.  Your decision will have no effect on your participation in the 
EXERT study.   
 
If you decide to participate, you are free to withdraw at any time without affecting those 
relationships.  The principle investigator or study staff may withdraw you from the study 
without your approval if you do not follow study instructions, or for any other reason(s) 
that they feel are appropriate.   
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Contacts and Questions 
 
If you have any questions now or in the future concerning your participation in this study, 
you may contact Erica Schorr at 612-381-4449.  You may ask any questions you have 
now.  You have the right to ask the study staff or the principle investigator any questions 
concerning this study at any time.   
 
 
If you have any questions or concerns regarding the study and would like to talk with 
someone other than the research(s), you are encouraged to contact the Fairview Research 
Helpline at 612- 672-7692 or toll free at 1-866-508-6961.  You may also contact this 
office in writing or in person at Fairview University Medical Center-Riverside campus, 
2200 Riverside Avenue, Minneapolis, MN 55454.      
 
Statement of Consent 
 
I have read the above information.  I have asked questions and have received answers.   
I consent to participate in the study.   
 
Signature of Subject       Date    
 
Signature of Investigator      Date    
 
 
                  You will be given a copy of this form to keep for your records.   
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Appendix L 
HIPAA Authorization Form 
 
HIPAA1 AUTHORIZATION TO USE AND DISCLOSE 
INDIVIDUAL HEALTH INFORMATION FOR RESEARCH PURPOSES 
 
1. Purpose.  As a research participant, I authorize Erica Schorr, RN and the 
researcher’s staff to use and disclose my individual health information for the purpose 
of conducting the research project entitled "Characterization of the Peripheral Artery 
Disease (PAD) Symptom Experience.” 
 
2. Individual Health Information to be Used or Disclosed.  My individual 
health information that may be used or disclosed to conduct this research includes: 
Demographic information, ABI results, medical history, interview transcripts, and 
treadmill testing descriptors and oxygenation status. 
 
3. Parties Who May Disclose My Individual Health Information. 
The researcher and the researcher’s staff may obtain my individual health information 
from other 
healthcare providers, such as laboratories, which are a part of this research, as well as 
healthcare providers that are not part of this research (other doctors, hospitals and/or 
clinics) for the purposes of carrying out this research study.  I authorize these parties to 
disclose my individual health information to the researcher and the researcher’s staff 
for the purposes of carrying out this research study. 
 
4. Parties Who May Receive or Use My Individual Health Information.  The 
individual health information disclosed by parties in item 3 and information disclosed 
by me during the course of the research may be received and used by Erica Schorr, 
RN and the researcher’s staff and [list any collaborators, other clinical sites involved 
in the research, sponsors if applicable, outside laboratories-N/A]. [OPTIONAL: Also, 
if I receive compensation for participating in this study, identifying information about 
me may be used or disclosed as necessary to provide compensation.] 
 
5. Right to Refuse to Sign this Authorization.  I do not have to sign this 
Authorization.  If I decide not to sign the Authorization, I may not be allowed to 
participate in this study or receive any research related treatment that is provided 
through the study. However, my decision not to sign this authorization will not affect 
any other treatment, payment, or enrollment in health plans or eligibility for benefits. 
 
6. Right to Revoke.  I can change my mind and withdraw this authorization at any 
time by sending a written notice to Erica Schorr; 5-140 Weaver-Densford Hall, 308 
Harvard St SE; Minneapolis, MN 55455 to inform the researcher of my decision.  If I 
withdraw this authorization, the researcher may only use and disclose the protected 
health information already collected for this research study. No further health 
information about me will be collected by or disclosed to the researcher for this study. 
 
1 HIPAA is the Health Insurance Portability and Accountability Act of 1996, a federal law related to privacy of health 
information. 
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7. Potential for Re-disclosure.  Once my health information is disclosed under this 
authorization, there is a potential that it will be re-disclosed outside this study and no 
longer covered by this authorization. However, the research team and the University’s 
Institutional Review Board (the committee that reviews studies to be sure that the 
rights and safety of study participants are protected) are very careful to protect your 
                  privacy and limit the disclosure of identifying information about you. 
 
       7A. Also, there are other laws that may require my individual health information to be     
          disclosed for public purposes.  Examples include potential disclosures if required for  
         mandated reporting of abuse or neglect, judicial proceedings, health oversight activities  
         and public health measures. 
 
       8A. [Optional Item] Suspension of Access.  I may not be allowed to review the  
                 information collected for this study, including information recorded in my medical record,  
                 until after the study is completed.  When the study is over, I will have the right to access     
                 the information again. 
 
               This authorization does not have an expiration date. 
 
              I am the research participant or personal representative authorized to act on           
              behalf of the participant. 
 
              I have read this information, and I will receive a copy of this authorization form after it is  
              signed.        
                    signature of research participant or research participant’s                   date 
                   personal representative 
 
 
 
                   printed name of research participant or research participant’s            description of personal representative’s  
                   authority to act on behalf personal representative                                of the research participant 
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 Appendix M 
Introductory & Treadmill (TM) Data Collection Form 
(Keep original as Source Document in participant’s file) 
 
Item 
#  
Data Item Data Entry 
 
1.  
 
Anthropometric measurements  
 
 
Height ________  inches            
Weight ________  pounds 
 
2.   Date of birth Month/day/year:  ______________               
Age _________ 
 
 
E-mail address _____________________________ 
3.   Co-morbid conditions 
 
Smoke? _______   
PPD _______ 
_______________       _____________          
_______________       _____________           
_______________       _____________          
_______________       _____________           
4.  Date of cardiac stress test Month/day/year: _________________ 
 
 Details of test 
 
 
 
EXERT Group: ___________ 
Max heart rate _________ bmp                  
Rest HR ________ 
Peak speed:  _________ mph                     
Rest BP ________ 
Peak incline: ___________ %                    
Peak BP_________ 
Onset  ______________                            
Max____________ 
Peak RPE __________                  
 ABI History Date:  
Value:    
 Symptoms & Location(s) 
 
Blockage(s) 
________________ 
_______________       _____________          
_______________       _____________   
_______________       _____________          
_______________       _____________          
_______________       _____________          
_______________       _____________            
4.   Calf circumference Right     or     Left   (circle one) 
__________ cm  
Participant Namecode ______________               Visit Date  ___/___/___ 
Participant ID _____________________       
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5.   Details of Exercise Test 
 
(based on treadmill 
familiarization) 
             
     TM speed: _________ mph 
     TM grade:___________ % incline 
 
 Additional comments 
 
 
 
 
 
 
 
 
 
Current Exercise Routine 
Participant was called about missed appointment?      
Yes         No 
Reason for missed session:                                                          
 
        Hospitalized            Forgot             Other  
                                                                ________________ 
 
        Not feeling well        Transportation problem  
 
  Make-up date scheduled?                 Yes          No 
  (mm/dd/yy)    _____________ 
 
______________________________________________ 
 
6.  
 
Pre-Exercise Blood Glucose 
 
 
___________________ 
7.   Baseline Measurements Blood pressure __________ mmHg     R  or   L 
Heart rate __________ bmp 
 
 
8. 
TM Test 1: 
 
 
 
TM Test 2: 
 
 
 
TM Test 3:   
 
Pre BP ______HR _____         
Post  BP _______  HR _____ 
Walking Time ____________minutes: seconds 
Recovery Time ___________ minutes: seconds 
 
Pre BP ______HR _____         
Post  BP _______  HR _____ 
Walking Time ____________minutes: seconds  
Recovery Time ___________ minutes: seconds 
 
Pre BP ______HR _____         
Post  BP _______  HR _____ 
Walking Time ____________minutes: seconds  
Recovery Time ___________ minutes: seconds 
9.   Baseline ABI Right __________       *indicates testing leg 
Left ___________ 
 
Participant Namecode ______________               Visit Date  ___/___/___ 
Participant ID _____________________       
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10.   Post-exercise ABI’s ______________ immediate 
 
______________ 2 minutes 
 
______________ 5 minutes 
 
______________ 10 minutes 
11.   Test #     
Exercise      OR        Rest 
Time  
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 
Participant Namecode ______________               Visit Date  ___/___/___ 
Participant ID _____________________       
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 Test #     
Exercise      OR        Rest  
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test # 
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 
Participant Namecode ______________               Visit Date  ___/___/___ 
Participant ID _____________________       
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 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 
Participant Namecode ______________               Visit Date  ___/___/___ 
Participant ID _____________________       
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 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #    
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 Test #     
Exercise      OR        Rest 
Time 
Intensity 
 
Descriptor 
 
Location 
 
12. 
 
Post-Exercise Blood Glucose 
 
 
________________________ 
 
Participant Namecode ______________               Visit Date  ___/___/___ 
Participant ID _____________________       
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        Appendix N 
       Individual Exercise Trajectories 
 
N1.  An initial rapid decline in TSI, followed by slowly declining or relatively unchanged TSI values throughout exercise (n=10).  
Time (seconds)
TS
I (
%
)
0
20
40
60
80
 : ID{ 3 }
0 200 400 600 800 1000
 : ID{ 6 }  : ID{ 7 }
0 200 400 600 800 1000
 : ID{ 8 }  : ID{ 9 }
0 200 400 600 800 1000
 : ID{ 15 }  : ID{ 16 }
0 200 400 600 800 1000
 : ID{ 20 }  : ID{ 23 }
0 200 400 600 800 1000
0
20
40
60
80
 : ID{ 32 }
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N2.  Relatively unchanged TSI values during exercise (n=10).   
 
Time (seconds)
TS
I (
%
)
0
20
40
60
80
 : ID{ 1 }
0 500 1000 1500
 : ID{ 4 }  : ID{ 5 }
0 500 1000 1500
 : ID{ 11 }  : ID{ 13 }
0 500 1000 1500
 : ID{ 28 }  : ID{ 31 }
0 500 1000 1500
 : ID{ 33 }  : ID{ 35 }
0 500 1000 1500
0
20
40
60
80
 : ID{ 38 }
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N3.  Exponentially declining TSI values during exercise (n=8).
 
Time (seconds)
TS
I (
%
)
0
20
40
60
80
 : ID{ 2 }
0 200 400 600 800 1000
 : ID{ 17 }  : ID{ 24 }
0 200 400 600 800 1000
 : ID{ 25 }
0 200 400 600 800 1000
 : ID{ 26 }  : ID{ 27 }
0 200 400 600 800 1000
 : ID{ 29 }
0
20
40
60
80
 : ID{ 40 }
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N4.  Gradual decline in TSI values throughout the exercise phase (n=8). 
 
Time (seconds)
TS
I (
%
)
0
20
40
60
80
 : ID{ 10 }
0 200 400 600 800 1000
 : ID{ 12 }  : ID{ 14 }
0 200 400 600 800 1000
 : ID{ 18 }
0 200 400 600 800 1000
 : ID{ 30 }  : ID{ 34 }
0 200 400 600 800 1000
 : ID{ 37 }
0
20
40
60
80
 : ID{ 39 }
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N5.  Quadratic change in TSI values during exercise (n=2).  
 
Time (seconds)
TS
I (
%
)
0
20
40
60
80
0 200 400 600
 : ID{ 19 }
0 200 400 600
 : ID{ 22 }
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N6.  Cubic change in TSI values during exercise (n=2).   
 Time (seconds)
TS
I (
%
)
0
20
40
60
80
0 200 400 600 800 1000
 : ID{ 21 }
0 200 400 600 800 1000
 : ID{ 36 }
224 
 
        Appendix O 
              Individual Recovery Trajectories 
O1.  Rapid peak TSI during recovery (n=3). 
Time (seconds)
TS
I (
%
)
0
20
40
60
80
 : ID{ 23 }
100 200 300 400 500
 : ID{ 27 }
100 200 300 400 500
0
20
40
60
80
 : ID{ 29 }
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O2.  Prolonged TSI recovery with a less pronounced peak (n=8). 
 
Time (seconds)
TS
I (
%
)
0
20
40
60
80
 : ID{ 4 }
0 200 400 600 800
 : ID{ 5 }  : ID{ 7 }
0 200 400 600 800
 : ID{ 8 }
0 200 400 600 800
 : ID{ 10 }  : ID{ 30 }
0 200 400 600 800
 : ID{ 35 }
0
20
40
60
80
 : ID{ 39 }
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O3.  Exponential TSI recovery (n=6).   
 
Time (seconds)
TS
I (
%
)
0
20
40
60
80
 : ID{ 14 }
200 400 600
 : ID{ 17 }  : ID{ 18 }
200 400 600
 : ID{ 24 }  : ID{ 33 }
200 400 600
0
20
40
60
80
 : ID{ 37 }
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O4.  Rapid cubic TSI recovery (n=2). 
 
Time (seconds)
TS
I (
%
)
0
20
40
60
80
50 100 150 200 250 300
 : ID{ 1 }
50 100 150 200 250 300
 : ID{ 9 }
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O5.  Slower cubic TSI recovery (n=4).   
 
Time (seconds)
TS
I (
%
)
0
20
40
60
80
100 200 300
 : ID{ 16 }
100 200 300
 : ID{ 20 }
100 200 300
 : ID{ 28 }
100 200 300
 : ID{ 38 }
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O6.  Relatively unchanged TSI values throughout the recovery phase (n=5). 
 
Time (seconds)
TS
I (
%
)
0
20
40
60
80
 : ID{ 6 }
0 200 400 600 800
 : ID{ 11 }  : ID{ 25 }
0 200 400 600 800
 : ID{ 31 }
0
20
40
60
80
 : ID{ 34 }
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O7.  Linear TSI recovery (n=4).   
 
Time (seconds)
TS
I (
%
)
0
20
40
60
80
0 100 200 300 400 500
 : ID{ 12 }
0 100 200 300 400 500
 : ID{ 13 }
0 100 200 300 400 500
 : ID{ 21 }
0 100 200 300 400 500
 : ID{ 40 }
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O8.  Rapid initial and full recovery (n=4).   
 
Time (seconds)
TS
I (
%
)
0
20
40
60
80
50 100 150 200 250 300
 : ID{ 22 }
50 100 150 200 250 300
 : ID{ 26 }
50 100 150 200 250 300
 : ID{ 32 }
50 100 150 200 250 300
 : ID{ 36 }
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O9.  Rapid initial TSI recovery, followed by gradually declining TSI values (n=3).   
 
Time (seconds)
TS
I (
%
)
0
20
40
60
80
0 500 1000
 : ID{ 2 }
0 500 1000
 : ID{ 3 }
0 500 1000
 : ID{ 15 }
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O10.  Unique recovery pattern (n=1). 
 Time (seconds)
TS
I (
%
)
0
20
40
60
80
50 100 150 200 250 300
 : ID{ 19 }
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     Appendix P  
   Individual Exercise Phase Summary 
 
ID # Gender Age ABI BMI Category Ratings M TSI      (SD)    Min.    Max. 
1 Male 55 0.65 Normal 30 17.12 (15.50) 00.00 61.12 
2 Male 63 1.03 Overweight 18 42.50 (8.25) 36.19 62.41 
3 Male 65 0.50 Obese 17 56.06 (6.68) 48.95 69.55 
4 Male 68 0.30 Overweight 16 42.50 (5.92) 35.94 57.90 
5 Female 79 0.41 Overweight 21 27.72 (3.90) 17.41 35.54 
6 Male 62 0.63 Underweight 21 41.67 (6.35) 29.93 55.29 
7 Male 81 0.64 Normal 18 45.31 (9.96) 32.34 66.99 
8 Male 68 0.48 Normal 22 37.43 (10.17) 25.08 62.20 
9 Male 77 0.60 Normal 17 37.67 (13.63) 25.39 68.71 
10 Male 81 0.53 Obese 17 59.40 (1.87) 57.57 64.51 
11 Male 58 1.05 Normal 17 60.14 (4.37) 49.76 64.87 
12 Male 55 1.12 Normal 18 58.12 (4.63) 52.49 68.40 
13 Male 73 1.15 Overweight 26 62.34 (3.47) 56.38 71.60 
14 Male 62 0.91 Overweight 20 63.11 (3.76) 55.84 67.63 
15 Male 58 0.94 Obese 18 54.30 (7.39) 40.28 68.99 
16 Female 78 0.94 Overweight 24 59.76 (4.03) 56.50 71.51 
17 Male 52 0.87 Overweight 20 49.39 (6.40) 44.34 65.39 
18 Male 83 0.57 Overweight 17 61.59 (5.04) 52.29 72.93 
19 Male 83 0.62 Overweight 12 48.71 (10.75) 32.13 69.07 
20 Male 63 0.63 Normal 18 46.19 (8.86) 34.27 67.69 
21 Male 65 1.15 Overweight 19 51.95 (6.72) 42.42 66.12 
22 Male 79 0.90 Normal 20 50.86 (8.84) 31.58 68.85 
23 Male 77 1.64 Obese 17 39.29 (10.83) 23.14 60.80 
24 Male 68 0.68 Overweight 18 47.73 (10.74) 39.16 75.31 
25 Male 64 0.66 Obese 18 52.42 (7.26) 44.81 70.47 
26 Male 66 0.90 Overweight 18 54.88 (7.28) 48.83 75.26 
27 Male 67 0.75 Obese 17 51.39 (7.72) 43.54 69.28 
28 Male 49 0.94 Obese 19 59.88 (2.84) 56.96 66.89 
29 Male 58 0.68 Normal 18 16.94 (23.36) 00.00 60.07 
30 Male 72 0.46 Overweight 22 49.77 (5.11) 41.63 63.76 
31 Male 68 1.27 Obese 21 62.03 (2.19) 58.41 66.54 
32 Male 68 0.74 Overweight 20 49.78 (7.97) 39.55 71.76 
33 Female 78 0.95 Overweight 19 59.20 (3.30) 52.58 64.79 
34 Male 63 0.90 Overweight 18 40.82 (8.81) 29.05 60.02 
35 Male 57 0.56 Normal 14 61.92 (2.92) 57.39 66.37 
36 Male 79 1.04 Overweight 23 47.54 (9.65) 22.51 63.02 
37 Female 75 0.64 Obese 20 62.56 (5.70) 55.12 77.95 
38 Female 63 1.14 Obese 18 63.57 (2.71) 59.31 67.37 
39 Male 59 1.06 Obese 18 62.57 (4.96) 56.67 74.58 
40 Male 63 0.66 Overweight 18 50.11 (10.34) 40.72 76.74 
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     Appendix Q 
         Individual Recovery Phase Summary 
 
ID # Gender Age ABI BMI Category Ratings M TSI      (SD)    Min.    Max. 
1 Male 55 0.65 Normal 16 16.10 (20.33) 00.00 51.37 
2 Male 63 1.03 Overweight 11 67.57 (3.85) 59.17 71.45 
3 Male 65 0.50 Obese 12 66.60 (6.10) 56.69 74.11 
4 Male 68 0.30 Overweight 14 45.91 (4.15) 37.85 53.98 
5 Female 79 0.41 Overweight 15 31.29 (14.39) 10.18 52.45 
6 Male 62 0.63 Underweight 15 35.25 (6.34) 15.81 44.15 
7 Male 81 0.64 Normal 15 52.31 (10.02) 37.37 67.01 
8 Male 68 0.48 Normal 16 44.47 (11.04) 32.81 63.84 
9 Male 77 0.60 Normal 10 43.65 (10.20) 33.25 62.91 
10 Male 81 0.53 Obese 13 57.55 (1.77) 55.13 60.07 
11 Male 58 1.05 Normal 11 61.95 (2.35) 57.25 66.88 
12 Male 55 1.12 Normal 12 63.35 (3.94) 54.81 68.40 
13 Male 73 1.15 Overweight 16 73.55 (3.22) 68.11 77.96 
14 Male 62 0.91 Overweight 12 65.97 (4.88) 51.85 69.78 
15 Male 58 0.94 Obese 16 69.92 (9.25) 42.74 79.26 
16 Female 78 0.94 Overweight 8 67.54 (3.95) 61.19 72.66 
17 Male 52 0.87 Overweight 12 65.94 (4.37) 57.68 70.31 
18 Male 83 0.57 Overweight 16 69.10 (5.15) 59.56 74.77 
19 Male 83 0.62 Overweight 7 41.93 (16.13) 28.34 70.50 
20 Male 63 0.63 Normal 15 50.57 (7.18) 39.13 60.03 
21 Male 65 1.15 Overweight 11 57.48 (3.73) 50.37 63.28 
22 Male 79 0.90 Normal 13 65.73 (10.54) 44.36 75.89 
23 Male 77 1.64 Obese 7 45.23 (9.15) 35.99 58.03 
24 Male 68 0.68 Overweight 16 67.23 (14.49) 39.92 82.70 
25 Male 64 0.66 Obese 13 53.47 (3.60) 48.84 59.53 
26 Male 66 0.90 Overweight 14 70.52 (8.65) 52.11 77.42 
27 Male 67 0.75 Obese 7 64.34 (7.21) 52.55 70.44 
28 Male 49 0.94 Obese 12 65.40 (5.59) 56.99 71.24 
29 Male 58 0.68 Normal 12 38.68 (23.43) 00.00 71.16 
30 Male 72 0.46 Overweight 12 56.67 (7.34) 43.74 63.66 
31 Male 68 1.27 Obese 11 64.85 (2.04) 61.52 67.49 
32 Male 68 0.74 Overweight 15 57.03 (15.69) 36.62 78.77 
33 Female 78 0.95 Overweight 12 64.32 (4.27) 52.96 67.77 
34 Male 63 0.90 Overweight 12 77.43 (9.43) 49.46 88.49 
35 Male 57 0.56 Normal 13 71.28 (3.60) 64.68 77.07 
36 Male 79 1.04 Overweight 8 56.22 (14.03) 39.80 78.87 
37 Female 75 0.64 Obese 13 70.07 (8.54) 56.43 80.56 
38 Female 63 1.14 Obese 15 70.88 (3.39) 64.78 75.98 
39 Male 59 1.06 Obese 9 71.48 (3.67) 65.74 76.48 
40 Male 63 0.66 Overweight 12 55.38 (7.39) 46.50 71.73 
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       Appendix R 
      Grouped Exercise Trajectories 
 
R1.  Treadmill Test 
 
237 
 
R2.  ABI 
 
238 
 
R3.  Diabetes 
 
239 
 
R4.  Smoking Status 
 
240 
 
R5.  Age 
 
241 
 
R6.  Neuropathy 
 
242 
 
 
R7.  Osteoarthritis 
 
243 
 
R8.  Gender 
 
244 
 
 
R9.  Body Mass Index (BMI) 
 
245 
 
R10.  Ethnicity 
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       Appendix S 
             Grouped Recovery Trajectories 
 
S1.  Treadmill Test 
 
247 
 
S2.  ABI 
 
248 
 
S3.  Diabetes 
 
249 
 
S4.  Smoking Status 
 
250 
 
S5.  Age 
 
251 
 
S6.  Neuropathy 
 
252 
 
S7.  Osteoarthritis 
 
 
253 
 
S8.  Gender 
 
254 
 
S9.  Body Mass Index (BMI) 
 
255 
 
S10.  Ethnicity 
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